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ABSTRACT  
Sequence-function relationship is a fundamental question for many branches of 
modern biomedical research. It connects the primary sequence of proteins to the function 
of proteins and fitness of organisms, holding answers for critical questions such as 
functional consequences of mutations identified in whole genome sequencing and 
adaptive potential of fast evolving pathogenic viruses and microbes. Many different 
approaches have been developed to delineate the genotype-phenotype map for different 
proteins, but are generally limited by their throughput or precision. To systematically 
quantify the fitness of large numbers of mutations, I modified a novel high throughput 
mutational scanning approach (EMPIRIC) to investigate the fitness landscape of 
mutations in important regions of essential proteins from the yeast or RNA viruses. Using 
EMPIRIC, I analyzed the interplay of the expression level and sequence of Hsp90 on the 
yeast growth and revealed latent effect of mutations at reduced expression levels of 
Hsp90. I also examined the functional constraint on the receptor binding site of the Env 
of Human Immunodeficiency Virus (HIV) and uncovered enhanced receptor binding 
capacity as a common pathway for adaptation of HIV to laboratory conditions. Moreover, 
I explored the adaptive potential of neuraminidase (NA) of influenza A virus to a NA 
inhibitor, oseltamivir, and identified novel oseltamivir resistance mutations with distinct 
molecular mechanisms. In summary, I applied a high throughput functional genomics 
approach to map the sequence-function relationship in various systems and examined the 
evolutionary constraints and adaptive potential of essential proteins ranging from 
molecular chaperones to drug-targetable viral proteins.       
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Chapter I – General Introduction 
 
Sequence-function relationship: an essential question in protein science  
 Proteins are essential and versatile functional units that enable growth and 
evolution of all kinds of organisms, from viruses to humans. The primary amino acid 
sequence of a protein determines its secondary, tertiary and quaternary structure; the 
structure of a protein dictates its function. Mapping this sequence-structure-function 
relationship has been a fundamental question that is constantly pursued by many branches 
of biomedical research. For example, numerous human diseases including cancer, 
immunological and neurological disorders, metabolic diseases and cardiovascular 
diseases can be traced back to variations in protein sequence, which cause aberrations in 
protein functions and thus dysfunctions on the cell and organ level [2]. In addition, 
progress in mapping a protein sequence to its function will greatly facilitate protein 
engineering and design. Improvements on proteins with known functions and de novo 
design of proteins with neo-functions have been central goals for this field with numerous 
breakthroughs and successful cases [3]. However, due to the remarkable complexity of 
physical and chemical constraints on protein structure and function, we are still far from 
mastering the art of creating or improving protein functions from scratch using available 
rule-based designs or blind selections that capture limited enhancing mutations [4]. 
Elucidation on sequence-function relationship of proteins will likely contribute to our 
understanding of biophysical constraints on protein structure and requirements on 
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specific protein functions as well as provide abundant information to train new advanced 
protein design algorithms. 
 
According to the central dogma, DNA serves as the template for RNA 
transcription; RNA then serves as the template for protein translation [5]. Changes in 
DNA or protein sequence are termed mutations. Most mutations in protein sequences 
result from non-synonymous mutations in coding regions of DNA or RNA because of 
replication errors of DNA or RNA polymerase. From a biochemical perspective, 
mutations in protein sequences may lead to changes in protein structure with an impact 
on protein folding, thermodynamic stability and solubility that alter protein functions. 
From an evolutionary perspective, inheritable mutations in DNA sequences generate 
mutations in protein sequences that affect organismal fitness, providing raw material for 
selection pressure to act upon. This iterative process provides the molecular basis for 
evolution and shapes the world full of different organisms with various adaptation 
strategies. Interestingly, evolution can be regarded as a massive experiment on genotype-
phenotype relationships that nature has conducted for billions of years. The result 
manifests as a big network of extant sequence spaces with mutational connections 
between them and collections of proteins with distinct properties and functions. Their 
linkage yields a genotype-phenotype map and provides rich mechanistic insights into 
protein sequence-function relationships. This entire mutagenesis followed by a natural 
selection process can be reproduced in the laboratory, though on a much smaller scale 
and shorter timeframe. Manually generating mutations of either known or unknown 
3 
 
identities in predetermined or random positions in proteins and interrogating the 
mutational effect on protein functions to understand sequence-function relationship of 
proteins has, therefore, become one of the most fundamental and powerful tools to 
characterize all aspects of proteins and associated cellular and organismal level properties. 
 
Mutagenesis approach to map sequence-function relationships 
Mutagenesis approach originally started as a technical cornerstone for the field of 
molecular genetics and evolution and then adopted by other disciplines of biology. The 
underlying logic is the structure, function, and regulation of a protein can be inferred 
from functional consequences of perturbation to the protein or elimination of the protein. 
Classic mutagenesis experiments adopt a forward genetics methodology, i.e. random 
mutagenesis and screening of specific phenotypes, followed by mapping, cloning, 
sequencing, and annotating the mutant genes [6]. Experimental geneticists applied x-rays 
[7] and chemical mutagens [8] to induce random mutations in purified DNA or organisms 
and investigated mutant phenotypes, e.g. eye pigmentation in Drosophila melanogaster 
[9] and auxotrophy in Neurospora crassa [10]. However, this approach is inefficient due 
to the randomness and low probability of mutations of interest and confounding effects 
from irrelevant secondary mutations. An improved and more targeted forward genetics 
mutagenesis approach is transposon mutagenesis, which results in one unique insertion 
mutation per genome, followed by phenotypic screening and subsequent transposon-
tagging to identify and clone genes of interest [11].  
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With advancements in recombinant DNA technology [12], it became feasible to 
precisely and efficiently introduce desired mutations into specific loci of DNA and 
therefore in the protein. Single-strand DNA repair by error-prone polymerase coupled 
with nucleotide analog and biased pool of nucleotides generates localized random 
mutagenesis that results in multiple mutations [13, 14]. Development of Polymerase 
Chain Reaction (PCR) [15] and advancements in oligonucleotide synthesis [16] opened 
new avenues for engineering single mutation at specific loci of the gene. For example, the 
Quikchange method [17], which allowed site-directed mutagenesis in one day with >80% 
efficiency, used synthetic oligonucleotides to amplify the whole plasmid in a 
thermocyling reaction to induce a single mutation; cassette mutagenesis constructed 
annealed oligonucleotides with single mutations (cassettes) and ligated them back to the 
gene with part of the wild-type sequence removed [18]. Conversely, error-prone PCR 
enables generation of mutations in a random fashion, but the average number of 
mutations per genome can be controlled through altering the PCR reaction condition [19]. 
These single mutations or combinations of mutations are then subject to a broad range of 
assays to measure defects or enhancements in stability [20], catalytic domains [21], 
binding interfaces [22] and phosphorylation [23], either in a purified system or model 
organism. The in vivo environment provides an endogenous condition where the protein 
naturally functions, including trafficking, post-translational modification, buffers and 
interacting partners. Protein in purified form enables careful characterization of the 
biophysical and biochemical properties of the protein in a highly controlled and 
reproducible in vitro environment.  
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One essential approach that analyzes mutational effects on protein function and 
genotype-phenotype relationships is protein display, which revolutionarily links the 
expressed protein and its encoding nucleotide sequence. Protein display presents a single 
mutant (e.g. introduced by site-directed mutagenesis) or a collection of diverse mutants 
(e.g. introduced by random mutagenesis or error-prone PCR) on the surface. These 
mutants are subject to functional screening, followed by sequencing of the selected 
encoding sequence, which is linked to the most optimized protein. This approach 
traditionally enables selection of the most optimized protein variants from a diverse 
library ribosome [24], phage [25], bacterial [26], yeast [27] and cellular [28] displays. 
Protein display is coupled to fluorescence activated cell sorting (FACS) to mediate high 
throughput quantitative screening with reduced background [29]. 
 
A special case of the site-directed mutagenesis that increases mutation screening 
throughput is alanine scanning [30]. Alanine scanning replaces wild-type amino acid with 
alanine and probes the impact of this mutation on protein stability or function to identify 
essential residues in vivo or in vitro. Alanine is chosen because its side chain terminates 
at the beta carbon, which results in little effect on the main chain conformation and 
limited electrostatic or steric restrictions; in addition, it is a frequent amino acid observed 
both in buried and exposed positions and all secondary structures [30]. Alanine scanning 
has become a prototype for all next generation mutational scanning approaches and 
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useful for identifying critical residues that are necessary for maintaining protein stability 
or function [31, 32].  
 
Directed evolution not only selects for mutations with enhanced or altered 
activities, but also reveals mutational effects on protein structure and function with 
associated mechanistic details. Directed evolution couples multiple rounds of 
mutagenesis on protein sequence to selection or screening for specific functions or 
properties. The process starts with a library of mutants and the pool of mutations in any 
round inherits mutations that pass selection/screening from the previous round. This is 
similar to an evolutionary process: the genotype walks the fitness landscape after each 
round of diversification and selection, which update the available sequence space, and 
climbs to the peak of fitness; when reaching the peak of fitness, this iterative process 
yields highly optimized proteins for certain selection pressures. Biophysical or 
biochemical characterization of any intermediate points during and the endpoint uncovers 
a combination of positions that modulate protein function [33, 34], stability [35, 36] and 
protein-protein interaction [37]. Directed evolution complements alanine scanning in 
analyzing protein binding, for example, alanine scanning on evolved receptors from 
directed evolution unlocked residues that were necessary for enhanced binding [37].  
 
Although the existing mutagenesis approaches have been generally successful in 
revealing sequence-function relationships in protein properties and uncovered many 
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biochemical or biophysical processes, they possess several inherent limitations. For 
common site-directed mutagenesis that converts one residue into another, throughput is 
usually quite limited due to its labor-intensive nature. Moreover, prior information like 
structural analysis or biochemical characterization is required for determining which 
residue to mutate. Alanine scanning yields mutational effects from only a single side 
chain substitution, although with an augmented scale of mutagenesis. Position specific 
biophysical requirements cannot be assessed without delineation of mutational effects 
from other side chains with distinct polarity, volume, shape or electrostatic effect. 
Similarly, directed evolution elucidates mutational effects only for a subset of highly 
optimized mutations and fails to illuminate impacts from the majority of other mutations. 
Furthermore, the phenotype is frequently derived from a combination of mutations; 
therefore, critical residues that alter protein stability/function still demand further 
clarification. 
 
Systematic mutational scanning – a high throughput functional 
genomics approach 
 The success of the human genome project (HGP) and the availability of the 
complete map of the human genomic sequence [38] facilitated unparalleled progress in 
development of new platforms of DNA sequencing technology and a boost in DNA 
sequencing capability [39]. The HGP accelerated development and commercialization of 
next generation sequencing platforms able to produce millions of short reads (50-500bp) 
in a single run [39]. This revolutionary technical advancement allows quick and accurate 
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decoding of the diversity of complex mixtures of DNA molecules, which results in fast 
and efficient genome sequencing as well as quantification of a relative abundance of 
individual unique DNA mutations. However, increasing human genome sequencing 
accentuates a long-standing problem: functional consequences of the prevailing genomic 
variability among the human population. Each individual is estimated to have, on average, 
approximately 300 rare but protein-encoding mutations with largely unknown functions 
[40], so functional annotation of these mutations will provide invaluable information to 
prompt timely diagnostics of a variety of diseases, accelerated developments of novel 
therapeutics and accurate prediction of prognosis. Increasingly accumulated sequencing 
of cancer cells, pathogenic bacteria and viruses has been revealing novel mutations that 
may affect pathogenicity, drug resistance and immune response escape.  
 
Currently available site-directed mutagenesis approaches are impractical for 
inspecting the phenotype changes of rapidly growing numbers of mutations mainly due to 
limited throughput. Computational approaches that predict impact of mutations on 
protein function or pathogenicity have limited accuracy [41]. Condel [42], GERP [43] , 
PolyPhen-2 [44], SIFT [45] and CADD [46] are examples of prediction algorithms that 
employ statistical analysis on conservation/ diversification of natural sequences or 
physicochemical constraints on amino acid residues. They make relatively accurate 
predictions on average, but fail in about half of the individual cases, which render them 
incapable for making reliable predictions of mutational effects on protein function [47, 
48]. Therefore, there is an immense necessity for high throughput functional genomics 
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methodologies that are able to efficiently interrogate effects of hundreds or thousands of 
mutations on protein function and phenotype changes in parallel, in particular for disease-
related mutations either in human or pathogen proteins. 
 
The massive power of next generation sequencing enables accurate determination 
of sequence identity of each individual DNA molecule in an ultra complex and 
heterogeneous pool of millions of DNA molecules. When coupled with saturation 
mutagenesis and bulk competition, the entire procedure provides a massive parallel 
estimate of functional consequences of mutations in proteins that mediate biochemical 
(e.g. binding to a partner protein) or physiological (e.g. cell proliferation) processes in a 
single experiment. This general experimental pipeline diversifies into two independently 
developed high throughput mutational scanning approaches—deep mutational scanning 
(DMS) [47] and exceedingly methodical and parallel investigation of randomized 
individual codons (EMPIRIC) [49]. The massive mutagenesis that generates most single 
amino acid substitutions and occasionally double/triple amino acid mutations can be 
realized through chemical DNA synthesis [47], error-prone PCR [50], or randomized 
cassette ligation [51]. All pooled mutations are analyzed in the same physical sample 
during bulk competition, which ensures equivalent experimental conditions for each 
mutation and therefore improves measurement precision. Selection pressure imposed 
during bulk competition can be any environmental perturbations that affect enzymatic 
function [52], protein-protein interaction [53], growth rate of organisms [54], including 
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antibiotics [55], varied salinity [56], and novel ligands [57]. Deep sequencing of the pool 
of mutations provides frequency estimates of each mutation both before and after 
selection and the change in frequency represents a direct measurement of mutational 
effects on protein function or organismal fitness compared to other variants and the wild-
type in the bulk competition.  
 
As a pioneer in developing deep mutational scanning (DMS), Fowler et al. 
combined phage display of a library of ~600,000 variants (including the majority of 
single mutations and a fraction of double/triple mutations) of a human WW domain and 
bulk selection on the binding affinity of each mutation to the peptide ligand [58]. Deep 
sequencing of the pool of mutations prior to and post selection yielded frequency change 
of mutations, which corresponded to their binding affinities [58]. They were able to 
construct a complete map of functional constraints on each position of the WW domain 
that revealed amino acid preferences at each position [58]. DMS was then adopted to 
screen for stabilizing mutations in the WW domain [59], identify mutations with 
enhanced auto-ubiquitination activity in a murine E3 ligase [60], construct a sequence-
function map and epistatic interaction network of RRM2 domain of a yeast polyA 
binding protein [61], predict homology-direct DNA repair and tumor suppression activity 
of mutations in the RING domain of BRCA1 [62].  
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Hietpas et al. independently developed a distinct approach coined EMPIRIC that 
explored the functional constraints on a nine-amino-acid region (a putative binding site) 
of yeast Hsp90 [51]. A saturation mutagenesis library consisting of every possible codon 
substitution (including single, double and triple nucleotide mutations) was assembled 
through randomized cassette ligation, transformed into a yeast temperature sensitive 
strain and subject to bulk growth competition at elevated temperatures. Samples were 
harvested at a series of time points and processed for deep sequencing. Changes in 
frequency of mutants over the time course were analyzed to estimate the impact of Hsp90 
mutations on yeast growth rate, which was termed (experimental) fitness effect in 
evolutionary biology. Hietpas et al. thoroughly mapped the sequence-function 
relationship for this nine amino acid region of yeast Hsp90, discovered correspondence 
and discordance between experimental and natural evolution and related their 
experimental fitness measurements to classic evolutionary theories about fitness 
landscapes. EMPIRIC-type systematic mutagenesis has been utilized in multiple studies: 
analyzing the impact of shifted environmental conditions (e.g. elevated salinity) on 
fitness landscape of yeast Hsp90 [56]; illuminating a intragenic epistatic landscape in 
yeast Hsp90 [63]; uncovering the mutation tolerant face, which comprises mostly core 
residues, and the mutation sensitive face, which encompasses mainly surface residues 
responsible for binding interactions in yeast ubiquitin [54]; characterizing functional 
effects of mutations in yeast ubiquitin on E1 activation [53]; mapping mutational 
sensitivity and adaptive potential for binding to a novel ligand for coevolved protein 
sector residues in a PDZ domain [57]; and inspecting fitness effect of single mutations in 
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TEM-1 -lactamase under purifying selection on ampicillin resistance and for a positive 
selection on cefotaxime resistance [55]. As a comparison, DMS is more often utilized to 
analyze the impact of mutations on protein stability, enzymatic function or binding 
affinity in vitro, whereas the EMPIRIC-type approach is commonly used for in vivo 
evaluation of the impact of mutations on organismal growth rate mediated by alterations 
in protein properties. DMS frequently employs large-scale randomized mutagenesis to 
cover most single mutations and a fraction of double or higher-order mutations while 
EMPIRIC generally implements systematic mutagenesis to cover every possible single 
amino acid substitution. 
 
Applying high throughput mutational scanning to analyze viral 
evolution 
High throughput mutational scanning has proved successful in dissecting 
evolutionary pathways of viruses, in particular RNA viruses. The high mutation rate [64], 
and large population size of RNA viruses [65] enables sampling of nearly all possible 
single mutations in a single round of viral replication [66]. This rapid evolution of RNA 
viruses results in viral adaption to constantly changing environmental conditions and 
spread of beneficial mutations under therapeutic selection pressures. Clinical relevant 
examples include viral escape from immune response [67], viral drug resistance [68] and 
zoonotic viral infection transmitted to humans [69, 70]. Therefore, analyzing the 
evolutionary trajectory of pathogenic RNA viruses will provide insights into control and 
treatment of viral infection, and inspection of mutational effects on viral protein functions 
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that affect viral replication and/or transmission capability (fitness) will unlock the 
consequences of the most common viral evolutionary steps in nature.  
 
As the first large scale mutagenesis study to measure purifying selection on RNA 
viruses, Loeb et al. applied a PCR based random mutagenesis strategy to measure HIV-1 
protease activity for a fraction of possible single mutations (20-55%) at each position and 
identified three separate regions that were sensitive to mutations, indicating their 
functional importance [1]. When high throughput mutational scanning became available, 
Wu et al. adapted this approach to measure fitness of mutations in the neuraminidase 
gene of H1N1 influenza virus and identified three permissive mutations that partially 
restored the fitness defect of the predominant drug resistance mutation H275Y (N1 
numbering system) [50]. Heaton et al. utilized a transposon dependent random insertion 
mutagenesis approach to screen the entire genome of influenza for regions tolerant of 
mutations and revealed inherent elevated mutation acceptance capacity of hemagglutinin 
(HA) and nonstructural protein 1 (NS1) of influenza virus [71].  
 
The first two studies that applied high throughput mutational scanning to 
characterize mutational effect in influenza virus presented exciting new methods, but 
lacked stringent statistical analysis and comparison of fitness effects of mutations in 
experimental conditions and in nature. Subsequent studies applied more advanced 
statistical approaches and often compared experimental fitness measurements with 
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frequency of mutations in isolates from patients. Bloom constructed a complete amino 
acid sequence preference map of influenza nucleoprotein and used experimentally 
determined positional amino acid preferences to build an evolutionary model that 
outperformed other computational approaches in phylogeny fit [72]. Thyagarajan and 
Bloom utilized the same approach to estimate amino acid preferences at each position of 
influenza HA and elucidated the inherent mutation tolerance of antigenic sites [73, 74]. 
Wu et al. coupled experimental fitness measurements and protein stability prediction for 
the majority of single mutations in influenza PA polymerase subunit and identified 
influenza type-specific functional constraints on many naturally non-conserved residues 
among different influenza types [74]. Wu et al. also performed high throughput 
mutational scanning on NS1 of influenza to measure fitness of most single mutants in the 
presence or absence of type I interferon and identified detrimental mutations that were 
sensitive to type I interferon [75]. Qi et al. first adopted systematical mutational scanning 
to determine drug effects on fitness of viral mutants: they tested sensitivity of all possible 
single amino acid mutations in the active site of nonstructural protein 5A (NS5A) of 
Hepatitis C to daclatasvir and identified critical residues that mediated drug resistance 
[76]. 
 
The mutational scans of whole viral genes generated remarkably detailed 
sequence-function maps of viral proteins of clinical significance and exciting insights 
into possible sequence space of viruses under diverse selection pressures. However, the 
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reproducibility of these scans, estimated by correlation of functional/fitness 
measurements on single mutants between biological replicates of the bulk competition or 
between bulk competition and individually generated clones, was generally modest. 
Bottleneck effect during transfer of libraries of massive numbers of mutations probably 
contributes to this suboptimal reproducibility. For example, influenza HA is composed of 
about 580 amino acids, so a saturation library of every possible single amino acid 
substitution will encompass at least 11,020 (580 x 19) mutations [73, 77]. The complexity 
of mutation libraries are likely to trigger a bottleneck effect that leads to stochastic 
changes in frequency of mutations during generation of a viral library by transfecting the 
plasmid library into mammalian cell lines and/or randomly sampling from the original 
viral library to initiate infection experiments. This moderate precision in measuring 
fitness effect of individual mutations is sufficient for estimating mutational tolerance and 
strength of selection on each position by averaging across different amino acid 
substitutions, but becomes suboptimal in precise determination of functional or fitness 
measurements on specific mutations, which is required for isolation of adaptive mutations 
with moderate benefit. Although including more experimental replicates and combining 
them to obtain average fitness estimates on individual mutations partially overcomes this 
technical challenge, increased precision in fitness estimates will benefit identification of 
adaptive mutations to therapeutic selection, for which small differences may result in 
quite distinct evolutionary outcomes. For that reason, high throughput approaches that 
facilitate systematical and precise functional or fitness measurements of large numbers of 
mutations are still in great demand. 
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Protein function as a product of protein expression and activity  
Expression (number of properly folded protein molecules) and activity (defined as 
activity per protein molecule) collectively determine the total function of a protein. The 
activity of a protein is mostly dependent on the primary amino acid sequence of the 
protein; thus, many mutations in the primary sequence alter the protein activity [78]. The 
impact of sequence variation on protein function or organismal fitness is well 
documented as discussed previously. On the other hand, protein expression is determined 
by many factors: promoter strength [79], non-translation regions [80], translational 
regulators [81], epigenetic factors [82], and gene dosages (either duplications or deletions) 
[83]. Several studies have looked into the effect of changes in expression level on protein 
function: one well known example is that expression level of Agouti protein regulates 
coat coloration of mice and drives adaption of mice to varied predation patterns [84]. 
However, most studies to date have been focused on effects of changes to either protein 
sequence or expression on protein function or organismal fitness individually, but these 
two factors are interdependent in shaping protein function and organismal fitness [85]. 
 
 Changes in protein expression modulate organismal fitness. Direct measurements 
of E. coli growth rate with varied expression of the Lac operon over a wide range of 
lactose concentrations demonstrated an optimal expression of the Lac operon that 
maximized the fitness of E. coli with different concentrations of lactose [86]. Several in 
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silico studies that simulated E. coli growth also suggested the maximization of fitness by 
tuning of protein expression levels [87-89]. However, significant reduction in expression 
of many essential proteins confers quite limited defects in fitness [90-93]. For example, 
heterozygotes with only one functional allele are often highly fit, which indicates even 
only half of total functional protein sustains growth [94]. This implies a non-linear 
relationship between protein expression and fitness: at close to wild-type expression 
levels, the decrease in protein expression causes much less reduction in fitness (the slope 
is less than one), while at significantly reduced expression levels (in the transition range 
of the function), reduction in protein expression levels leads to a significant decrease in 
fitness [95]. This apparent contradiction was addressed by a cost-benefit model, which 
proposes a balance between the cost of using cellular resources for protein synthesis and 
the benefit of the specific protein function to improve fitness of the organism [86]. Of 
note, since total protein function is a product of its expression and activity, the effect of 
reduction in protein expression (with protein sequence unchanged) on protein function is 
equivalent to the effect of reduction in protein activity conferred by deleterious mutations 
(with protein expression unchanged). When combined with elasticity function, this points 
to a testable prediction: intermediate deleterious effects of mutations on fitness can be 
hidden at high protein expression levels. Therefore, experimental examination of fitness 
effect of mutations at varied expression levels are likely to uncover latent detrimental 
effects of mutations in highly expressed protein and provide a plausible explanation for 
the mechanism behind this elasticity function, i.e. seemingly over-expression of essential 
proteins may buffer negative effects of deleterious mutations on fitness. 
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Hsp90: a molecular chaperone that enhances evolvability of other 
proteins  
Heat shock protein 90kDa (Hsp90), also known as Hsp82 in Saccharomyces 
cerevisiae, is a conserved and highly expressed molecular chaperone with a large 
network of interacting partners. It was first discovered in Drosophila melanogaster as a 
highly expressed protein after exposing the fly larvae to elevated temperatures [96]. 
Hsp90 is one of the most conserved proteins; even distantly related eukaryote species like 
yeast and human share at least 50% amino acid sequence identity [97] and eukaryotic 
Hsp90 shares about 40% amino acid sequence identity with its counterpart in E. coli [98]. 
Hsp90 is highly expressed in the cytoplasm and other cellular compartments, constituting 
about 1-2% of total proteins in the cytoplasm [91]. Its expression is further up-regulated 
to 5-6% under stress conditions, such as heat shock [99]. In response to stresses, a 
transcription factor known as Heat shock factor 1 (HSF1) dissociates from Hsp90 and 
translocates into the nucleus, where it becomes transcriptionally activated and drives 
elevated Hsp90 expression [100]. Other factors such as nuclear factor-κB subunit p65 
[101], nF-Il6β [102] and STAT3 [103] also induce expression of Hsp90 following 
different stimulation. 
 
Hsp90 is a homodimer comprising of two 709 amino acid monomers, dimerized 
by their C terminals (Figure 1.1). Each monomer is composed of three domains: N-
terminal domain (NTD), middle domain (MD) and C-terminal domain (CTD) [104]. The  
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Figure 1.1: Hsp90 is a homodimer and each monomer encompasses three domains 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.1 Hsp90 is a homodimer and each monomer encompasses three domains. Molecular 
image based on the PDB ID: 2CG9 structure of Hsp90 [104] shows the two identical monomers 
of Hsp90. For one monomer, the N-terminal domain is colored green; Middle domain is colored 
blue; C-terminal domain is colored red [105].  
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NTD encompasses the highly conserved ATP binding site that binds to and hydrolyzes 
ATP subsequent to clients and co-chaperones binding [106]. Of note, a ‘lid’ formed by 
several conserved residues closes over and covers the nucleotide binding site when bound 
to ATP [107]. The MD is connected to the NTD within the monomer through a flexible 
and charged linker that affects Hsp90 function [108]. In the MD, two αβα motifs connect 
with each other by several α-helices [107]. The MD associates with the NTD to facilitate 
ATP hydrolysis [109], and heavily involves in interactions with co-chaperones [110] and 
client recognition and maturation [107, 111]. The CTD comprises a mixed α- and β-
structures and mediates dimerization of the homodimers with a four-helix bundle dimer 
interface formed by two α-helices from each monomer [112]. The five C-terminal 
residues form a motif (Met-Glu-Glu-Val-Asp; MEEVD) that recognizes a 
tetratricopeptide repeat (TPR) binding domain and interact with many co-chaperones and 
clients [113].  
 
 Hsp90 undergoes a conformational change driven by hydrolysis of ATP [106]. 
Although the structural and mechanistic details are still under investigation, a generally 
agreed model was derived from accumulated biophysical and structural data. Binding of 
ATP to NTD (mediated by D79 of NTD) followed by closure of a molecular lid gradually 
shifts the conformational equilibrium of open and closed state to a more closed and active 
conformation. This closed conformation enables dimerization of two NTD monomers and 
intramonomer contacts between NTD and MD. Hydrolysis of ATP (mediated by E33 in 
NTD and R380 in MD) to ADP leads to a second, but unclear state. Then dissociation of 
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ADP “resets” the conformation to its originally open state [114]. In the ATP cycle, 
multiple co-chaperones individually or collectively affect functions of Hsp90 by 
organizing interactions between Hsp90 and other chaperones (HOP) [115], activating 
(Aha1) or inhibiting (Cdc37 and p23) ATP hydrolysis [116-118], and recruiting clients 
(Cdc37) [119].  
 
Hsp90 facilitates maturation and proper folding of its clients. More specifically, it 
keeps the often inherently unstable client (such as kinases and transcription factor) poised 
for activation until stabilized by conformational changes [120]. Presumably, Hsp90 
clients are recognized by their unstable structural features, sequestered by Hsp90 and 
protected from exposure and aggregation, so that they have higher probability to fold into 
its native conformation and become activated or functional [97]. Hsp90 also cooperates 
with E3 ligase to target clients that stay unfolded after multiple rounds of chaperone 
interaction to ubiquitin-mediated proteasomal degradation [121]. The mechanistic detail 
of client recognition and the possible role of the ATP cycle on client maturation are still 
mostly unknown and require further study.  
 
Hsp90 is a central hub in the intracellular protein network and has direct 
interactions with 3% of the yeast proteome estimated by yeast two-hybrid and SGA 
analysis [122, 123], although the biological significance of the majority of these 
interactions are unknown partially due to their transient nature [124]. However, owing to 
this massive interactome network, the clients of Hsp90 fall into diverse categories, 
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including signal transduction, innate immunity, steroid and calcium signaling, protein 
trafficking, viral infection and telomere maintenance [97].  
 
Hsp90 is also known to play mixed roles in the evolution of cryptic mutations. On 
the one hand, Hsp90 functions as a capacitor that buffers morphological or phenotypic 
variations, as shown in Drosophila melanogaster and Arabidopsis thaliana [125, 126]. 
These studies demonstrated that Hsp90 masks effects of existing variations on 
morphology or phenotype in nature, while compromised Hsp90 function unleashes the 
morphological or phenotypic variations associated with these cryptic variations. These 
traits continue to express under selection, even after restoration of Hsp90 function. On 
the other hand, Hsp90 potentiates evolution of new traits, in particular drug resistance, by 
instantly revealing the phenotypic consequences of new mutations [127, 128]. When the 
Hsp90 mediated protein-folding reservoir is compromised, traits from potentiator-
dependent variants disappear, while traits from capacitor-dependent variants reveal [128]. 
In Saccharomyces cerevisiae, Hsp90 appears to act as a capacitor as frequently as a 
potentiator [128]. In summary, Hsp90 imposes distinct control on the emergence of new 
traits, followed by selection driven and Hsp90 independent fixation of new traits. 
 
As a capacitor, Hsp90 is predicted to promote fixation of adaptive mutations 
under stress conditions and confers robustness to deleterious mutations under normal 
conditions. By buffering traits from cryptic mutations, Hsp90 protects normal 
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development from detrimental effects of random mutations [125]. Although the buffering 
capacity of Hsp90 is regarded as a byproduct of its chaperoning function, it facilitates 
evolution under stress conditions (e.g. increased temperature) that reduce the capacitor 
function of Hsp90 and thus reveal selective advantages of previously invisible mutations 
[129]. For example, multiple cryptic mutations exhibit resistance to antibiotics with 
pharmacologically inhibited Hsp90 [128]. Moreover, accumulation of multiple cryptic 
mutations enables exploring phenotype of combinations of mutations in a single step 
[129]. The capacitor or buffering function of Hsp90 has also been demonstrated in zebra 
fish with a highly selective mechanism that only affects certain traits [130]. Taken 
together, these studies showed that buffering function of Hsp90 is associated with 
strength and timing of Hsp90 inhibition, strains (with different pre-existing genetic 
variants) and developmental stages of organisms and dependence of phenotypes on 
Hsp90 function. Although more specific targets of Hsp90 buffering system have been 
mapped, the detailed molecular mechanism remains largely unknown.  
 
Human immunodeficiency virus type 1: discovery, life cycle, 
pathogenesis and treatment   
Human immunodeficiency virus type 1 (HIV-1) was first transmitted from 
chimpanzees to local residents in sub-Saharan Africa as a zoonotic disease in the 1920s 
[131, 132] and by the 1970s HIV-1 (referred to as HIV) had been introduced to North 
America. In 1981, five strange medical cases, termed Acquired Immunodeficiency 
Syndrome (AIDS), were reported in the United States [133]. It wasn’t until 1983 that 
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HIV was isolated from AIDS patient biopsies [134, 135], and confirmed as the causative 
agent of AIDS one year later from serological tests and large scale sero-epidemiological 
studies . The nucleotide sequence of the HIV genome was determined in 1985 [136, 137], 
which facilitated PCR based measurement of plasma HIV titer [138] and the monitoring 
of HIV evolution patterns globally. Both serological and molecular based methods 
contributed to the rapid and accurate diagnosis of HIV infection. With more than 70 
million reported cases and 25 million deaths, HIV is one of the most widely disseminated 
and deadly pandemics of the 20th century.   
 
The replication cycle of HIV starts with the surface trimeric spike (Env) binding 
to the CD4 receptor on host cells. Env then binds to a co-receptor (either CCR5 or 
CXCR4) and mediates fusion of the viral and host membranes. Upon membrane fusion, 
the viral genome and associated proteins are released into the cytosol. Viral RNA is 
reverse transcribed into cDNA, which is then transported into the nucleus. In the nucleus, 
viral integrase enables stable integration of cDNA into the human genome, most 
frequently within the introns of actively expressed genes. The integrated viral genome is 
expressed in a highly coordinated fashion to produce viral proteins that are trafficked to 
the cell surface, packaged into budding viral membrane, and cleaved by protease for 
mature virus assembly.  
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Many HIV proteins, including reverse transcriptase, integrase and protease, are 
validated drug targets with potent inhibitors in clinical use. However, due to the high 
mutation rate and the large population size of HIV, these viral proteins rapidly develop 
resistance to individual agents [139]. Combinations of drugs targeting different HIV 
proteins, e.g. (non-)nucleoside analog reverse transcriptase inhibitors and protease 
inhibitors [140-142], significantly raise the barrier for evolved drug resistance and are 
able to clear more than 99% of circulating viruses within two weeks [143]. However, 
integration of the HIV genome into resting CD4+ T cells produces a latent reservoir of 
HIV that is inaccessible to antiviral therapies and can re-establish infection upon 
disruption of therapy. Highly effective antiviral therapy has converted HIV-1 from an 
acute, life-threatening disease into a chronic condition that requires continuous therapy 
throughout a person’s lifetime [144, 145]. An imminent consequence is approximately 37 
million chronically infected people and two million newly infected cases in 2014 alone, 
which imposes a heavy burden on the healthcare systems. Thus, HIV vaccines that would 
prevent the spread and reduce HIV-associated economic burden are in great need. 
 
Vaccines are responsible for the eradication/control of many once deadly diseases, 
such as smallpox, polio, and measles [146-149]. HIV vaccine development has been 
focused on the sole surface protein, Env [150]. Unfortunately, vaccine trials based on Env 
have been mostly unsuccessful [150] due to the unique properties of Env, such as 
extensive glycosylation, masked receptor binding sites and steric exclusion from 
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trimerization [151]. However, the moderate success from the recently completed clinical 
trial (RV144) has revitalized the interest to develop immunogens based on trimeric Env 
to induce protective antibodies [152]. The regime of RV144 combined vector-expressed 
trimeric Env and recombinant monomeric gp120, while previous unsuccessful trials only 
used recombinant monomeric gp120 [152]. RV144 exhibited 60% efficacy against HIV 
acquisition at 12 months and 31.2% efficacy even at 42 months. Neutralizing antibodies 
targeting V2 of Env with antibody-dependent cell-mediated cytotoxicity was isolated 
from RV144 and correlated with vaccine efficacy. The success of RV144 highlighted the 
importance of using the native trimeric Env as immunogen for vaccine trial.    
 
The surface trimeric Env spike 
The trimeric Env spike, which mediates viral entry, is the sole protein on the 
surface of HIV. It is composed of three identical exterior envelope glycoproteins gp120 
and three identical trans-membrane subunits gp41 (Figure 1.2). The precursor gp160 is 
cleaved to form gp120 and gp41, which are non-covalently attached to each other [153]. 
gp120 is responsible for binding to both the primary receptor (CD4) [154, 155] and the 
co-receptor (CCR5 or CXCR4) [156, 157], while gp41 anchors the trimeric spike in the 
viral membrane. A multiple sequence alignment of gp120s from a large collection of 
natural isolates identified 5 variable loops (V1-V5) that modulate antigenicity along with 
several conserved regions that form the discontinuous quaternary structure important for 
CD4 binding [158]. Both the variable loops and the conserved regions are heavily  
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Figure 1.2: Env is a homotrimer and each monomer encompasses two non-
covalently linked subunits: gp120 and gp41 
 
 
 
 
 
Figure 1.2 Env is a homotrimer and each monomer encompasses two non-covalently linked 
subunits: gp120 and gp41. Molecular image based on the PDB ID: 4NCO [159] structure of Env 
shows gp120, which points away from the viral membrane, and gp41, which is embedded into the 
viral membrane. In the right panel, after 90 degree rotation, the three identical monomers are 
colored differently (green, red and yellow).  
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glycosylated [158]. While glycosylation helps to mediate immune escape, broadly 
neutralizing antibodies can be solicited to target the glycans [160]. This extensive 
glycosylation and the inherent conformational flexibility impeded efforts to determine the 
gp120 structure by crystallography; however, in a landmark study by Kwong et al., the 
first high quality crystal structure of gp120 was determined through the use of a 
deglycosylated gp120 core with the inherently disordered variable loops removed [161]. 
This crystal structure revealed that gp120 folds into two parallel aligned major domains: 
an inner domain and an outer domain. The inner domain is composed of a small five-
stranded -sandwich stacked on a two-helix and two-strand bundle that encompasses V1-
V2 loops; the outer domain is comprised of a parallel double barrel that encompasses the 
V3-V5 loops and the CD4 binding site (Figure 1.3). Crystal structures based on gp120 
monomers with variable loops or trimers that resemble the native spike further reveal 
different conformation states with considerable details and resolution [159, 162-166]. 
Crystal structures of gp120 monomers shared a similar conformation as those observed 
for gp120 within the native trimer [159]. The detailed structural information of Env 
enables dissection of the conformational changes of Env, which are critical for its 
function and immune escape.      
 
Conformational change and epitope exposure of the Env complex  
gp120 has substantial conformational flexibility and undergoes a conformational 
change upon binding to CD4 (Figure 1.4) [167]. Before binding to CD4, gp120 maintains  
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Figure 1.3: gp120 of Env encompasses three domains 
 
 
 
 
 
 
 
 
Figure 1.3 gp120 of Env encompasses three domains. Molecular image based on the PDB ID: 
1gc1 [161] structure of gp120 highlights an inner domain (purple), an outer domain (blue) and 
bridging sheet [38]. 
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Figure 1.4: Env undergoes conformational change before and after binding to CD4 
 
 
 
 
 
 
 
Figure 1.4 Env undergoes conformational change before and after binding to CD4. 
Molecular image based on the PDB ID: 4NCO structure of Env [159] shows the conformation of 
one gp120 monomer before binding to CD4. In particular, the bridging sheet (colored red) and 
co-receptor binding site (colored cyan) are not completely formed; V3 loop (colored blue) is 
masked by V1V2 loop. After binding to CD4, Env undergoes conformational change. The 
molecular image based on the PDB ID: 2b4c [163] shows that the bridging sheet and co-receptor 
binding site are now well formed and the V3 loop is exposed.  
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a closed ground state conformation that facilitates evasion from antibody recognition; 
upon binding to CD4, gp120 switches to an open state that unmasks the co-receptor 
binding site (either CCR5 or CXCR4). Once bound to both CD4 and the co-receptor, 
gp120 changes conformation to a post-fusion state that presents gp41 with the penetrating 
peptide to initiate membrane fusion [165]. In the closed state, the trimer resembles the 
shape of a “mushroom” or a “three-blade propeller” [159, 165]. The V1/V2 loops shield 
the CD4 binding site, while the V2/V3 loops shield the co-receptor binding site. The apex 
of V3 loop is covered by the glycan of N197 from the V2 loop, so it is not exposed in the 
closed state. Of note, the V1, V2 and V3 loops together constitute the trimer associate 
domain [168] at the membrane-distal apex of the spike [169]. The trimeric Env spike in 
the closed state is generally resistant to neutralizing antibody binding. This resistance is 
due to both the extraordinary density of surface glycans, which prevents epitope 
accessibility [170], and a conformational barrier, which stimulates entropy penalty for 
antibody-binding induced conformational change [171]. Notably, only 2% of the gp120 
surface has significant sequence conservation and therefore remains accessible to 
antibody recognition. However, the majority of these conserved residues are located at 
the base of gp120, proximal to the viral membrane and therefore sterically occluded from 
antibody binding [165].  
 
Upon binding to CD4, the trimeric Env spike undergoes a major conformational 
change: the TAD dissociates at the trimeric apex due to movements of V1-V3 loops [172]. 
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The V1 and V2 loops separate and shift away from the inner domain, unmasking the V3 
crown and orienting it towards the host cell [161, 163]. An antiparallel, four-stranded 
minidomain, coined “bridging sheet”, is formed between the outer and inner domains, 
which is critical for CD4 binding (Figure 1.3 and 1.4) [161]. The exposed V3 crown and 
part of the bridging sheet form the co-receptor binding site (Figure 1.4) [161]. It is the 
interaction between gp120 and co-receptor that pulls the trimeric Env spike to the host 
cell membrane to initiate membrane fusion [165]. Compared to the closed state, the CD4-
bound state exhibits a considerably higher level of conserved, non-glycosylated surface 
residues that are better targets for neutralizing antibodies [165]. The major 
conformational change of Env exposes sites critical for not only viral entry, but also for 
neutralizing antibody recognition.     
 
Antibodies that target HIV surface receptor       
 Antibodies that target gp120 either as a trimer or a monomer recognize highly 
specific epitopes, many of which exist only in the closed or CD4-bound intermediate 
state. These antibodies can be utilized as molecular probes to inspect the conformational 
state of the trimeric Env spike. Of note, broadly neutralizing antibodies, which are able to 
neutralize diverse primary isolates, frequently bind to the highly conserved regions in the 
closed state, whereas strain-specific antibodies, or non-neutralizing antibodies, often 
target the gp120 surface that is only accessible in the monomer [173]. For example, 
VRC01, a broadly neutralizing antibody, binds to an epitope in the CD4 binding site that 
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exists in both monomeric and trimeric gp120 and neutralizes more than 90% of primary 
isolates, whereas b6 and b12, strain-specific antibodies, bind to an epitope in the CD4 
binding site of monomeric gp120 and neutralize less than 30% of primary isolates (Figure 
1.5A). Of note, comparison of epitopes between strain-specific and broad neutralizing 
antibodies uncovers a general strategy of HIV escape from humoral immunity: HIV viral 
particles releases shedding gp120 subunit as decoys that display masked epitopes in the 
trimeric spike and induces antibodies that mostly fail to neutralize trimeric Env spike in 
the closed state [174].  
 
Although strain-specific neutralizing antibodies are less therapeutically valuable, 
they can be used to probe the conformational state of the Env complex. For instance, 
PGT121-131 and 135-137 recognize conserved V3 glycans (N301 and N322), while 447-
52D recognizes the V3 apex (Figure 1.5B); PG9/16 and PGT 145 targets V1V2 glycans 
that is properly presented in the intact TAD, but not disrupted TAD (Figure 1.5C) [173]. 
Therefore, sensitivity of HIV to b6/b12 gauges exposure of the CD4 binding site and 
transition to the CD4 bound conformational state. Sensitivity of PG9/16 or PGT145 
reveals integrity of the TAD and openness of the trimeric spike. Sensitivity of PGT135-
137 reflects glycan patterns at the V3 loop, while 447-52D probes exposure of the V3 tip 
that forms the co-receptor site.  
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Figure 1.5: Neutralizing antibodies bind to different epitopes of Env 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.5 Neutralizing antibodies bind to different epitopes of Env. (A) Epitopes of two 
antibodies that bind to the CD4 binding site of Env: b12 and VRC01. (B) Epitopes of two 
antibodies that bind to the V3 loop: 447-52D and PGT128. (C) Epitopes of two antibodies that 
bind to the V2 loop and trimer association domain: PG9 and PGT145. For each panel, the former 
one is narrow neutralizing antibody and the latter one is broad neutralizing antibody. All 
molecular images are based on the PDB ID: 4NCO structure of Env [159].   
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Env: CD4 interaction and the CD4 binding site 
 The binding of the trimeric Env spike to CD4 is the initial step in the entry stage 
of HIV. Characterizing the residues that form the interfaces between these proteins 
yielded insightful mechanistic details of the early events in HIV entry and inform 
potential therapeutic interventions. The crystal structure of gp120 bound to CD4 by 
Kwong et al. provided a high-resolution snapshot of this interaction [161]. In gp120, the 
outer domain, inner domain and the bridging sheet form the binding interface (Figure 1.3). 
Residues that constitute the CD4 binding site (CD4BS) are from six different segments of 
gp120 (Figure 1.6A). In particular, the interactions between residues 365-371 and 425-
430 (HxB82 numbering) of gp120 [175] and residue 43 of CD4 account for 57% of the 
total interaction between gp120 and CD4 (Figure 1.6B). The core of the CD4BS is the 
“CD4 binding loop” composed of residues 366-370 (GGDPE). The CD4 binding loop 
and Trp427 make multiple contacts with Phe43 and Arg59 of CD4 (Figure 1.6B). These 
contacts make up a large fraction of the total interactions between gp120 and CD4. At the 
contacting surface, an imprecise complementing electrostatic interaction (positively 
charged CD4 and negatively charged gp120) stabilizes binding and a mismatch in surface 
topology creates two interfacial cavities: a large cavity that is solvent accessible and a 
small cavity with limited solvent accessibility. The large cavity is predominantly lined by 
hydrophilic residues, half of which are gp120 derived and the other half are CD4 derived. 
The lining residues from gp120 are mostly adjacent to CD4 contact residues and show 
significant sequence variation, which suggests a tolerance to mutation and possible role 
in viral escape from antibody neutralization. The small cavity is called “The Phe43  
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Figure 1.6: Env has a defined binding site for CD4 
 
 
 
 
 
Figure 1.6 Env has a defined binding site for CD4. (A) Molecular image based on the PDB ID: 
4NCO structure of Env trimer shows the CD4 binding site [38]. (B) Molecular image based on 
the PDB ID: 1gc1 structure of gp120 (grey) monomer bound to CD4 (yellow) [161] shows the 
two regions of gp120 (365-371 and 425-430) with most interactions with major contact residues 
of CD4: Phe43 and (green) and Arg59 (cyan).  
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cavity”, because Phe43 of CD4 protrudes into it. The Phe43 cavity is deeply rooted in the 
hydrophobic core of gp120, at the intersection of the inner, outer domain and the bridging 
sheet. It is mainly lined with highly conserved, hydrophobic residues that favor small 
substitutions with little steric hindrance, indicating functional constraints. Indeed, many 
mutations in the Phe43 cavity affect the gp120 and CD4 interaction [176].   
 
 The flanking regions of the CD4 binding loop have varied sequence conservation 
and biological functions. Many residues of the N-terminal flanking region, including 
residues 362-365, are located in close proximity to the large interfacial cavity and exhibit 
significant sequence variability [161]. Mutations at residues 361-364 modulate HIV 
infection/tropism in macrophages through modulating the exposure of the CD4 contact 
residues (Asp368 and Glu370) [177]. In contrast, many residues in the C-terminal 
flanking region (e.g. residues 375-377) reside in the Phe43 cavity and are more conserved 
across primary isolates [161]. This conservation is likely due to the direct role these 
residues play in the gp120:CD4 interaction. Of note, aromatic mutations (e.g. Trp, Tyr, 
Phe and His) at residue Ser375 appear to occupy the Phe43 cavity and drive the 
conformation of gp120 closer to a CD4-bound state with a large decrease in entropy. 
These mutations also cause reduced sensitivity to b12 and the entry inhibitor BMS-
599793, although they are more sensitive to soluble CD4 (sCD4) [176, 178, 179]. S375H 
cooperates with layer1 of the inner domain to mediate increased binding to CD4 and 
CCR5, contributing to adaptation of SIV to infect the macrophages of non-human 
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primates, which express lower levels of CD4 and CCR5 [179].  The flanking regions of 
the CD4 binding loop harbor residues that are part of the epitopes of neutralizing CD4BS 
antibodies (e.g. b12 and VRC01) [166, 180]. In fact, the CD4 binding site represents a 
supersite that is the target of diverse broad neutralizing antibodies isolated from 
chronically infected individuals [181]. Mutations at residue 386 in the C terminal 
flanking region of CD4 binding loop also affects neutralization sensitivity to 2G12, a 
glycan-specific antibody [182]. In summary, the CD4 binding loop and its flanking 
regions modulate the interactions between gp120 and CD4 and the sensitivity of gp120 to 
various neutralization antibodies. 
 
Influenza A virus and pandemics  
As a member of the Orthomyxoviridae family, influenza virus can be classified 
into three distinct serological types (A, B and C) that differ in their host ranges and 
pathogenicity [183]. Only influenza A and B virus are pathogenic in humans, and 
influenza A virus (IAV) is more pathogenic and evolvable [183]. IAV infects a wide 
range of animals including birds, pigs, horses and dogs, while aquatic birds appear to 
serve as the natural reservoir. Close and frequent contact between humans and these 
animals result in multiple cross-species transmissions [184]. IAV can be classified based 
on the antigenicity of its surface glycoproteins hemagglutinin (HA) and neuraminidase 
(NA). HA and NA co-determine the subtype of IAV, e.g. H1N1 and H3N2. IAV causes 
seasonal influenza outbreaks every winter that results in approximately 23,000 associated 
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deaths on average (data from CDC) and 10.4 billion dollars in costs for hospitalization 
and treatment [185]. H3N2 and H1N1 are currently co-circulating in the human 
population. Interestingly, the seasonal strain is usually the strain from the last pandemic.  
 
IAV also causes intermittent global pandemics that give rise to millions of 
infections, higher mortality and heavy burdens on the medical care system. The most 
notorious pandemic is the 1918 “Spanish Flu” that killed approximately 50 million 
people worldwide (675000 in the United States): the mortality rate exceeded 2.5%, much 
higher than the usual rate of less than 0.1% [186]. Most people died of concomitant 
bacterial/viral pneumonia. Notably, besides infants under the age of four years and senior 
people above the age of 75 years, this pandemic also resulted in unusually high mortality 
rates in young people aged 20-35 years who typically possess strong immunity to 
influenza infection [183]. Analysis of the viral genome isolated from preserved samples 
demonstrated that “Spanish flu” was caused by an avian-like H1N1 strain that adapted to 
infecting epithelial cells lining the human upper respiratory tract, indicating a direct 
transmission from birds [187]. Reverse genetically reconstructed “Spanish flu” strain 
elicited aberrant innate immune responses in animal models and provided a plausible 
explanation for the high mortality rate in young people [188-190]. Of note, the direct 
descendants of the 1918 H1N1 strains have been circulating in the human and swine 
population and contributing genes to new IAV genetic reassortment [183].  
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The second pandemic was the 1957 “Asian flu” that originated in China, 
disseminated in East and Southeast Asia and then spread to North America and Europe. 
This pandemic caused about two million influenza related deaths worldwide and 70,000 
deaths in the United States alone [183]. Genomic analysis showed that avian-flu genes 
combined with seasonal human influenza viral genes to create a human/avian H2N2 
influenza reassortant that caused this pandemic [191, 192]. The third pandemic was the 
1968 “Hong Kong flu” that started in Hong Kong and spread to the rest of world, causing 
pandemics in the winter of 1968-1970. This pandemic killed around one million people 
globally (33,800 deaths in the United States alone) [183]. The responsible IAV was an 
H3N2 reassortant from the previous pandemic strain (H2N2) and an HA gene of avian-
flu origin [191, 192]. The most recent pandemic was the 2009 “Swine flu” that originated 
in Mexico, spread to the United States and then the rest of the world. It was caused by an 
H1N1 reassortant between a North America H1N2 “triple” reassortant and an H1N1 
Eurasian avian-like swine virus that was transmitted from pigs to humans [193]. Owing 
to epidemiological control and availability of antibiotics that treat pneumonia, the total 
number of global respiratory deaths and related cardiovascular diseases (approximately 
0.3 million) was lower than all the past pandemics [194].    
 
Viral proteins and the replication cycle of IAV 
IAVs are negative-strand RNA viruses that have segmented genomes, compared 
to a single cohesive genome of HIV that encompasses multiple genes. IAV is an 
enveloped virus that utilizes a lipid membrane from host cells to enclose viral proteins 
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and the genome. IAV has eight gene segments that encode at least 11 open reading 
frames. Three of them are embedded membrane proteins: hemagglutinin (HA), 
neuraminidase (NA) and matrix 2 (M2). The matrix 1 protein (M1) that lies beneath the 
membrane interacts with the surface proteins as well as ribonucleoproteins (RNPs), so it 
serves as a structural scaffold for a viral particle. Each RNP consist of a viral RNA strand, 
the polymerase complex heterotrimers including polymerase basic protein 2 (PB2), 
polymerase basic protein 1 (PB1) and polymerase acidic protein (PA) and nucleoprotein 
(NP) [37]. As a RNA binding protein, NP serves as the scaffold for the viral RNA. The 
polymerase heterotrimers bind to short hairpins in the 5’ and 3’ untranslational regions 
(UTRs) of each RNA segment. There are two non-structural proteins (NS1 and NS2): 
NS1 plays a variety of functions including enhancing viral mRNA translation, impairing 
host mRNA translation, and mediating type I interferon antagonism; NS2 mainly 
mediates nuclear export of viral RNPs.  
 
During viral entry, HA recognizes sialic acid (SA, N-acetyl neuraminic acid) and 
binds to SA-associated host glycoproteins. After the initial binding, the viral particle is 
internalized into the endosome. An acidic pH environment in the endosome triggers 
conformational change in HA, which mediates protrusion of the hidden fusion peptide 
into the endosomal membrane. Subsequent structural rearrangements in HA facilitates 
fusion of the viral and endosomal membrane. Meanwhile, M2 forms an ion channel to 
facilitate proton influx and acidification of the interior of viral particles, assisting 
dissociation of the M1 from RNP complexes. Viral RNP is released into the cytoplasm 
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and exported into the nucleus. The polymerase heterotrimers enable viral RNA to “hijack” 
host cell machinery for its own replication and transcription: PB2 binds to the 5’ cap 
structure of host mRNAs; PA cleaves the cap structure through its endonuclease activity 
and seizes the cap for priming viral mRNA synthesis (namely “cap snatching”) by the 
RNA-dependent polymerase activity of PB1. Two viral mRNAs (M and NS) are spliced 
to yield M1/2 and NS1/2 respectively. Viral mRNA is then exported into the cytoplasm 
for translation. Of note, “cap-snatching” appears to deplete host mRNA of their caps, 
targeting host mRNA for rapid degradation. “Cap-snatching” and several NS1 related 
“tricks” down-regulate the translation of host mRNAs and redirect the host translational 
apparatus to preferentially translate viral mRNAs in the cytoplasm. The newly 
synthesized polymerase subunits and NP are then imported back into the nucleus for 
catalyzing another round of replication, transcription of viral RNA and formation of RNP, 
while M1 and NS1/2 are imported into the nucleus to assist export of RNP. Notably, NP 
regulates the trafficking of RNPs between the nucleus and cytoplasm.  Surface proteins 
HA, NA and M2 are transported to the cell membrane through endoplasmic reticulum, 
undergoing glycosylation and additional post-translational modifications. At the site of 
viral budding on the cell membrane where HA and NA are enriched, the eight viral RNPs 
are incorporated through viral RNA segment-specific packaging signals, followed by 
M2-dependent membrane scission. NA cleaves SA on cell as well as viral surface 
through its sialidase activity to allow efficient release of viral progenies and to prevent 
aggregation of newly produced viral particles.  
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HA and NA: substrate binding/processing and functional balance  
 HA is a type I membrane glycoprotein (single transmembrane pass with N-
terminus exposed on the exterior side) integrated into the viral membrane. Mature HA is 
a homotrimer and each monomer encompasses two subunits (HA1 and HA2) connected 
by disulfide-bonds (Figure 1.7A). Proteolytic cleavage to generate disulfide-bonds linked 
HA1 and HA2 from the progenitor HA0 is necessary for HA activation. The cleavage of 
HA is generally carried out by exogenous serine proteases that recognize Q/E-X-R motif 
[195]. However, insertional mutations in the HA cleavage site of H5 and H7 subtype 
enable a furin-like (R-X-R/K-R) recognition, a polybasic cleavage site that broadens 
specificity of protease, enhancing intracellular cleavage activation and systemic  
replication [198]. HA recognizes disaccharides made up of SAs and underlying sugars 
including N-Acetylgalactosamine (GalNAc) or galactose. SA is linked to Gal/GalNAc 
with either 2,6 or 2,3-linkage, i.e. SA2,6Gal or SA2,3Gal. SA2,6Gal is 
predominantly expressed in the human upper respiratory tract including the trachea, so 
IAV adapted to infecting humans preferentially expresses SA2,6Gal. SA2,3Gal is 
predominantly expressed in the lower intestinal tract of birds, so IAV adapted to infecting 
birds preferentially expresses SA2,3Gal. A panel of amino acids in the receptor-binding 
site of HA (mainly amino acid position 130-139, 190-199 and 220-229) determines the 
binding specificity and mutations in these positions lead to a switch in binding specificity 
and thus host preference. IAV is largely asymptotic in its natural reservoir, wild birds. 
Transmission to domestic poultry increases the likelihood for secondary transmission to 
mammals including human and swine, and occasionally leads to a highly pathogenic 
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Figure 1.7: HA is a homotrimer while NA is a homotetramer 
 
 
 
 
 
 
 
 
 
Figure 1.7 HA is a homotrimer while NA is a homotetramer. (A) Molecular image based on 
the PDB ID: 1ruz structure of HA [196] shows the three identical monomers of HA. In one 
monomer, the HA1 subunit is colored red while HA2 subunit is colored green. (B) Molecular 
image based on the PDB ID: 3B7E structure of NA [197] shows the four identical monomers of 
NA. Each monomer binds to a NA competitive inhibitor, zanamivir (yellow) at its substrate 
binding pocket.  
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avian strain [198]. Sporadic avian influenza transmission from wild birds and domestic 
poultry to mammals reiteratively introduces novel influenza strains into humans and pigs. 
Expression of both 2,3 and 2,6 glycosidic bonds in epithelial cells lining the upper 
respiratory tract of pigs makes pigs susceptible to infections with both avian and human 
strains, so pigs become “mixing-vessels” or intermediate media for potential incubation 
of human pandemic influenza strains [199]. Most influenza infection in humans is 
restricted to the upper respiratory tract and causes mild to intermediate respiratory 
syndrome. However, highly pathogenic avian strains are able to reach the lower 
respiratory tract and lung (bronchiole and alveolar wall) lined with epithelial cells that 
express SA2,3Gal and cause life-threatening pneumonia and systematic infection [200, 
201].  
 
 NA is a type II transmembrane protein (single transmembrane pass with C-
terminus exposed on the exterior side) that cleaves the 2,3 or 2,6 glycosidic bonds in 
the SA and Gal/GalNAc disaccharide to facilitate release of viral progenies and prevent 
aggregation of virions. Mature NA is a homo-tetramer with a well-defined substrate 
binding site (Figure 1.7B). The crystal structures of NA in apo- or substrates/inhibitors-
bound state have been solved as monomer, dimer or tetramer in diverse subtypes, 
revealing the biophysical details of NA structure and substrate recognition [197, 202-205]. 
Although up to 50% sequence variation exists between different subtypes (e.g. N1 and 
N2), residues that constitute the substrate binding sites are highly conserved in IAV, 
ensuring a conserved three-dimensional structure. The mushroom-shaped NA tetramer 
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encompasses four identical monomers in a square-planar arrangement and is anchored to 
the viral membrane by a long and thin stalk at its N-terminus [197, 205].  The large 
binding pocket is located on the upper surface of each subunit, surrounded by densely 
clustered charged residues. Eight functional residues (including R118, D151, R152, R224, 
E276, R292, R371 and Y406) contact the substrate (SA) and form electrostatic-force-
based hydrogen bonding network to poise the substrate in the appropriate angle for 
catalytic cleavage reaction [206].  Of note, the carboxylate group of C-1 of SA forms a 
salt bridge with R371 as well as charge-charge interactions with R118 and R292. These 
interactions make the greatest contribution to binding of SA to NA [206]. Moreover, 11 
framework residues (including E119, R156, W178, S179, D198, I222, E227, H274, E277, 
N294 and E425) that are also highly conserved in IAV contribute to stabilization of the 
substrate binding site [207]. Catalytic cleavage by NA consists of four major steps [206]. 
(1) R118, R292 and R371 forces SA to undergo conformational change and become 
activated for hydrolysis. The involved energy loss is partially compensated by the 
hydrogen bond network of NA. (2) R151 and R152 activate a water molecule that 
donates protons to the carboxylate groups of SA and induces formation of a transition-
state. The endocyclic sialosyl cation transition-state intermediate is stabilized by E277 
[208]. SA is (3) formed through a SN1 mechanism and (4) released along with a 
transition from -anomer to a more stable -anomer. The detailed information about the 
substrate binding pocket, catalytic steps and active site residues has made NA an ideal 
drug target.  
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 HA and NA co-determine the subtype of IAV and exhibit a delicate functional 
balance. Eighteen HA subtypes and eleven NA subtypes have been identified up to now, 
resulting in 198 possible HA-NA combinations. A large fraction of them have been 
isolated in birds, so they may “splash” to humans after accumulating adapting mutations. 
Phylogenetic evidence suggests birds as the original source of evolved novel IAV strains 
in mammals [183]. HA and NA share the same substrate (SA) and play nearly opposing 
roles (binding of HA to SA versus removal of SA by NA), so there must be a precise 
balance between the relative function of HA and NA, coordinating the relative strength of 
their functions to ensure successful infection [209]. Perturbation to this balance is likely 
to cause either delayed viral entry or insufficient release of viral progenies. Indeed, much 
experimental evidence has demonstrated the importance of HA:NA functional balance. 
Deletions in the stalk region or mutations in the active site frequently reduce enzymatic 
activity of NA and impede propagation of influenza virus in chicken eggs; mutations in 
the receptor binding site of HA that reduces SA binding activity of HA is able to restore 
growth of influenza virus in eggs [210, 211]. Meanwhile, deglycosylating mutations in 
HA often enhance substrate binding, causing impaired viral growth kinetics in susceptible 
cell lines; NA with elongated stalk region or stronger enzymatic activity is able to rescue 
the growth defect [212, 213]. Of note, HA and NA activity is unbalanced in the swine 
precursor of the 2009 pandemic strain, whereas reassortment of a new HA into the 
precursor restores the HA:NA balance, allowing for efficient air-borne transmission of 
the 2009 pandemic strain in human population [214, 215]. Despite these studies 
providing exciting discoveries, they are dependent on limited number of individual 
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mutations, so further studies are warranted to systematically map the coordinating or 
balancing effect between HA and NA and to quantitatively explore the optimal ratio 
between the activity of HA and NA for efficient IAV infection.   
 
Evolutionary pathways of IAV 
 IAV rapidly adapts to varied selection pressures through accumulation of 
mutations or reassortment of gene segments. The mutation rate of influenza is estimated 
to be 10-6 to 10-5 mutations per nucleotide per infectious cycle [216, 217], which is ~200-
fold higher than DNA viruses and ~10,000-fold higher than bacteria and eukaryotes [183]. 
Such high mutation rates, coupled with the large population size of influenza, allow for 
sampling of every possible single nucleotide mutation even in a single replication cycle 
and rapid fixation of spontaneous mutations that provide growth advantage [68]. Humoral 
immunity against IAV depends on pre-existing neutralizing antibodies that bind to 
antigenic sites of HA to thwart viral infections [218]. Antibodies that bind to NA do not 
prevent infection, but reduce illness duration and/or severity [219, 220]. However, IAV is 
able to evade pre-existing immunity through two mechanisms: accumulation of amino 
acid mutations in the antigenic site of HA that impedes recognition of HA and 
reassortment of gene segments encoding HA and NA to create novel combinations of 
surface antigenic glycoproteins. In H3N2, accumulation of mutations in HA (genetic 
evolution) facilitates punctuated dramatic changes in viral sensitivities to antibody 
neutralization (antigenic evolution) and escape from immune response [221, 222]. 
Phylogenetic evidence based on the genetic sequences of HA from H3N2 strains, which 
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were harvested at different dates and locations, highlighted a single central trunk in the 
phylogenetic tree that indicated massive lineage extinction, limited genetic diversity at 
any time point and a single successful lineage that continuously evades human immunity 
[223-225]. Other influenza viral proteins also exhibited high rates of substitutions, which 
indicates functional constraints on possible combinations of influenza gene segments, 
optimal compatibility to accommodate escaping mutations in HA and a potential buffer 
of fitness loss conferred by HA mutations [224].   
 
Antiviral agents against IAV 
 Two types of inhibitors have been developed for the prophylaxis and treatment of 
influenza infection: M2 ion channel inhibitors and NA inhibitors. M2 ion channel 
inhibitors include Amantadine [226], rimantadine [227] and adamantane derivatives 
[228]. These agents block the ion channel pore of the M2 helix bundle and prevent H+ 
ions from being imported into the endosome with internalized influenza virions. 
Inhibition of ion transport impedes pH drop and associated conformational change of HA, 
which is necessary for uncoating of viral particles [229, 230]. The usage of amantadine 
and rimantadine has been limited due to rapid emergence and transmission of replication 
competent and pathogenic drug resistance mutations, mainly M2 mutation S31N [231, 
232]. In addition, adamantanes cause severe central nervous system (CNS) side effects, 
which further limit its use [227]. NA inhibitors include FDA approved oseltamivir, 
zanamivir and peramivir; laninamivir is approved in Japan and still under clinical trial in 
the United States. All of these inhibitors compete with the natural substrate sialic acid 
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(SA) in NA binding, inhibiting NA enzymatic activity to obstruct release of viral 
progenies. Both zanamivir and oseltamivir are highly specific and potent inhibitors of NA 
with IC50 ≤ 1ng/ml. They inhibit viral replication in vitro and in animal models (mice 
and ferrets). Both are well tolerated and highly effective in prophylaxis (reducing the 
number of illnesses) and treatment (shortening illness duration) of influenza infection in 
humans [233]. In particular, early administration of NA inhibitors has been shown to 
more effectively reduce the duration of illness, the severity of syndromes (fever and 
sinusitis) and complications (bronchitis and pneumonia), the burden on healthcare 
systems (elevated demand on antibiotics and hospitalization), and the transmission 
among healthcare or household contacts [234, 235]. Post-exposure usage of oseltamivir 
has also been shown to prevent household transmission [236].     
 
Competitive inhibitor of NA 
The first available NA inhibitor is zanamivir (trade name: Relenza), which was 
approved by the FDA in 1999. The discovery and development of zanamivir serve as one 
of the most successful examples of structural based drug design. Two derivatives of sialic 
acid (Neu5Ac, Figure 6.1), 2-deoxy-2,3-didehydro-N-acetylneuraminic acid (Neu5Ac2en, 
DANA) and 2-deoxy-2,3-didehydro-N-trifluoroacetylneuraminic acid (FANA) inhibit 
NA function at micromolar concentrations and have become the core leads for 
development of more potent inhibitors [237]. The Crystal structure of NA bound to SA 
with improved resolution [238] has enabled computational chemistry based structural 
modification of the micromolar potent leads to obtain nanomolar potent compounds [239]. 
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Particularly, the interactions between residues within the NA substrate binding pocket 
and functional groups of inhibitors are refined to be energetically favorable (Figure 1.8) 
[240]. The key discovery was the capability of the C-4 hydroxyl group of DANA to 
accommodate a larger basic group. Replacement of the hydroxyl group by a guanidinyl 
group markedly enhances the affinity of the inhibitor to NA (Figure 6.1) [239]. The 
increased affinity is estimated to be a result of fully occupying the active site by the 
larger basic moiety, which interacts with E119 and E228 of NA[206, 241]. Zanamivir is 
10000 fold more potent compound in vitro and in vivo [242]. In addition, zanamivir is 
highly specific for influenza NA, exhibiting limited affinity to sialidase from other 
sources [244] including the human sialidase, which reduces the likelihood of severe side 
effects [245]. Zanamivir is formulated as an inhaled powder (10mg twice daily) due to its 
highly polar nature and limited oral bioavailability. Inhalation delivers the drug directly 
to the upper respiratory system where the infection predominantly occurs. Intravenous 
delivered zanamivir was developed and approved during the 2009 swine flu pandemic for 
patients unable to take inhaled zanamivir.     
 
The second FDA approved NA inhibitor is oseltamivir (trade name: tamiflu), an 
orally administered drug for treating IAV. It is more commonly used in the clinic and 
stockpiled by many countries in preparation for future pandemics [246]. Based on 
cyclohexenes, oseltamivir is designed to mimic the predicted transition state sialosyl 
cation using extensive medicinal chemistry optimization [247]. Moreover, the glycerol 
group at C-6 of SA and zanamivir is replaced with a highly hydrophobic pentyloxy  
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Figure 1.8: Differential binding interactions of oseltamivir and zanamivir with NA 
 
 
 
 
 
 
 
 
 
Figure 1.8 Differential binding interactions of oseltamivir and zanamivir with NA. 
Molecular image of NA bound to oseltamivir (A, PDB ID: 3TI6) and zanamivir (B, PDB ID: 
3TI5) [243]. The competitive inhibitors are colored yellow in the center of the binding pocket. All 
contact residues of NA with the substrate are highlighted as sticks, with each amino acid labeled. 
The hydrogen bonds formed are shown as black dashes. Hydrogen bonds are formed between 
oseltamivir/ zanamivir and Arg118, Arg151, Arg152, Arg293, and Arg372. For oseltamivir, its 
C6 pentolxy group interacts with Arg225 and fits into the hydrophobic pocket near Glu277. For 
zanamivir, its C6 glycerol group forms hydrogen bonds with Glu277.   
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substituent to improve lipophilicity (Figure 6.1) [247]. Owing to this hydrophobic group 
at C-6 of oseltamivir, binding of oseltamivir to NA induces conformational change. E277 
orients away from the active site; the hydrophobic group at C-6 interacts with R225, 
generating a hydrophobic pocket to accommodate itself (Figure 1.8A) [247, 248]. This is 
distinct from hydrogen bond interactions between E277 and the glycerol group of 
zanamivir or SA [238]. The oseltamivir induced conformational change potentially 
exposes an Achilles heel for evolution of drug resistance. Interestingly, replacing the 
hydrophilic glycerol group with a hydrophobic pentyloxy group does not provide enough 
oral availability, so a more oral available prodrug was synthesized by adding an ethyl 
ester group at the termini of the carboxyl group at C-3. The ethyl ester group is cleaved 
by endogenous esterases to generate the active form in vivo. Oseltamivir is orally 
administered (75mg or 150mg twice a day).   
 
Resistance mutations of influenza to NA inhibitors  
Multiple mutations with reduced sensitivity to NA inhibitors (NAI) imposes a 
significant threat to sustained use of NAI for treatment and prophylaxis of influenza 
infection. These mutations are broadly categorized as drug resistance mutations. 
Detection of drug resistance mutations relies on in vitro drug titration experiments. 
Briefly, influenza virus is isolated from patient samples and subject to biochemical assays 
(fluorescent, chemiluminescent, colorimetric) to measure the enzymatic activity of NA as 
a function of increasing dose of NA inhibitors [249]. The 50% inhibitory concentrations 
(IC50) can be determined from the dose-response curve: samples with IC50 greater than 
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the normal range of the sensitive wild-type strain show drug resistance potential. WHO 
established a relatively more quantitative metric: samples with IC50 10-100 fold above 
the normal range are classified as showing reduced inhibition and samples with IC50 
greater than 100-fold above the normal range are classified as showing highly reduced 
inhibition. Samples that show (highly) reduced inhibition are subject to Sanger 
sequencing to identify resistance mutations that confer the reduction in drug sensitivity. 
Both oseltamivir and zanamivir exhibited low frequency of resistance in early clinical 
trials in adults (less than 1%) and higher frequency in children (approximately 4%) [250, 
251].  
 
In spite of the low frequency of resistance for oseltamivir and zanamivir, the 
concern for the emergence and circulation of influenza mutants with resistance to NAI 
continued. Of note, binding of oseltamivir for NA induces a conformational change of 
NA that is not necessary for natural substrate binding, so it appears to be more prone to 
drug resistance. For the first few years, oseltamivir resistance mutations were only 
identified by reverse genetics experiments in cell culture [252]. Resistance substitutions 
in HA reduced the substrate binding affinity of HA, attenuating the dependency of IAV 
on NA for release of viral progenies [253], whereas resistance substitutions in NA 
directly decreased the affinity of NA to oseltamivir [254]. However, a 2004 study 
conducted in Japan, which sequenced HA and NA of H3N2 IAV from 50 pediatric 
samples, revealed mutations in NA associated with drug resistance in 9 samples, 
indicating that about 18% of patients treated with oseltamivir developed drug resistance 
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mutations [255]. This was the first time that a large number of drug resistance mutations 
were isolated from patients. Before 2008, only Japan and the US had intensive usage of 
oseltamivir. Sporadic cases of drug resistance mutations were identified in oseltamivir 
treated patients, mainly in immunosuppressed patients that under prolonged treatments 
[246]. However, during the 2007-2008 influenza season, a strain that harbored a known 
drug resistance mutation became the dominant strain that circulated globally [256, 257]. 
For example, high frequency of resistant strains was reported in Norway despite 
negligible usage of oseltamivir [257]. Fortunately, the frequency of resistant strains fell 
significantly the next influenza season and stayed relatively stable between 1-10% after 
that, but resistance mutations have been constantly isolated from untreated people in 
several geographically separate countries such as the US and Australia [258-260]. 
Because of increasing reports of oseltamivir resistance mutations, considerable efforts 
have been invested to characterize various properties of isolated drug resistant mutations 
using interdisciplinary approaches including virology, animal model, structural biology, 
biochemistry, experimental evolution and bioinformatics.  
 
Common oseltamivir resistance mutations  
The predominant oseltamivir resistance mutation in the N1 subtype is H275Y (N1 
numbering, Figure 1.9). This histidine to tyrosine mutation at position 275 of NA was 
first reported in 2001: healthy volunteers experimentally infected with an H1N1 IAV and 
treated with oseltamivir developed low frequency of H275Y (~4%) [261]. However, this 
mutation was not detected in patients treated with oseltamivir until the influenza season  
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Figure 1.9: Residues with known oseltamivir resistance mutations are clustered in 
the substrate binding site 
 
 
 
 
 
 
 
 
 
Figure 1.9 Residues with known oseltamivir resistance mutations are clustered in the 
substrate binding site. Molecular image based on the PDB ID: 3CL0 structure of NA [264] 
shows the binding substrate, oseltamivir (yellow) and residues with known oseltamivir resistance 
mutations (purple).  
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of 2005-2006. H275Y exhibits highly reduced inhibition by oseltamivir (IC50 > 400 fold 
than the sensitivity wild-type virus) [262]. H275Y has only been associated with 
oseltamivir resistance in N1 subtype [263]. The frequency of H275Y has been primarily 
modest, ranging from 1-10% in the tested population, though it is the only drug resistance 
mutation with greater than 1% frequency in humans [258-260]. One plausible explanation 
is that H275Y reduces the surface enzymatic activity of NA, leading to attenuated 
replication and transmission of the mutant IAV, which was confirmed by several in vitro 
and in vivo studies [252, 262, 265]. However, the frequency of the H275Y mutation was 
greater than 50% during the influenza season of 2007-2008 and caused tremendous 
concern that this mutation would circulate globally and render oseltamivir ineffective 
[256, 257]. The H1N1 IAV with H275Y exhibits very little defect in replication, 
transmission and virulence compared to the wild-type [266-270], resulting in its sustained 
circulation in the human population. Collins et al. solved the crystal structure of N1 with 
H275Y and uncovered the biophysical underpinnings of reduced affinity of H275Y to 
oseltamivir. The bulkier side chain of Y275 pushes the carboxyl group of E277 further 
into the active site; protrusion of the charged group into the binding site disrupts the 
hydrophobic pocket to accommodate the hydrophobic pentyloxyl group at C-6 of 
oseltamivir, severely impeding the binding affinity of oseltamivir for oseltamivir [202]. 
This has little effect on binding of zanamivir to NA because movement of Y275 and 
E277 does not interfere with the hydrogen bond interactions between the glycerol group 
of zanamivir and the carboxyl group of E277 [202]. Moreover, Y253 lies beneath residue 
275 and disrupts the hydrophobic binding pocket together with Y275 in N1. However, 
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T253, with a smaller side chain in N2, preserves the binding pocket and therefore enables 
accommodation of H275Y in N2 [202]. Taken together, the combined steric effects at 
residues 275 and 253 determine the binding affinity of H275Y for oseltamivir in a 
subtype specific manner.  
 
E119V and R293K are N2 subtype specific oseltamivir resistance mutations 
(Figure 1.9). They were first isolated from children in Japan under treatment with 
oseltamivir in 2004. Since that time they have showed a low prevalence in H3N2 IAV 
infected patients treated with oseltamivir [255]. Both mutations highly reduced sensitivity 
of NA to oseltamivir (IC50 > 500 fold compared to the sensitive wild-type strain) in 
H3N2 subtype. However, they imposed different impacts on replication and transmission 
capacity of H3N2 IAV. R293K caused severely compromised replication and virulence in 
in vitro viral growth experiments and in vivo mice experiments [21, 265, 271]. R293K 
also showed attenuated transmission in animal models [265, 271, 272]. In contrast, 
E119V maintained comparable replication and transmission fitness compared to wild-
type virus [265, 271]. R293K appeared to be completely lethal in N1 subtype, so its 
sensitivity to oseltamivir was not evaluated in the N1 [262]. E119V was lethal in lab 
adapted H1N1 strains (e.g. WSN) [262], but was viable in the 2009 pandemic H1N1 
strain (pH1N1) [273]. Although E119V displayed considerable resistance to oseltamivir 
in pH1N1 (approximately 60 fold increase in IC50), strong fitness cost probably impeded 
its spread in humans [273]. Crystal structural analysis on group1 NA (including N1) and 
group2 NA (including N2) shed light on the structural basis of reduced binding of R293K 
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for oseltamivir in N2, but not N1 [203]. Apparently, K293 abolishes a hydrogen bond 
between the side chain of wild-type arginine and the carboxylate group at the C-4 of 
oseltamivir and changes the conformation of E277 to push away the pentyloxyl group at 
C-6 of oseltamivir. However, a conserved tyrosine at residue 348 in N1 forms a hydrogen 
bond with the carboxyl group of oseltamivir and partially compensates for the loss of 
interactions due to R293K mutations. No such compensations are observed in N2.   
 
 N295S confers resistance to oseltamivir in multiple subtypes, though its 
frequency is very low in humans (Figure 1.9). It was first isolated from H3N2 infected 
children treated with oseltamivir [255], later from H5N1 infected patients [274] and then 
from pandemic H1N1 infected patients [275]. N295S induces intermediate to strong 
resistance in these subtypes (IC50 increases by 20-300 fold) [255, 263, 273, 276]. N295S 
only causes mild defect to viral replication and virulence in lab-adapted H1N1 strains 
[263], but exhibits comparable replication capability in pH1N1 and H5N1[273, 276]. 
There has been no study on the effect of N295S on IAV transmission in animal models, 
so it is not clear whether N295S impairs transmission of IAV. The structural mechanism 
of reduced binding of N295S for oseltamivir has been solved using the crystal structure 
of N1 bound to oseltamivir [202]. The side chain of the wild-type asparagine stabilizes 
the conformation of Y348, which coordinates the bound calcium ion and forms a 
hydrogen bond with the carboxyl group at C-4 of oseltamivir; substituted serine instead 
forms a hydrogen bond with E277 and drives Y348 away, which leads to a weaker 
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hydrogen bond interaction between Y348 and oseltamivir, reducing the binding of N295S 
for oseltamivir.    
  
 Position 223 of NA is a hotspot for mutations with reduced sensitivity to 
oseltamivir (Figure 1.9). The wild-type residue, isoleucine, is part of a smaller pocket that 
contributes to accommodation of the pentyloxyl group at C-6 of oseltamivir [277]. I223R 
was the first isolated mutation with reduced binding of NA for oseltamivir (45-48 fold 
increase in IC50) [277-279]. In the pH1N1, I223R showed comparable in vitro 
replication kinetics and transmission capacity among ferrets, although its virulence was 
slightly milder compared to that of wild-type in a ferret pathogenic model [279]. 
Biochemical assays showed a two-fold increase in KM for I223R, indicating slightly 
reduced binding of NA for the natural substrate [277]. The crystal structure of N1 with 
I223R bound to oseltamivir demonstrated that R223 shrinks the small hydrophobic 
pocket that accommodates the pentyloxyl group of oseltamivir and interacts with residue 
S247 to hinder binding of oseltamivir [277]. Other mutations at this residue also convey 
oseltamivir resistance in different subtypes. For example, I223T and I223M exhibited 
reduced oseltamivir binding in a H5N1 strain [280]; I223K and I223T showed decreased 
sensitivity to oseltamivir in a pH1N1 strain [281]. In summary, mutations at residue 223 
appear to change local conformation and disrupt the smaller pocket that is important for 
oseltamivir binding. There are also sporadic cases of other spontaneous mutations that 
confer reduced sensitivity to oseltamivir, although with very low frequency [249, 282, 
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283]. The vast majority of spontaneous mutations exhibit attenuated replication fitness in 
vitro viral and/or in vivo, indicating that they are unlikely to circulate in human 
populations.  
  
Standing Questions and the Scope of this Dissertation 
The sequence-function relationship of proteins has been under intensive 
investigation since the dawn of molecular biology and maturation of DNA sequencing. It 
is a central question that holds keys to unlock breakthroughs for many branches of 
biological studies such as the effect of protein functions on organismal fitness and 
evolutionary trajectories. Numerous methods have been developed to approach this 
question, including mutagenesis, protein surface display, structural analysis, directed 
evolution and computational prediction, yielding countless exciting findings, which 
substantially enrich and advance our understanding of protein sequence-function 
relationship and impact of protein function on organismal fitness. However, it remains an 
open question owing to the tremendous sequence space and inherent difficulty in 
measuring biochemical functions of many proteins.  
 
Mutagenesis coupled with functional selection is a powerful and widely used tool 
in mapping the sequence-function relationship, but a major technological caveat is its 
throughput. The development of high throughput mutagenesis approaches that couple 
bulk competition of systematically engineered mutations with deep sequencing to 
determine the fitness of each mutation enables parallel functional characterization of 
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large numbers of mutations (on the magnitude of hundreds to millions) in a short time 
window. The high throughput mutagenesis approaches open up new avenues to 
efficiently map sequence to fitness relationship, incorporate additional factors (e.g. 
protein expression) into mutagenesis analysis, identify adaptive mutations to distinct 
selection pressures (e.g. beneficial mutations in RNA virus under therapeutic selection 
pressure) and elucidate unexplored sequence space available for protein evolution.  
 
The work presented in this dissertation focused on applying high throughput 
systematic mutagenesis approaches to understand the sequence-function relationship and 
explore sequence space for molecular adaptation in diverse proteins and organisms. I first 
applied the EMPIRIC approach to investigate a fundamental question of the interplay of 
the relationship of protein sequence-function relationship between protein expression and 
sequence on organismal fitness, which I describe in Chapter II. Chapter III and IV 
describe optimization of the EMPIRIC approach: Chapter III reports mapping the 
functional constraint on the CD4 binding loop and flanking regions of the trimeric env 
complex of HIV; Chapter IV describes using this approach to quantify fitness of 
mutations in the active site and proximal regions of NA in IAV in the presence or 
absence of a NA competitive inhibitor (oseltamivir) to screen for beneficial mutations 
that adapt to drug selection. A summary and discussion of my results are presented in 
Chapter V. 
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Chapter II  
 The impact of protein expression or sequence on protein total function and 
organismal fitness has been separately characterized, but their integrated effects have not 
been systematically interrogated. Several studies have demonstrated that the expression 
of essential proteins have been optimized for maximal growth, while other studies 
showed that even half reduction in protein expression led to negligible effects on 
organismal growth rate. The apparent contradiction may be reconciled by systematic 
quantification of fitness effect of mutations with varied expression levels to probe the 
interaction between protein expression and sequence. Moreover, stability has been 
proposed as the predominant determinant of distribution of fitness effect with the 
assumption that mutations that directly affect protein activity are rare. Effect of mutations 
on protein activity can be derived from mutational fitness estimated at altered protein 
expression levels and used to examine this critical assumption as well as prevalence of 
mutations that directly affect protein activity.  
 
Chapter III 
 The CD4 binding loop (GGDPE) of the HIV trimeric spike mediates a large 
proportion of the binding interactions between CD4 and the trimeric spike. The CD4 
binding loop is highly conserved across different clades of HIV, but its N- and C-terminal 
flanking regions harbor variable sequences. Previous structural and functional studies 
have identified residues of functional importance in the flanking region of the CD4 
binding loop. For example, a number of N-terminal residues modulate exposure of the 
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trimeric spike to CD4, while several C-terminal residues are part of the Phe43 cavity as 
well as epitopes of neutralizing antibodies. These residues contribute to the determination 
of the affinity of the trimer complex to CD4 and several neutralizing antibodies. However, 
there is an absence of systematic studies delineating the detailed biophysical constraints 
on these regions. EMPIRIC is optimized for investigating mutational effects on HIV 
replication and enables comprehensive study of functional constraints on the CD4 
binding loop and its flanking regions. 
 
Chapter IV  
 Drug resistance has been a daunting problem that severely reduces efficacy of 
precious drugs developed with the expense of billions of dollars. This is especially true 
for oseltamivir, the only orally available drug that competitively inhibits NA enzymatic 
function and helps treatment and control of influenza infection. Comprehensive isolation 
and characterization of mutations with reduced sensitivity to oseltamivir will facilitate 
clinical monitoring of oseltamivir resistance, appropriate administration of alternative NA 
competitive inhibitors to minimize selection of pre-existing oseltamivir resistance 
mutations, and the rationale for the design of new inhibitors and/or improvement of 
existing ones. The current standard approach to identify oseltamivir resistance mutations 
is biochemically measuring the sensitivity of the virus isolated from persons treated with 
oseltamivir, and Sanger sequencing of viruses to pinpoint mutations with reduced 
sensitivity resistance. There are two major caveats associated with this approach. Firstly 
it only evaluates the sensitivity of mutations to drug inhibition, which fails to take into 
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account the fitness of mutations in the presence or absence of drugs. In this chapter, I 
argue that the relative fitness of mutations under oseltamivir selection pressure, which 
integrate various factors beyond just biochemical sensitivity to drugs, should more 
accurately determine if these mutations out-compete the drug sensitive wild-type, while 
the relative fitness of mutations without oseltamivir selection should determine the 
likelihood of fixation and spread of these mutations in treatment-naïve populations. 
Secondly, manual isolation, biochemical characterization and Sanger sequencing of 
individual patient samples is tedious and time-consuming, significantly delaying the 
investigation of oseltamivir resistance mutations. To more systematically identify 
oseltamivir resistance mutations and interrogate the underlying biochemical mechanisms, 
we optimized EMPIRIC to determine the fitness effects of large number of mutations in 
the active site of NA, where oseltamivir adaptive mutations are most likely to occur, in 
the presence and absence of oseltamivir. Drug adaptive mutations are then subjected to 
biochemical assays to examine various features that may contribute to reduced sensitivity 
to oseltamivir. 
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Chapter II - Latent effects of Hsp90 mutants revealed at reduced 
expression levels 
 
 This chapter has been published previously as Jiang L*, Mishra P*, Hietpas RT, 
Zeldovich KB, Bolon DNA.”Latent effects of Hsp90 mutants revealed at reduced 
expression-levels”. PLoS Genet. 2013;9:e1003600. (* equal contribution) 
 
 The work presented in this chapter was a collaborative effort. I performed the 
yeast growth competition, lysis of yeast cells and DNA extraction, DNA sequencing 
library preparation and sequencing, and sequence analysis. Dr. Parul Mishra performed 
growth rate analysis of wild-type yeast strain and biochemical analyses including western 
blots, FACS analysis, and circular dichroism. Dr. Ryan T. Hietpas contributed to the 
yeast growth competition experiments and cloned individual Hsp90 mutations for protein 
expression, purification and circular dichroism analysis. Dr. Konstantin Zeldovich 
performed Rosetta analysis to estimate G of individual Hsp90 mutations. Dr. Daniel 
N.A. Bolon constructed the model and computed the estimate of protein function per 
molecule. I, Dr. Parul Mishra, Dr. Ryan T Hietpas, Dr. Konstantin Zeldovich, and Dr. 
Daniel N. A. Bolon analyzed the data and prepared the manuscript.  
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Abstract 
In natural systems, selection acts on both protein sequence and expression level, 
but it is unclear how selection integrates over these two dimensions. We recently 
developed the EMPIRIC approach to systematically determine the fitness effects of all 
possible point mutants for important regions of essential genes in yeast. Here, we 
systematically investigated the fitness effects of point mutations in a putative substrate 
binding loop of yeast Hsp90 (Hsp82) over a broad range of expression strengths. 
Negative epistasis between reduced expression strength and amino acid substitutions was 
common, and the endogenous expression strength frequently obscured mutant defects. By 
analyzing fitness effects at varied expression strengths, we were able to uncover all 
mutant effects on function. The majority of mutants caused partial functional defects, 
consistent with this region of Hsp90 contributing to a mutation sensitive and critical 
process. These results demonstrate that important functional regions of proteins can 
tolerate mutational defects without experimentally observable impacts on fitness. 
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Introduction 
Genetic changes that alter protein sequence or expression level can lead to 
adaptation, suggesting these protein properties are central to evolutionary processes. 
Many studies have individually investigated the effects of changes to either protein 
sequence or expression level. For example, protein sequences have been optimized under 
selective pressure using in vitro evolution[284]. In addition, changes in protein sequence 
relative to synonymous substitutions are a hallmark of positive selection in natural 
populations[285, 286]. The influence of protein expression level on fitness has also been 
well documented[287]. For example, changes to the expression level of the Agouti 
protein (but not its sequence) have been shown to affect fitness in wild mice by 
modulating coat coloration[84]. In addition, experiments in E. coli demonstrate that 
expression from the lac operon is rapidly tuned for optimal growth over a wide range of 
lactose concentrations[86]. While most studies to date have focused individually on either 
expression level or protein sequence, in principle the fitness effects of these two protein 
properties are interdependent[85, 288]. Here, we systematically investigate selection on 
the sequence and expression level of yeast Hsp90 (Hsp82).  
 
 We recently developed an approach termed EMPIRIC[51], which is a genetic 
screen that provides fitness measurements of all possible amino acid substitutions in short 
regions of important genes in yeast. By sampling across the variety of different amino 
acid substitutions, EMPIRIC provides detailed information about the physical constraints 
on protein function. We previously reported a bimodal distribution of fitness effects 
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(DFE) for an evolutionarily conserved region of the yeast Hsp90 gene[51], an essential 
chaperone required for the maturation of many kinases[289-291]. Bimodal DFEs, where 
most mutants have fitness effects close to either null or wild type (WT), appear common 
in nature as they have been observed in many other fitness studies[93, 292-295]. 
 
Bi-modal DFEs are consistent with a recently proposed model where the impacts 
of mutations on protein stability have a dominant impact on fitness[296]. This model is 
founded on two concepts: positions that contribute directly to rate-limiting steps in 
protein function are rare; and the natively folded structure is required for function. Under 
these conditions, selection results in stably-folded proteins[297, 298], such that modestly 
destabilizing mutations can be tolerated without dramatic changes to the fraction of 
natively folded protein molecules and hence function. Because protein folding is 
cooperative there is a narrow range of stability where both the folded and unfolded state 
are highly populated, consistent with relatively few mutations having intermediate 
function. In this stability-dominated model, mutations to critical functional positions (e.g. 
catalytic sites in enzymes) destroy activity, but are presumed rare and so do not 
contribute greatly to the DFE. Of note, the prevalence of positions in proteins that 
directly contribute to rate-limiting steps in protein function and the fragileness of these 
positions to mutation have not been thoroughly investigated. 
 
The effects of mutations on protein function can be investigated based on fitness 
effects; however, fitness effects need not correspond directly to functional effects. For 
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example, many essential proteins can be dramatically reduced in net function (defined 
here as the product of expression level and function per molecule) without dramatic 
reductions of fitness[90, 91, 93, 299, 300]. Heterozygotes with one null allele are often 
highly fit, indicating that 50% reductions in net function can be tolerated[94]. The 
relationship between fitness and the net function of a protein is formally an elasticity 
function[299]. Around the wild type net function, the elasticity function often has a slope 
less than one indicating that reductions in net function have dampened impacts on 
fitness[89, 301]. Experimental analyses of fitness effects are also constrained by 
experimental measurement precision, which is currently on the order of 1%[302]. In 
natural systems, the resolution of selection depends upon the inverse of effective 
population size and is on the order of 10-7 for yeast[303, 304]. Thus, the effects of 
mutations on function that are important in natural selection can be hidden to 
experimental fitness analyses. For example, the net function of lysozyme in phage T4 
must be reduced about 30-fold before experimentally measurable impacts on growth are 
observed[93]. At the endogenous expression level in this system, large defects in per 
molecule function are hidden to experimental fitness analyses. 
 
We searched for hidden fitness effects in Hsp90 by examining the Hsp90 elasticity 
function. We varied the expression level of the native protein sequence and monitored 
effects on yeast growth rate. Determining theHsp90 elasticity function enabled us to 
estimate mutant effects on per molecule function from fitness measurements. The 
elasticity function was non-linear such that at the endogenous expression level, mutant 
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defects up to 79% in per molecule function were hidden to experimental fitness analyses. 
To reveal potentially hidden functional defects of mutants, we repeated EMPIRIC 
analyses at reduced expression strengths, which systematically varied fitness sensitivity 
to amino acid substitutions in Hsp90. Using this approach, we were able to construct a 
full distribution of mutant effects on function for a region of Hsp90. Structural analyses 
suggest that the region we chose to analyze is a putative substrate binding loop[305]. Our 
experimental fitness analyses at the wild type expression level resulted in a bimodal DFE, 
which is a hallmark of a scaffolding region with stability dominated effects on 
fitness[296]. By analyzing fitness at varied expression strengths, we found that the 
majority of Hsp90 point mutants had intermediate (10-90%) defects in per molecule 
function that were hidden to our analyses at wild type expression level. These 
observations indicate the region of Hsp90 we analyzed is involved in a rate-limiting step 
in function, and supports its putative role in binding to substrates[305]. Because many 
mutant defects may be hidden to experimental measurement at the wild type expression 
level, our results suggest that rate-limiting functional sites in proteins may be more 
prevalent than previously appreciated, and provides a useful guide for interpreting the 
growing field of systematic mutant analyses[51, 57-59, 306-309]. 
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Results and Discussion 
While our initial EMPIRIC study [51] was performed with a temperature sensitive allele 
of Hsp90 co-expressed with all mutants; here, we report results in an Hsp90 shutoff strain 
where mutants were analyzed without potential co-expression artifacts.  We developed a 
yeast shutoff strain (DBY288) where the only chromosomal copy of Hsp90 is regulated 
by a strictly galactose-dependent promoter [310]. In galactose media, the DBY288 strain 
expressed Hsp90 at endogenous levels and grew robustly. When switched to dextrose 
media, the DBY288 strain stalled in growth with Hsp90 levels rapidly dropping below 
detection (Figure 2.1).  This strain enabled plasmid encoded Hsp90 variants to be 
maintained and amplified under non-selective conditions (galactose media).  Switching to 
dextrose media then applied selective pressure on the plasmid encoded Hsp90 variants.  
We analyzed the fitness effects of Hsp90 point mutants by performing a bulk competition 
in the DBY288 strain.  A library of plasmids containing all possible single codon 
substitutions at amino acid positions 582-590 (Figure 2.2A) was transformed into a single 
batch of yeast.  These experiments used a plasmid and promoter construction previously 
shown to match the endogenous expression level of Hsp90 [311].  Transformed yeast 
cells were preferentially amplified in galactose media that allowed all mutations 
including null alleles to propagate.  The bulk culture was transferred to shutoff conditions 
to initiate selection on the mutant library. The beginning of strong selection on the mutant 
library was estimated from the growth plateau of control cells harboring a null rescue 
plasmid (Figure 2.1). After the initiation of selection on the mutant libraries, samples  
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Figure 2.1: Hsp90 shutoff strain 
 
 
 
 
 
 
 
 
Figure 2.1 Hsp90 shutoff strain. (A) The DBY288 strain grows robustly in dextrose when 
provided with a rescue plasmid that constitutively expresses Hsp90, but stalls in growth with a 
null-rescue plasmid. (B) Expression level of Hsp90 in DBY288 is near-endogenous in media with 
galactose (SRGal), but below Western blot detection after 19 h in dextrose media (SD).  
 
 
 
 
 
 
 
 
74 
 
Figure 2.2: Fitness effects of Hsp90 amino acid substitutions 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.2 Fitness effects of Hsp90 amino acid substitutions. (A) The fitness effects of all 
possible amino acid substitutions were analyzed for the region highlighted in cyan. This 
representation is based on the crystal structure of yeast Hsp90[104]. (B) At endogenous 
expression strength, the distribution of fitness effects was bimodal with many mutations resulting 
in either WT-like (green) or null-like [38] growth rates.  
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were harvested over the following 36 hours and the relative abundance of each mutant 
quantified using focused deep sequencing. By comparing the trajectory of each mutant 
relative to wild type, we directly determined competitive advantage or disadvantage of 
each amino-acid substitution as an effective selection coefficient (s) that represents the 
competitive asexual growth advantage/disadvantage of each mutant in a defined 
environment [302]. We have previously demonstrated that the EMPIRIC approach 
provides highly reproducible measures of fitness effects that strongly correlates with the 
growth rate of individual mutants grown in monoculture [312]. Consistent with our 
previous work, effective selection coefficients were highly reproducible (R2=0.96) in a 
full experimental repeat (Figure 2.3).  At the endogenous expression strength, the 
distribution of fitness effects for this region of Hsp90 was bi-modal (Figure 2.2B, Table 
2.1), with peaks near wild type and null. Bi-modal fitness distributions are predicted 
based on a model where fitness effects are dominated by the impact of mutations on 
protein stability [296]. Thus, our fitness analyses at wild type expression level are 
consistent with this region of Hsp90 serving a primarily scaffolding purpose. 
To further probe the relationship between the net function of Hsp90 and fitness, we 
varied expression level of the WT sequence and analyzed impacts on growth rate (Figure 
2).  To vary expression level, we swapped both promoter and terminator (3’ untranslated) 
sequences.  Closely following the start of strong shutoff selection (19 hours in dextrose), 
we observed a 2-fold range in growth rate with these constructs (Figure 2.4A) and a 100-
fold range in expression level (Figure 2.4B). We quantified expression level using a 
Western blot assay directed against an 6xHis epitope tag only present on the rescue copy  
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Figure 2.3: Correlation between effective selection coefficients measured in a full 
experimental repeat at endogenous expression level 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.3 Correlation between effective selection coefficients measured in a full 
experimental repeat at endogenous expression level. Strongly deleterious mutants rapidly 
deplete in bulk competition and are not monitored as precisely as more fit mutants. Relative 
selection coefficients are strongly reproduced in these full experimental repeats performed on 
different days. The slope of this correlation is 1.7, likely due to a linear influence from estimates 
of the WT growth rate in these separate experiments. 
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Table 2.1: Relative Expression Measurements 
 
Relative Expression Measurements 
Construct GFP/FACS Western Average 
GPD 1 1 1 
TEF 0.31 0.32 0.32 
TEFΔter 0.12 0.067 0.094 
CYC 0.055 0.032 0.044 
ADH 0.014 0.014 0.014 
CYCΔter 0.026 0.013 0.019 
ADHΔter 0.014 0.001 0.008 
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Figure 2.4: Effect of reduced Hsp90 expression on yeast growth 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.4 Effect of reduced Hsp90 expression on yeast growth. (A) Growth of Hsp90 shutoff 
yeast harboring rescue Hsp90 plasmids with varied promoters with or without a terminator in the 
3’ UTR. Yeast were grown at 30 °C and monitored by optical density at 600 nm. (B) Hsp90 
expression in cells grown in dextrose for 19 hours was monitored by Western blotting. (C) 
Relationship between observed Hsp90 expression level and growth rate.   
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of Hsp90 that we had previously optimized to yield a linear response [313]. These 
expression level measurements were performed after 19 hours in dextrose, where the 
second copy of Hsp90 driven by the galactose regulated promoter was undetectable 
(Figure 2.1). To further investigate expression level, we developed an Hsp90-GFP fusion 
construct that we monitored by flow cytometry. Across all promoter constructs, the 
Hsp90-GFP fusion supported similar yeast growth rates to non-GFP tagged versions 
(Figure 2.5). These findings indicate that the GFP fusion has minimal impacts on Hsp90 
function. The expression levels determined by GFP and flow cytometry were in close 
agreement with those measured by Western blotting and the average of both measures 
was used to estimate expression levels (Table 2.1). 
Both the Western and GFP experiments demonstrate that the expression level of Hsp90 
can be reduced dramatically (15-fold) without major impacts on growth rate, which is 
consistent with previous reports [91, 314]. The growth rate to Hsp90 expression level 
profile that we determined has the shape of a binding curve (Figure 2.4C), and can be fit 
to a binding equation that represents the elasticity function for Hsp90. This elasticity 
function defines how yeast growth rate varies with the net Hsp90 function and enabled us 
to calculate per molecule function of mutants from fitness measurements. 
The non-linear elasticity function for Hsp90 describes the coupling of mutant effects on 
function and fitness.  For example, when expressed at endogenous levels, an Hsp90 
amino acid substitution would need to reduce per molecule function by 79% in order to 
result in a readily measureable growth defect of 5%.  Thus the bimodal DFE that we  
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Figure 2.5: Hsp90-GFP fusions 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.5 Hsp90-GFP fusions. (A) Growth rate supported by Hsp90-GFP fusion in shutoff 
yeast. (B) Comparison of growth rates observed with and without GFP fusion. (C) GFP levels 
observed by flow cytometry. To estimate bulk expression comparable to the Western analyses in 
Figure 2.4, mean fluorescence was calculated and corrected for the auto fluorescence from cells 
lacking GFP. 
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observe for Hsp90 (Figure 2.2B) does not necessarily imply a bimodal distribution of 
mutant effects on function. In particular, the fitness analyses do not provide detailed 
information on mutants with up to 79% defects in function. Due to the shape of the 
Hsp90 elasticity curve, the bimodal DFE is consistent with either a bimodal distribution 
of function as predicted by the stability dominated fitness model [296], or a primarily 
unimodal distribution of functional effects (Figure 2.6). To distinguish between these 
possibilities we sought to reveal effects on function that could be hidden at wild type 
expression strength. 
To reveal the latent function of Hsp90 mutants, we analyze fitness effects at reduced 
expression strengths (Figure 2.7, Table 2.2).  The population in all bulk competitions was 
managed such that the population size at constriction points was always in gross excess to 
library diversity (Figure 2.8). Because there is selection pressure to increase expression in 
these experiments, we examined the expression level of the wild type Hsp90 sequence 
over time in shutoff conditions using Hsp90-GFP fusions (Figure 2.9). Cells respond to 
selection by increasing expression from weak promoters over time. As predicted by the 
elasticity function (Figure 2.4), the increased expression from weak promoters results in 
an increase in growth rate (Figure 2.10). The observed increase in growth rate closely 
matches predictions based on the expression increase we observed by flow cytometry and 
the elasticity function, indicating that the underlying model is sound. To minimize the 
impact of time dependent changes in expression on fitness analyses of coding sequence 
mutations, we performed bulk competition of Hsp90 mutants over a short time window, 
12-48 hours in dextrose (Figure 2.8). We performed simulations to investigate how the  
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Figure 2.7: Distribution of observed fitness effects 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.7 Distribution of observed fitness effects. EMPIRIC results for Hsp90 mutants with 
varied promoters with and without terminator sequences in the 3’ UTR: (A) TEF promoter, (B) 
TEF promoter without a terminator, (C) CYC promoter, (D) CYC promoter without a terminator, 
(E) ADH promoter, and (F) ADH promoter without a terminator.  
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Figure 2.8: Population management during bulk competitions 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.8 Population management during bulk competitions. (A) Outline of experiment from 
transformation through selection. For all steps, the smallest population bottleneck is indicated. 
These bottlenecks were managed so that they were always in gross excess to the diversity of 
engineered mutations (64 codons х 9 positions = 576). (B) Population management during 
selective growth competition (after 12 hours in dextrose). Dashed lines represent dilutions to 
maintain cells in logarithmic growth, and arrows at the top indicate when samples were harvested 
for sequencing. 
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Figure 2.9: Expression of Hsp90-GFP fusions as a function of time in shutoff 
i i  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.9 Expression of Hsp90-GFP fusions as a function of time in shutoff conditions. (A) 
GFP levels observed by FACS after 19 hours (grey filled), 36 hours (green dashed line), or 48 
hours (red dashed lines) in dextrose for each promoter strength construct. To estimate the bulk 
expression level, mean fluorescence was calculated and corrected for the autofluorescence of 
cells lacking GFP. While the observed distribution of expression level among populations of cells 
was complex and will be interesting to examine in future studies, straightforward analyses of the 
population mean provided useful estimates for this study. (B) The fold increase relative to the 19 
hour time point for each construct was plotted and fit to a linear model. 
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Figure 2.10: Influence of time in dextrose on growth rates 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.10 Influence of time in dextrose on growth rates. (A) Shutoff yeast harboring rescue 
plasmids with the WT Hsp90 coding sequence under different promoter strengths were monitored 
after 26 or 50 hours in dextrose. The TEF and TEFΔter constructs exhibit less than a 5% change 
in observed growth rate, consistent with the robust growth observed for these constructs 
immediately after selection begins in dextrose. (B) Relative growth rate of strains exhibiting 
growth defects upon selection in dextrose. Growth estimates at 50 hours were estimated from the 
growth rate at 26 hours, the elasticity function, and the observed increase in expression of Hsp90-
GFP fusions. 
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observed increase in expression level over time in shutoff conditions would impact 
competition trajectories (Figure 2.11). The impact of increasing expression level has a 
minor impact on competition trajectories and indicates that constant expression models 
provide estimates of sufficient quality to interpret general features of the distribution of 
mutant effects on fitness and function, which is the focus of this study. 
 The DFEs that we observed exhibited a consistent trend as expression strength was 
reduced.  At high expression strength, the majority of mutants had WT-like growth rates, 
with very few mutants of intermediate effect.  As expression strength was reduced, the 
WT-like peak decreased and the prevalence of mutants with intermediate effects 
increased.  In terms of epistasis, the fitness effects of amino acid substitutions displayed 
pervasive negative epistasis with expression strength (Figure 2.12).  In terms of function, 
these results strongly indicate that the DFE at endogenous expression strength (Figure 
2.2B) does not mirror the underlying effects of point mutations on Hsp90 function. 
We estimated mutant effects on Hsp90 function (Figure 2.13, Table 2.3) based on fitness 
measurements at distinct expression strengths and the elasticity function. As described in 
the methods section, we employed the elasticity function to calculate per molecule 
function from fitness taking into account bounds on measurement and calculation 
precision.  For example, at the endogenous expression strength, mutants with activity 
defects of up to 79% were obscured to fitness analyses and were demarcated as such 
(functional efficiency > 0.21).  Because a distinct range of function is revealed to 
selection at each expression strength (Table 2.4), our integrated analyses provided  
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Figure 2.11: Models of time-dependent changes in expression level 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.11 Models of time-dependent changes in expression level. (A) Mathematical 
descriptions of numerical integration models relating abundance to function per molecule and 
expression level. (B) Trajectories of theoretical competitions of mutants with different impacts on 
function and WT. Trajectories simulations use Dt of 0.1 hours and growth and expression 
parameters from the CYCΔter construct (E0=0.016 - calculated from observed growth rate and 
elasticity function, Em=0.014 - from the elasticity function, τ = 0.11 hr
-1 - based on flow 
cytometry of Hsp90-GFP fusions over time, Gmax = 0.45 hr
-1 - based on observed growth curves 
with the GPD construct). Simulations were performed for other constructs and exhibited less 
variation between CE and LIE models, indicating that the model is most sensitive to changes in E 
around Em. (C) Comparison of the slope of linear fits to the plots in panel B. (D) Representative 
data for competition trajectories of mutants in the CYCΔter constructs with linear fits. 
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Figure 2.12: Epistasis between expression strength and amino acid substitutions 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.12 Epistasis between expression strength and amino acid substitutions. Fitness 
effects of point mutants under reduced expression strength compared to endogenous expression 
strength. Results observed for Hsp90 mutants with varied promoters with and without terminator 
sequences in the 3’ UTR: (A) TEF promoter, (B) TEF promoter without a terminator, (C) CYC 
promoter, (D) CYC promoter without a terminator, (E) ADH promoter, and (F) ADH promoter 
without a terminator. 
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Figure 2.13: Effects of mutations on Hsp90 function  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.13 Effects of mutations on Hsp90 function. (A) Distribution of mutant effects on 
Hsp90 function calculated from fitness effects at varied expression levels. (B) Impact of 
mutations at two solvent exposed hydrophobic amino acids in Hsp90 on yeast growth at different 
expression strengths. (C) Mutant impacts on folding stability (-ΔΔG estimated from structural 
simulation) related to function. (D) Similarity of amino acid substitutions to wild type (based on 
Blosum62 matrix) relative to observed functional effects. 
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Table 2.4: Activity ranges interrogated at each expression-strength 
 
Table 2.4. Activity ranges interrogated at 
each expression-strength 
Construct Expression Function 
Name Strength Range1 
GPD 1.0 0.034-0.21 
TEF 0.32 0.067-0.45 
TEFTer 0.094 0.16-0.71 
CYC 0.044 0.38 and above 
CYCTer 0.019 0.38 and above 
ADH 0.014 0.39 and above 
ADHTer 0.008 0.43 and above 
1Function range with informative 
fitness effects (sapp>null-like – where 
mutants persist in the culture and are 
more accurately monitored; and 
observed growth rates at least 5% 
slower than Gmax where growth rate and 
function are strongly coupled.  
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estimates of the functional effects of all mutants. Estimates of mutant effects on function 
based on fitness measurements at different expression strengths exhibit a reasonable 
correlation (R2 = 0.75) (Figure 2.14).  The strength of this correlation, despite simplifying 
assumptions (further discussed in the methods section), indicates that the calculated 
mutant effects on function are fair estimates.  
The distribution of functional effects for a region of a protein provides information about 
the contributions of that region to biochemical activity.  For example, scaffolding regions 
that are not directly involved in a critical or rate-limiting step in protein function should 
be hard to break by mutation (due to selection for stability in the wild type protein), but 
once broken destroy activity [297, 315].  In contrast, regions that contribute to a rate-
limiting step should be easy to injure by mutation, with the severity of mutant defects 
mediated by the rigidness of chemical and physical requirements (e.g. catalytic sites in 
enzymes being ultimately rigid with any mutation destroying activity). 
The distribution of functional effects (Figure 2.13A) for the region of Hsp90 we analyzed 
had one main peak with most mutations exhibiting partial defects relative to wild type.  
Our finding is consistent with this region of Hsp90 contributing to a critical and rate-
limiting step in function.  The intermediate functional defect of most mutants indicates 
that the chemical and physical requirements are flexible, consistent with this region of 
Hsp90 providing a hydrophobic docking site for binding to substrates, as was inferred 
from structure [316].  Taking a closer look at the aromatic amino acids at position 583 
[38] and 585 (Trp) located on the surface of the Hsp90 structure, most amino acid  
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Figure 2.14: Mutant effects on function 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.14 Mutant effects on function. (A) Cross-correlation between function estimates 
generated at different expression-strengths. Comparisons were made between non bounded 
estimates of function in constructs that neighbored in expression strength (e.g. GPD was 
compared to TEF., TEF to TEFΔter, etc.) (B and C) Functional estimates for positions oriented 
towards the protein interior or exterior. Distribution of mutant effects on function for positions 
582, 583, and 585 that are oriented towards solvent (B), compared to positions (584, 586-590) 
that are oriented towards the protein core (C). 
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substitutions are tolerated when expressed at endogenous levels, but a clear functional 
preference for hydrophobic amino acids is revealed at reduced expression strengths 
(Figure 2.13B). Hydrophobic interactions [317] are malleable to slight alterations in 
geometry and physical composition compared to other physical interactions (e.g. 
hydrogen bonds). Thus, it is reasonable that some substitutions that maintain 
hydrophobicity would be well tolerated, but that most non-conservative substitutions 
would result in strong defects. 
Our fitness-based estimates of mutant effects on function integrate over all properties that 
contribute to cell growth including catalysis, binding affinity, as well as the 
thermodynamic stability of folding to the native state [296, 297, 301, 315, 318]. In terms 
of stability, the prevalence of intermediate functional defects that we observe is 
inconsistent with this region of Hsp90 serving a purely scaffolding function, which 
theory predicts should exhibit a bi-modal distribution [296].  Furthermore, we observed a 
similar distribution of functional effects for positions located on the protein surface, 
which should have relatively small impacts on stability [319], as those that orient towards 
the protein interior (Figure 2.14).  This finding suggests that the functional effects of 
mutants at solvent shielded positions are caused primarily by local structural changes that 
impact the organization of solvent exposed positions (e.g. as required for efficient 
binding to substrate).  We have observed a similar surface-core relationship in ubiquitin 
[312], and at a lower resolution this type of surface-core association has been postulated 
based on the slow evolutionary divergence of sites in proteins located proximal to 
binding sites [320]. Of note, Hsp90 is a dimeric protein and subunit folding and 
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association are coupled [313].  Thus, decreased expression strength could increase 
sensitivity to destabilizing mutations.  In this case, destabilizing mutations would exhibit 
larger activity defects at lower expression strength.  Across the dataset our functional 
estimates are largely independent of expression strength (Figure 2.14, Panel A).  Thus, 
the effects of mutations on dimer stability appear to have at most a minor impact on our 
activity estimates, consistent with the location of this region of Hsp90 far from the dimer 
interface [104].  
To further examine the effect of mutations on stability, we simulated the stability effects 
of each possible point mutation based on the structure of Hsp90 [104] using Rosetta [321], 
which accurately predicts the experimental effects of mutations on stability.  The 
simulated stability effects for Hsp90 correlate extremely weakly with activity (Figure 
2.13C), consistent with our conclusion that stability is not a dominant contributor to 
activity for this region of Hsp90. Of note, substitutions of amino acids with similar 
physical and chemical properties (as estimated by BLOSUM similarity) to the wild type 
residue tend to be compatible with function (Figure 2.13D).  The stronger correlation of 
function with amino acid similarity compared to stability suggests that the stability 
simulations do not fully capture all biologically relevant structures.  For example, high 
resolution structures of Hsp90 bound to substrate are not available; but if they were 
available, might provide a stronger structural explanation for the observed functional 
effects of mutations. 
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To further test our model and conclusions, we experimentally investigated the 
biochemical properties of five non-conservative amino acid substitutions. We chose 
mutations that dramatically change the hydrophobic binding surface and largely destroy 
function (F583D and W585D), mutations that disrupt intra-molecular interactions and 
severely impair function (S586H disrupts a buried hydrogen bond, and A587D introduces 
a buried charge at a solvent shielded location), and a charge reversal mutation (E590K) 
on the surface that causes a moderate functional defect. The growth rate of these mutants 
in monoculture closely matched the fitness effects observed in the bulk competitions 
(Figure 2.15). As discussed above, our estimates of function integrates over multiple 
protein properties. For example, a mutation that increases the degradation rate (with the 
synthesis rate unchanged) should exhibit reduced steady state levels leading to a defect in 
net function. All of the disruptive individual mutations that we investigated accumulated 
at similar steady state levels (Figure 2.16A), suggesting that individual mutations do not 
commonly disrupt Hsp90 protein levels. 
We examined the biophysical properties of these non-conservative Hsp90 mutant proteins 
in purified form. To maximize the sensitivity of these analyses for potential alterations to 
structure and stability, we generated C-domain constructs. All of the mutations we 
analyzed are located in the C-domain and do not contact other domains in the Hsp90 
structure.  The circular dichroism (CD) spectra of all five mutant proteins overlay closely 
with WT (Figure 2.16B) indicating that all of the mutants fold into native conformations 
with similar secondary structure content to WT. We investigated the stability of each 
mutant protein to urea-induced unfolding (Figure 2.16C). Similar concentrations of urea  
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Figure 2.15: Monoculture growth of individual mutants 
 
 
 
 
 
 
 
 
 
 
Figure 2.15 Monoculture growth of individual mutants. Individual mutants were generated in 
the GPD construct, introduced into DBY288 yeast, and growth observed after switching to 
shutoff conditions. We chose to analyze mutants with large differences in effective selection 
coefficients from the bulk competitions. Both mutants (W585D and A587D) with null-like 
EMPIRIC selection coefficients exhibited dramatic growth defects, while both mutants (E590K 
and F583D) with WT-like effective selection coefficients exhibited robust growth in monoculture. 
The S586H mutant that had an intermediate fitness defect in the bulk competitions also exhibited 
an intermediate growth defect in monoculture. For this data, the Spearman’s rank correlation was 
-0.99 using identical EMPIRIC rankings for WT-like variants (WT, E590K, F583D) as well as 
for null-like variants (W585D and A587D). The negative sign in the correlation indicates that 
selection coefficients and growth are inversely related by definition. 
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Figure 2.16: Expression level and stability of five non-conservative mutations 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.16 Expression level and stability of five non-conservative mutations. (A) Expression 
level in shutoff yeast analyzed by Western blotting. The vertical line represents intervening lanes 
that were removed for clarity. (B) Secondary structure of purified C-domain constructs analyzed 
by circular dichroism. The spectrum of a denatured sample in 5M urea is shown for comparison 
(below 218 nm absorbance from urea interferes with signal). (C) Urea induced unfolding of 
purified C-domain constructs. The fraction unfolded was determined based on ellipticity at 222 
nm. 
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were required to unfold all mutants and WT indicating that none of the mutants 
compromises folding under native conditions. These findings demonstrate that non-
conservative mutations in this region of Hsp90 are generally capable of folding to stable 
native states, and strengthen our conclusions that the 582-590 region of Hsp90 that we 
analyzed is not critical for folding stability, and is instead a structurally malleable region 
that forms a critical hydrophobic docking site. 
Our studies as well as those of others [90, 92, 299, 301, 322, 323] demonstrate that 
biochemical flux models and the elasticity function in particular provide a fundamental 
link between molecular and cellular/organismal properties. Non-linear elasticity functions 
of the identical form to those described here for Hsp90 have also been observed in E. coli 
for -galactosidase [323], isopropylmalate dehydrogenase [92], and dihydrofolate 
reductase (DHFR) [90]. In E. coli, DHFR point mutations were commonly observed to 
impact protein degradation rates leading to fitness effects that were strongly dependent on 
the level of protein quality control [90]. In addition, flux models can provide a 
mechanistic explanation for many common fitness features including pleiotropy and 
epistasis [324].  
This study clearly demonstrates that functional defects of mutants can be hidden to 
experimental fitness measurements due to a non-linear elasticity function.  Uncovering 
these latent effects revealed that the region of Hsp90 we analyzed contributes to a rate-
limiting step in Hsp90 function.  These findings indicate that critical functional regions in 
proteins are more prevalent than considered based on fitness analyses performed without 
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consideration of the elasticity function. The elasticity function relating net function and 
fitness is critical for a thorough understanding of mutant fitness effects.  
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Methods 
Plasmid and strain construction. For expression analysis, the yeast Hsp90 gene was 
cloned into the pRS414 plasmid with different promoters and 3’ untranslated region 
(UTR). We used constitutive promoters previously demonstrated to generate a wide 
variation in expression level [79] including GPD, TEF, ADH, and CYC. Constructs were 
generated with or without the 3’ UTR from the CYC gene, which allowed further 
variation in expression level [80]. In constructs lacking the CYC terminator, the 3’UTR 
was composed of sequence from the plasmid vector. All Hsp90 plasmids contained a 6X-
His sequence (GGHHHHHHGGH) at the N-terminus to facilitate detection by Western 
blotting. Point mutant libraries previously generated in p417 plasmids [51] were 
transferred to the pRS414 promoter variant plasmids using SLIC cloning [325]. Briefly, 
for each promoter strength construct, we prepared a destination vector with the first and 
last 30 bases of Hsp90 bracketing a unique SphI restriction site. We excised the Hsp90 
library from the original 417GPD plasmid using restriction enzymes that cut immediately 
upstream and downstream of the Hsp90 gene. We cut destination vectors with SphI. We 
generated ~30 base complementary overhangs using T4 DNA polymerase in both the 
destination vectors and the Hsp90 library, annealed the complementary DNA, 
transformed into competent bacteria, grew in bulk selective (Amp) cultures and prepared 
plasmid. A small portion of the transformation was plated and the number of independent 
transformants (~30,000) was in gross excess to the library diversity. In addition, all 
replication is performed in bacteria where multiple systems ensure high fidelity reducing 
the probability of undesired secondary mutations. The DBY288 Hsp90 shutoff strain 
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(can1-100 ade2-1 his3-11,15 leu2-3,12 trp1-1 ura3-1 hsp82::leu2 hsc82::leu2 ho::pgals-
hsp82-his3) was generated from the Ecu Hsp90 plasmid swap strain [311] by integration 
of Hsp90 driven by a GalS [310] promoter together with a HIS3 marker into the HO 
genomic locus. 
Yeast growth rate. DBY288 cells were transformed with pRS414 plasmids and selected 
on synthetic raffinose and galactose (SRGal) plates lacking tryptophan (-W). Single 
colonies were then grown in liquid SRGal-W on a rotator at 30°C to late-log phase 
(OD600 ~0.8). Cells were collected by centrifugation, washed with synthetic dextrose (SD) 
–W media, and then grown in SD-W medium at 30 °C in an orbital shaker. Culture 
density was maintained in log phase (OD600 between 0.1 and 0.8) by periodic dilution. 
Culture growth was monitored based on increases in OD600 taking into account 
cumulative dilution. The log of OD600 versus time was fit to a linear equation to 
determine growth rate.  Analyses were performed on time points in dextrose where 
control cells lacking a rescue Hsp90 had depleted Hsp90 by Western analyses (Figure 
2.4B & Figure 2.1) and had stalled in growth (Figure 2.4A and Figure 2.1). 
Analyses of Hsp90 expression level by Western. To analyze expression levels of 
different promoter constructs, cells were grown for 19 hours in SD -W media, and 108 
yeast cells were collected by centrifugation, and frozen as pellets at -80 °C. Cell lysates 
were prepared by vortexing thawed pellets with glass beads in lysis buffer (50mM Tris-
HCl pH 7.5, 5mM EDTA and 10mM PMSF), followed by addition of SDS to 2%.  Lysed 
cells were centrifuged at 18,000g for 1 minute to remove debris, and the protein 
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concentration of the supernatants was determined using a BCA assay (Pierce Inc.).  
Lysates with 15μg of cell protein were resolved by SDS-PAGE, transferred to a PVDF 
membrane, and Hsp90 probed using -HisG antibody (Invitrogen Inc.).  Importantly, we 
have previously shown that detection of this 6xHis Hsp90 construct in yeast can be 
detected with a broad linear range using this antibody and Western blot approach [313].  
Analyses of Hsp90 expression level using flow cytometry. Flow cytometry was used as 
an alternative approach to measure the expression level of Hsp90 at the single cell level 
in yeast cells. A gene encoding EGFP was inserted into the unstructured tail of Hsp90 
after amino acid position 684. This Hsp90-GFP fusion construct was cloned into the 
variable strength promoter constructs used with non-GFP tagged Hsp90. These plasmids 
were transformed into DBY288 yeast competent cells and grown on SRGal-W plates. A 
single colony of each strain was grown for two days at 30°C in SRGal-W media to near 
saturation. These cultures were diluted 1:50 into SRGal-W media and grown to late log 
phase (~106 cells/ml). Each strain was then further diluted 1:50 in SD-W media for 48 
hours at 30°C with dilution every 12 hrs in order to maintain cells in log phase growth. 
Samples of cells were collected after 19, 36, and 48 hours in dextrose. Collected cells 
were washed twice in wash buffer (50mMTris, 150mMNaCl, pH 7.6, 0.1% w/v BSA), 
diluted to 107cells/ml in wash buffer and analyzed on a Becton-Dickinson FACSCalibur 
flow cytometer equipped with a 15mW air cooled 488nm argon-ion laser using a 530 nm 
high-pass filter. Greater than 100,000 cells were analyzed for each sample. Data were 
processed and analyzed using FlowJo software. Debris including clumped cells was 
excluded by gating on the forward and side scatter (excluded less than 5% of points). To 
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compare with bulk Western measurements, mean fluorescence was calculated using cells 
without GFP in order to subtract out background due to autofluorescence. 
 
Circular Dichroism. C-domain constructs of Hsp90 bearing an N-terminal 6xHis tag 
were generated in a bacterial over-expression plasmid, expressed, purified, and analyzed 
by circular dichroism (CD) as previously described [313]. Briefly, CD spectra were 
obtained using a 1 mm path length cuvette at a protein concentration of 20M in 20 mM 
potassium phosphate at pH 7 and 25 °C. Urea titrations were performed under the same 
conditions using samples that were equilibrated for 30 minutes. Urea concentrations were 
determined based on their refractive index. CD ellipticity at 222 nm was used to follow 
urea induced unfolding and the resulting data was fit to a two-state unfolding model as 
previously described [313]. 
 
EMPIRIC analyses of point-mutants. The effect of point mutants on yeast growth was 
analyzed as previously described [326]. Time points in dextrose were selected for 
analysis where control cells lacking a rescue Hsp90 began to stall in growth in order to 
observe the rapid decrease in relative abundance of deleterious mutants (e.g. premature 
stop codons). The growth rate of cells harboring the WT coding sequence in bulk 
competitions was estimated from monoculture growth of WT constructs performed in 
parallel to the bulk competitions. For the GPD, TEF and TEFter constructs we analyzed 
time points in dextrose of 12, 16, 20, 24, 32, 40, and 48 hours (Table 2.5). For the CYC, 
ADH, CYCter, and ADHter constructs where the relative decrease of deleterious 
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mutants was less severe (due to slower growth rate of fit mutants) we analyzed time 
points in dextrose of 16, 20, 24, 32, 40, and 48 hours. To process these time point 
samples, yeast pellets were lysed with zymolyase and total DNA was extracted and 
purified through a silica column. The DNA encoding amino acids 582-590 was PCR 
amplified, and prepared for 36 base single-read Illumina sequencing. 3.4 × 107 high 
quality reads (>99% confidence across all 36 bases) were obtained and analyzed. The 
relative abundance of each point mutant at each time point for each promoter was 
tabulated. Effective selection coefficients for yeast growth were determined by linear fits 
to the change in mutant abundance relative to wild type for each possible codon 
substitution. To account for the rapid depletion of null-like mutants to noise levels, only 
the first three timepoints in selection were used to determine effective selection 
coefficients for stop codons and all other mutants with effective selection coefficients 
within two standard deviations of stop codons (corresponding to s=-0.28 for GPD, s=-
0.37 for TEF, s=-0.4 for TEFter, s=-.0.35 for CYC, s=-0.46 for ADH, s=0.44 for 
CYCter, and s=-0.43 for ADHter). Because these null and near-null mutants rapidly 
deplete from the culture it is challenging to precisely measure their relative growth 
effects and they were binned as “null-like” (Table 2.2).Potential noise was analyzed by 
calculating normalized residuals (residuals/time points fit). Codon substitutions with 
residuals per time point greater than 0.25 or low initial mutant abundance (mutant/wt less 
than 0.004) were omitted (~7% of codons). For mutants that persist in the bulk 
competition (s>-0.1) synonymous codons exhibit a narrow distribution (Figure 2.17) 
indicating that the amino acid sequence is a dominant determinant of fitness. The  
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Figure 2.17: Effects of synonymous substitutions 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.17 Effects of synonymous substitutions. For all mutations that persisted in the bulk 
competitions (s>-0.1), we calculated synonym variance as the difference between the effective 
selection coefficient for each codon and the average of all synonyms encoding the same amino 
acid. 
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effective selection coefficient for each amino acid substitution was estimated as the 
average of the effective selection coefficients of all synonymous codons. Epistasis 
between expression strength and amino acid substitutions was calculated as the difference 
in effective selection coefficient at reduced expression strengths relative to endogenous 
strength.  For the epistasis calculations, null-like mutants were considered as true nulls. 
Thus, a mutant with wild type fitness at endogenous expression strength, and null-like 
fitness at the reduced expression strength would have an epistasis of -1. 
Estimations of mutant effects on function. Function per molecule was calculated based 
on observed selection coefficients, the elasticity function, and the expression level for 
each different promoter construct using the following equations. 
G=Gmax/(1+Em/EF) (1) 
Gmut/GWT = Wmut = 1+s (2) 
Where G is growth rate, Gmax is the maximal growth rate, Em is the relative expression 
level that results in half maximal growth, E is the expression level relative to the 
endogenous level, F is the per molecule functionof a mutant relative to WT, Wmut is the 
growth rate of a mutant relative to WT, and s is the effective selection coefficient. 
Equation 1 is an extension of the elasticity equation (Figure 2.4), where the expression of 
functional molecules or net function (EF) is explicitly modeled. With the WT coding 
sequence (F=1 by definition), equation 1 simplifies to the elasticity function in Figure 2. 
These equations can be combined and rearranged to define F as follows. 
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F=EmWmut/(E+Em-EWmut)  [1] 
Equation 3 was used to estimate mutant effects on function (Table 2.3) using the 
observed selection coefficients (Table S2.2), Em=0.014 (Figure 2.4), E for each promoter 
construct based on experimental measurements (EGPD=1,ETEF=0.32,ETEFter=0.094), or 
estimated from the observed growth rate and the elasticity function for weak promoter 
constructs where experimental measures of expression were noisier 
(ECYC=0.028,ECYCter=0.015,EADH=0.014,EADHter=0.010). Where growth rates prohibited 
accurate estimation of fitness (null-like mutants, or absolute growth rates within 5% of 
Gmax), bounds on relative per molecule function were calculated (Table 2.4). For each 
amino acid substitution, a final per molecule function estimate was generated by 
averaging across all promoter constructs that yielded a numerical estimate (and not a 
bound). For all pair-wise numerical function estimates (e.g. at two different expression 
strengths), we compared function effects between all constructs with adjacent expression 
levels (Figure 2.14).  To facilitate biophysical comparisons, we used the Blosum62 
matrix [327] to calculate the amino acid similarity to wild type for each possible point 
mutation, and Rosetta [321] to simulate effects on thermodynamic folding stability. 
Model assumptions. We make the simplifying assumption that expression level is 
independent of mutations to the coding sequence. Steady state expression level is 
determined by the rates of both synthesis and degradation.  Because degradation occurs 
after protein synthesis, it should depend primarily on the protein sequence such that 
synonymous substitutions minimally impact degradation rates. Across our data set we 
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noted that synonymous substitutions did not have dramatic impacts on fitness, suggesting 
that synthesis rates were relatively independent of mutation.  Protein degradation rates 
vary depending on protein sequence, but all of the mutants that we analyze are single 
amino acid substitution, and hence minimally differ in overall sequence.  In the event that 
a point mutant impacts degradation rate, it should be consistent across each promoter 
construct.  Thus, mutant impacts on degradation should be rare (see Figure 2.16), but 
would be incorporated into our estimates of function. 
In analyzing the effect of mutations relative to wild type, we make the simplifying 
assumption that function is independent of expression level. We examined the validity of 
this assumption by analyzing the standard deviation in function for each amino acid 
substitution determined at different expression levels. The average standard deviation 
was 0.1, indicating that this assumption is valid on a rough scale (on the order of 0.1) and 
is appropriate for interpreting the main features of the distribution of mutant effects on 
function. Of note, the mutations that we observe to improve function at reduced Hsp90 
expression levels (Figure 2.13, Table 2.3) may be an artifact of this assumption.  
The elasticity function does not include a cost of expression and as such has a maximum 
fitness at infinite expression level. Thus, we assume that expression cost is negligible 
relative to expression benefit over the range of our analyses. As the expression cost of 
native proteins is below experimental detection in yeast [328], this assumption appears 
reasonable. 
110 
 
We infer differences in cellular growth rates from measurements of DNA abundance. 
This inference is valid if DNA and cellular abundance are coupled. In previous work, we 
demonstrated that EMPIRIC measurements of fitness based on measures of plasmid 
abundance correlate strongly with cellular growth rates for a large set of mutants [312], 
indicating that plasmid abundance and cellular abundance are coupled. In addition, the 
copy number of the CEN plasmids utilized in this study is regulated, as cells maintaining 
multiple CEN plasmids grow slowly [329]. In addition, the low copy number of CEN 
plasmids is dominant to the addition of high copy genetic elements [330] and genetic 
alterations that increase CEN abundance are rare [331]. Nonetheless, CEN plasmids are 
not as stable as chromosomally encoded DNA, which may lead to a small amount of 
noise in our measurements. 
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Chapter III - Saturation mutagenesis of the HIV-1 Envelope CD4 
binding loop reveals residues controlling distinct trimer conformations 
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Abstract 
The conformation of HIV-1 envelope (Env) glycoprotein trimers is key in 
ensuring protection against waves of neutralizing antibodies generated during infection, 
while maintaining sufficient exposure of the CD4 binding site (CD4bs) for viral entry. 
The CD4 binding loop on Env is an early contact site for CD4 while penetration of a 
proximal cavity by CD4 triggers Env conformational changes for entry.  
The role of residues in the CD4 binding loop in regulating the conformation of the 
trimer and trimer association domain [168] was investigated using a novel saturation 
mutagenesis approach. Single mutations identified, resulted in distinct trimer 
conformations affecting CD4bs exposure, the glycan shield and the TAD across diverse 
HIV-1 clades. Different trimer conformations will affect the specificity and breadth of 
neutralizing antibodies elicited in vivo and are important to consider in design of Env 
immunogens for vaccines. 
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Introduction 
The HIV-1 envelope glycoprotein (Env) comprises a surface gp120 and a 
transmembrane gp41 non-covalently associated on heterodimeric trimers. When gp120 
on the Env trimer binds CD4 at the cell surface, conformational changes are triggered 
that open the trimer to expose a site for binding to a coreceptor, usually CCR5. Trimer 
opening involves the disengagement of the trimer association domain [168] at the trimer 
apex enabling (1) movement of the V1V2 loops to expose the V3 loop and (2) full 
exposure of determinants on the V1V2 stem recruited by CD4 to assemble the bridging 
sheet. The V3 loop and sections of the bridging sheet form the coreceptor binding site 
[332]. 
The CD4 binding loop on Env is an early contact site for CD4[161], while 
penetration of a proximal cavity by the hydrophobic side chain of CD4’s Phe-43 triggers 
Env conformational changes and trimer opening [176, 333, 334] (Figure 3.1). 
HIV-1 Envs in brain tissue use CCR5 as a coreceptor and are highly macrophage-
tropic. These Env variants interact efficiently with low CD4 levels on macrophages for 
infection [335, 336]. Determinants that modulate mac-tropism of R5 Envs lie within or 
proximal to the CD4bs [177, 337] as well as in V1V2 and V3 loops of the TAD [177, 338, 
339]. They include residues within the variable N-terminal flank of the CD4 binding loop 
that together with V3 loop amino acids modulated mac-tropism in a highly mac-tropic 
brain Env from a subject with neurological complications [177].  
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Here, a novel saturation mutagenesis approach; EMPIRIC (Exceedingly 
Meticulous and Parallel Investigation of Randomized Individual Codons) was exploited 
to investigate individual residues in a 20 amino acid region encompassing the CD4 
binding loop, for effects on replication and Env conformation. This 20 residue region 
includes conserved residues that contact CD4 and/or form part of the Phe-43 cavity 
(Figure 3.1). 
EMPIRIC involves the generation of libraries of mutations encoding all possible 
individual amino acid substitutions across important regions of genes [51, 54, 56, 326, 340, 341]. 
Libraries are subject to selection or competition before analyzing by deep sequencing to quantify 
the frequency change of each mutation. Using EMPIRIC, substitutions in the CD4 binding loop 
and flanks were identified that conferred enhanced or wt levels of replication in peripheral blood 
mononuclear cells (PBMCs). Several substitutions modulated the Env trimer with different 
mutations imparting distinct conformations that enhanced the exposure of the CD4bs and had 
varying effects on the TAD including the V3 loop and the glycan shield. One mutation enhanced 
the presentation of the trimer specific V2q, PG9/PGT145 epitope in V1V2 of the TAD, consistent 
with a modified but closed trimer conformation. The effects of the different mutations were 
transferable to diverse clade B and C Envs. These observations confirm the capacity of EMPIRIC 
to identify single Env residues in the CD4 binding loop region that induce different 
conformational states in the TAD and trimer. This data is relevant for design of trimeric Env 
immunogens in vaccines that aim to protect against diverse HIV-1. 
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Results 
The primary LN40 Env and saturation libraries 
Saturation mutant libraries were introduced into the primary LN40 Env [177, 182, 
342]. LN40 env was PCR amplified and cloned from the lymph node of an AIDS patient 
with neurological complications. The LN40 R5 Env is not mac-tropic and is typical of 
Envs from immune tissue throughout disease [335, 343-345]. Most transmitted, founder 
R5 Envs are also not mac-tropic [346-349]. LN40 and other non-mac-tropic R5 Envs may 
form tightly closed trimers that protect against neutralizing antibodies (nabs). 
Determinants of LN40 non-mac-tropism were previously mapped to residues on the N-
terminal flank of the CD4 binding loop in addition to residues within V3. Presumably, 
these residues reduce access to CD4 (as well as nabs) and restrict replication to T-cells 
expressing high CD4 levels [168, 177, 182, 342]. It was predicted that mutations in the 
CD4 binding loop, its flanks and Phe-43 cavity would have strong potential to increase 
viral fitness by enhancing efficiency of Env/CD4 interactions.  
Two plasmid libraries were made containing all possible point mutations for Env 
amino acids 361-380 (361-370 and 371-380 in each library) of LN40 env in full length, 
replication competent, pNL4.3 [343]. The vast majority of the mutants were present in 
the plasmid libraries and virions (P0) produced by transfection of 293T cells (Figure 3.2a, 
b). The frequency of most mutants in plasmid and P0 libraries was well above the 
background from all processing steps including RT, estimated by sequencing virus 
recovered from a plasmid with wt env (Figure 3.2d). The frequency of mutants in the P0  
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Figure 3.2: Frequency of mutations in plasmid library, P0 and P1 viruses 
 
 
 
 
 
 
 
 
 
 
Figure 3.2 Frequency of mutations in plasmid library, P0 and P1 viruses. The frequency of 
mutations at position 377 in plasmid library (a), P0 library (b), P1 library (c) and wt plasmid as 
noise level estimate (d). (e) The frequency of mutants were strongly correlated in P0 library and 
in plasmid library. The data from library-371-380 is shown.  
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library was highly correlated with that in plasmid library, indicating that P0 library 
recovery by transfection achieved a good sampling of mutants in the plasmid library 
(Figure 3.2e). 
 
Bulk competition of mutant libraries in PHA/IL-2 stimulated PBMCs 
P0 virus of each library was competed in bulk for amplification in PBMCs 
(Figure 3.3a).  The abundance of each mutant was measured before and after 
amplification using Illumina deep sequencing and fitness estimated (see Methods). Stop 
codons were consistently depleted in both libraries (Figure 3.3b). All wt-synonyms in 
library-371-380 displayed wt-like fitness effects, although slightly more variation in 
fitness effects of wt -synonyms in library-361-370 was noted.  
Following eight days of infection, a strong correlation between enrichment and 
depletion of mutants in replicates was observed in library-371-380, but a weaker 
correlation between replicates in library-361-370 (Figure 3.3c, d). One explanation for 
the difference in reproducibility is that library-361-370 had less infectivity, and fewer 
virions mediated infection of PBMC. It was therefore more prone to insufficient sampling 
of P0 library, perhaps leading to stochastic enrichment or depletion of mutants.  
Despite slightly higher variation in library-361-370, the results indicate that the 
majority of selection was reproducible and caused by introduced mutations. Data from 
the two replicates were pooled to obtain more precise measurements for analysis  
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Figure 3.3: EMPIRIC protocol, depletion of stop codons and reproducibility 
between assays 
 
 
 
 
 
 
 
 
 
 
Figure 3.3 EMPIRIC protocol, depletion of stop codons and reproducibility between assays. 
(a) A cassette ligation strategy was used to introduce all 64 possible codons into each position of 
the CD4 binding loop region to form two libraries encompassing residues 361-370 and 371-380. 
(b) Depletion of stop codons and enrichment of wt synonyms (change in log2 frequency) in two 
experimental replicates of each library. Stop codons are shown in red and wt synonyms are shown 
in green. (c and d) Reproducibility of EMPIRIC measurements in HIV. Correlation in relative 
abundance of ~600 point mutants at amino acid positions 361-370 (c) and 371-380 (d) in the Env 
gene following infection of PBMCs. Green spots in panels b and c represent codons synonymous 
with wt codons. 
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(Table 3.1). The fitness effect of each amino acid was compared to that of repeatedly 
resampled wt -synonyms and an empirical p value of each amino acid  (significantly 
lower fitness than wt, synonyms), or statistically wt-like  (Tables 3.1 and 3.2). The 
majority of mutations in both libraries were strongly deleterious, indicating the 2 regions 
are extremely sensitive to missense mutations. 
Both libraries had a limited number of mutants with wt -like fitness or above 
(Tables 3.1 and 3.2; Figure 3.4a), with library-361-370 containing more fit mutations 
(19%) than library-371-380 (16%), consistent with an increased variability of amino 
acids N-terminal to the CD4 contact residues. No other amino acids except wt residues 
were fully functional in CD4 contact residues (GGD368_E370) (Figure 3.4b, c). In contrast, 
substitutions of proline at position P369 to cysteine, alanine, glutamine and aspartic acid 
conferred wt -like fitness. Positions 361-365 exhibited relatively higher tolerance of 
mutations, especially positions 362 and 363, where the wt amino acids are asparagine and 
glutamine respectively. Charged amino acids (except for histidine) were well tolerated at 
these two positions (Figure 3.4b, c). At position 365, the wt is serine, whereas valine and 
alanine exhibited slightly increased fitness. 
In the 371-380 library, positions 373, 375 and 377 were tolerant of mutations. 
Even residues carrying side chains with different structures were at least wt -like in 
fitness (Figure 3.4b, c). For example, at position 373, glutamic acid was strongly 
beneficial over wt arginine. At position 375, where the wt amino acid is serine, all amino  
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Table 3.2: Beneficial mutations   
  
Mutant Fitness effect      
R373E 0.36  
R373K 0.34 
R373N 0.24 
R373Q 0.43 
S375F 0.63 
S375H 0.63 
S375T 0.44 
S375W 0.36 
S375Y 0.64 
N377L 0.16 
N377T 0.18 
N377V 0.49    
G380P 0.27 
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Figure 3.4: EMPIRIC analysis of the CD4 binding loop and flanks of LN40 Env and 
catergorization of mutations as beneficial, wt or deleterious 
 
 
 
 
 
 
 
 
 
Figure 3.4 EMPIRIC analysis of the CD4 binding loop and flanks of LN40 Env and 
catergorization of mutations as beneficial, wt or deleterious. (a) Most mutations were 
deleterious. However, subsets of mutations that imparted wt or higher levels of replication were 
identified. (b) Mutations that affect CD4 contact residues were strongly deleterious. However, 
twelve mutations in regions downstream of the CD4 contact residues dramatically increased the 
efficiency of viral replication. These residues are proximal to the Phe-43 cavity. (c) The most 
common amino acids in positions 361-380 following PBMC passage of the two libraries. (d) The 
most common amino acids in positions 361-380 in all subtypes in the patient sequence database 
(http://www.hiv.lanl.gov/content/sequence/HIV/mainpage.html). 
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acids with aromatic rings as well as threonine and histidine were strongly beneficial. 
Glycine is the wt residue at position 380, and this residue is relatively conserved in 
natural isolates (Figure 3.4d). Proline was slightly beneficial at 380. Positions 371, 372, 
374, 376 and 378 were resistant to change, although substitutions to amino acids with 
very similar structures (e.g. Ile/Val and Phe/Tyr) were tolerated at some positions e.g. 
371 and 376.  
Overall, 13 beneficial mutations were identified, all in library-371-380 (Table 3.2). 
Although a few mutations in library-361-370 exhibited small positive fitness effects, they 
were not statistically significant. This could be partly attributable to higher variation of 
fitness measurements in this library (leading to reduced statistical power) or to the 
optimal adaptation of this region to its function. All beneficial mutations in library-371-
380 have a greater than 15% increase in fitness, which is very large compared to 
EMPIRIC studies in other systems [51].  
 
Fitness benefit and wt mutations identified by EMPIRIC result in changes in LN40 
Env conformation and function 
35 mutations that conferred increased or wt levels of replication in PBMCs were 
investigated to elucidate effects on Env conformation. Each mutation was introduced into 
the pSVIIIenv Env expression construct carrying LN40 env, before producing Env+ 
pseudoviruses (Methods). Changes in Env conformation were evaluated by testing 
sensitivity LN40 Env+ pseudovirions to inhibition by soluble CD4 (sCD4) and Env 
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monoclonal antibodies (mabs) including CD4bs mabs, b6, b12, V3 loop mab, 447-52D, 
the glycan specific 2G12, V3 specific PGT128 and CD4i mab, 17b (Table 3.3).  
 
Increases in sCD4 sensitivity 
LN40 is relatively resistant to sCD4 inhibition due either to steric restrictions to 
binding and/or to resistance to CD4-induced conformational changes [168]. Sharp 
increases in sCD4 sensitivity for mutant Envs are consistent with changes in Env 
conformation that enhance CD4 interactions. Substitutions that increased sCD4 
sensitivity included several at residue 375 e.g. S375W. Residue 375 is proximal to the 
Phe-43 cavity and S375W was reported to increase Env sampling of the CD4-bound form 
in gp120 monomers [176]. Substitutions at residues 373 (R373E), 377(N377V) and 380 
(G380P) also conferred increases in sCD4 sensitivity. Other substitutions had less or no 
effect on sCD4 sensitivity (Table 3.3).  
 
Increases in sensitivity to CD4bs mabs 
LN40 is resistant to the CD4bs mab b12. The b12 epitope is present on 
monomeric LN40 gp120 but occluded on the trimer [168]. Five substitutions at residue 
373 (373E, 373M, 373N, 373Q and 373K) increased LN40 sensitivity to b12. This 
observation is not surprising since it was previously reported that the side chain of R373 
(together with the glycan at N386) sterically restricted W100 of b12 from accessing a 
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Table 3.3: The effect of LN40 mutations identified by EMPIRIC on Env 
structure and function.  
LN40 Env wt  and 
mutants 
sCD4 447-
52D 
-V3 
crown 
b6 
-
CD4bs 
b12 
-
CD4bs 
17b 
-CD4i 
PGT128 2G12 
-glycans 
IC50s (μg/ml) 
LN40 wt >50 40 >50 34.9 >50 0.008 5.2 
361 
F361I 49.1 32.8 >50 >50 nt 0.007 3.1 
F361L >50 34.6 >50 40.7 nt 0.007 3.5 
F361Y 35.8 30 >50 >50 nt 0.008 1.9 
362 
N362D 39.9 33.8 >50 29.6 nt 0.008 9.3 
N362E >50 29.2 >50 >50 nt 0.008 3.5 
N362K >50 21.6 >50 >50 nt 0.007 1.1 
N362S >50 >50 >50 >50 nt 0.006 1.9 
N362T >50 20 >50 >50 nt 0.008 2.0 
N362A >50 >50 >50 >50 nt 0.007 1.9 
363 
Q363D 36.8 17.8 >50 4.5 nt 0.008 11.1 
Q363E 34.7 18.1 >50 2.5 nt 0.007 10.7 
Q363G >50 29.4 >50 >50 nt 0.007 6.3 
Q363H 27.2 14.5 >50 >50 nt 0.008 6.1 
365 
S365A 32.1 21.7 >50 >50 nt 0.009 5.0 
S365V 44.6 28.5 >50 >50 >50 0.008 5.2 
369 
P369A >50 >50 >50 >50 nt nt 9.0 
P369C >50 >50 >50 >50 nt nt 5.1 
P369D >50 26 >50 >50 nt nt 14 
P369E >50 29 >50 >50 nt nt 10 
371 R371V >50 >50 >50 34.5 nt 0.01 5.0 
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373 
R373K >50 35.2 >50 2.8 nt 0.009 8.2 
R373M >50 >50 >50 1.1 nt 0.009 7.5 
R373Q 44.2 25.2 >50 1.5 nt 0.012 14.9 
R373E 23.9 2.4 >50 2.0 >50 0.012 26.4 
R373N 43.9 12.9 >50 3.4 >50 0.01 9.9 
375 
S375H 15.3 >50 >50 <50 nt 0.014 15.9 
S375T 38.2 >50 >50 34.0 nt 0.009 8.4 
S375F 7.6 >50 >50 >50 nt 0.013 21.3 
S375W 8.7 >50 >50 42.8 >50 0.014 32.4 
S375Y 5.9 >50 >50 45.4 >50 0.01 30.1 
377 N377V 19.0 1.3 >50 41.2 >50 0.01 12.3 
380 
G380A 32.0 <0.2 33.5 26.9 >50 0.01 11.4 
G380P 21.7 <0.2 15.3 25.2 >50 0.02 26.4 
nt; not tested 
green, >10<25; yellow, >1<10, red, <1. 
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pocket on gp120 for binding [342]. All substitutions at 373 with a shorter side chain than 
arginine might be expected to expose the W100 pocket for b12 [342]. Substitutions 
Q363E and Q363D also conferred sensitivity to b12. These negatively charged residues 
may alter the structure of the b12 W100 pocket (e.g. by moving the glycan at N386) so 
that it is now open. Decreased 2G12 sensitivity supports a shift in the glycan shield 
including the glycan at N386, a 2G12 target [182]. The same 363 and 373 substitutions 
also impacted the TAD as detected by increases in 447-52D sensitivity indicating a more 
exposed V3 loop. 
Mab b6 also targets the CD4bs. However, its epitope is occluded on primary Envs 
[336, 350]. Here, b6 failed to neutralize any mutant, except for G380A and G380P, which 
conferred weak sensitivity. This indicates that other substitutions tested did not 
sufficiently open the trimer to enable b6 binding.  
 
Increased sensitivity to 447-52D and V3 loop exposure 
Mab 447-52D recognizes a GPGR motif on the V3 crown which is occluded 
within the trimers of most primary HIV-1 strains, including LN40.  
Substitutions that increased sensitivity to 447-52D, indicating a more exposed V3 
loop, included Q363D, Q363E, Q363H, R373E and R373N.  Substitutions at 377 
(N377V) and 380 (G380A and G380P) also conferred enhanced sensitivity to 447-52D as 
well as to sCD4, consistent with a larger impact on the TAD. G380A and G380P mutants 
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were exquisitely sensitive to 447-52D implying a more dramatic shift in the TAD and V3 
loop exposure. In contrast, substitutions at residue 375 (e.g. S375W, S375Y and S375F) 
that conferred increased in sCD4 sensitivity, remained resistant to 447-52D, indicating 
that the V3 loop was not exposed and that these changes induced a distinct trimer 
conformation. 
 
Decreased sensitivity to 2G12 indicates a shift in the glycan shield 
All the substitutions that increased sensitivity to sCD4 and/or CD4bs and V3 loop 
mabs also had modestly increased resistance to the glycan specific mab, 2G12, consistent 
with a shift in the orientation of the glycan shield. 
 
Env mutants do not carry an exposed CD4i epitope 
We focused on substitutions at 373, 375, 377 and 380, which imparted the most 
significant shifts in Env conformation and tested their sensitivity to the CD4i mab, 17b 
[161, 351]. All were resistant, indicating that changes in trimer conformation for these 
mutant Envs did not expose the CD4i epitope or coreceptor binding site. 
 
Several different residues substituted at P369 impart wt LN40 replication 
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 CD4 contact residues, GGD368_E370, in the CD4 binding loop were not readily 
substituted. However, mutations that substituted P369 with A, C, D and E residues 
imparted wt-like replication. P369 is relatively conserved in clade B Envs and its 
replacement with other amino acids might be expected to confer properties selected 
against in vivo. However, 369 mutants carrying A, C, D E, did not exhibit differences in 
sensitivity to sCD4, 447-52D, b6 or b12, while only D and E slightly decreased 
sensitivity to 2G12. These results indicated that this position accepts several different 
amino acids without detectable changes in Env conformation or replication fitness. 
  
Summary of LN40 mutants 
The use of multiple neutralizing mabs to investigate each substitution allowed an 
assessment of the changes distal to the residue in question and in overall Env 
conformation. The data presented show that different residues within or closely 
associated with the Phe-43 cavity have distinct effects on the conformation of the TAD 
and trimer. 
 
The effect of introducing an N160 glycan into LN40 Env 
 V2q mabs, PG9, PG16 and PGT145 bind the V2 glycan N160 and preferentially 
recognize the TAD at the apex of trimers rather than monomers. These mabs can be used 
as probes to assess whether this site has been disrupted consistent with trimer opening 
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[168, 352]. Unfortunately, LN40 Env does not carry the N160 glycan, critical for binding 
V2q mabs, although a glycan at N156 is also targeted by V2q mabs. The N160 potential 
N-linked glycosylation signal was restored to LN40 Env by mutagenesis in the hope of 
reconstituting V2q mab binding.  However, LN40 Y160N remained resistant to V2q 
mabs PG9, PG16 and PGT145 (not shown) and presumably doesn’t bind these mabs.  
Nevertheless, the introduction of N160 conferred increased sensitivity to sCD4 (Figure 
3.5a, Table 3.4), consistent with a TAD conformation that enhances access to the CD4bs. 
Several substitutions identified by EMPIRIC conferred further enhancement in sensitivity 
to sCD4, the V3 mab 447-52D and CD4bs mab b6 when introduced together with Y160N  
(Figure 3.5a-c, Table 3.4). In particular, LN40 160N mutants, 377V and 380P, were more 
sensitive to sCD4 compared to Env mutants without Y160N. The presence of N160 also 
enhanced sensitivity of 377V to V3-specific 447-52D and more modestly to b6 (Figure 3.5b-c, 
Table 3.4). In contrast, the LN40 160N 375W mutant was only modestly more sensitive to sCD4 
and remained relatively resistant to both 447-52D and b6.  
These data indicate that the N160 glycan on LN40 conferred a trimer conformation where 
the CD4bs site is more exposed enabling enhanced interactions with CD4 and antibodies 
targeting V3 and the CD4bs. 
 
Mutations that change LN40 Env conformation conferred similar effects on another 
clade B Env and a clade C transmitter, founder Env 
Several mutations were introduced into another clade B Env, LN8, and into a clade C 
Env, Z1792M. LN8 is an R5 envelope derived by PCR cloning from the lymph node of 
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Figure 3.5: The effect of N160 on LN40 wt and mutant Envs on sensitivity to sCD4 
 
 
 
 
 
 
 
Figure 3.5 The effect of N160 on LN40 wt and mutant Envs on sensitivity to sCD4 (a), V3 
loop mab, 447-52D (b) and CD4bs mab, b6 (c). 
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Table 3.4: N160 enhances the sensitivity of LN40 wt and mutant Envs to sCD4 and 
mab neutralization. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Mab, inhibitor Env IC50s 
+/- N160 
- + 
sCD4 
wt >50 21.2 
R373E 27.0 8.4 
S375W 8.7 4.6 
S377V 19.0 2.1 
G380P 22.2 6.1 
447-52D 
wt 32.4 4.7 
R373E 2.4 <0.2 
S375W >50 24.2 
N377V 1.1 0.008 
G380P 0.014 0.004 
b6 
wt >50 >50 
R373E >50 19.5 
S375W >50 >50 
N377V >50 18.7 
G380P 15.3 4.3 
b12 
wt 28.9 45.9 
R373E 2.0 1.4 
S375W >50 >50 
N377V >50 >50 
G380P >50 >50 
green, >10<25; yellow, >1<10, red, <1. 
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subject NA20, who died of AIDS with neurological disease [335, 343], while Z1792M is 
a transmitter, founder, clade C R5 Env from Zambia [353]. 
 
Substitutions at residue S375  
Substitutions S375H and S375W both enhanced sCD4 sensitivity of LN8 and clade C, 
Z1792M, as they did for LN40 (Figure 3.6a; Tables 3.5 and 3.6). These S375 
substitutions had little effect on LN8 sensitivity to b12, b6 and 447-52D, yet conferred 
more resistance to 2G12. This is consistent with a shift in the orientation of one or more 
glycans resulting in a more exposed CD4bs and increased sCD4 sensitivity. The changes 
implicated in LN8 Env conformation closely follow those described above for LN40 Env. 
Z1792M does not carry the b12, 447-52D or 2G12 epitopes. However, S375 substitutions 
had no effect on b6 resistance.  
 
The N377V substitution  
N377V conferred increased sensitivity to sCD4 for LN8 and Z1792M and 
modestly increased sensitivity of LN8 to V3 mab, 447-52D, following observations made 
for the equivalent LN40 mutant (Figure 3.6a, b).  
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Figure 3.6: Substitutions at residues 375, 377 and 380 confer similar effects on clade 
B LN40, LN8 and clade C Z1792M Envs 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.6 Substitutions at residues 375, 377 and 380 confer similar effects on clade B LN40, 
LN8 and clade C Z1792M Envs. Neutralization profiles for sCD4 (a), 447-52D (b) and b6 (c) 
are shown. Each substitution had similar effects on the three different Envs: consistently 
increasing sensitivity to sCD4. However, only 380P conferred sensitivity to mab b6, while 377V 
and 380P exposed the V3 loop crown (447-52D epitope), while 375W didn’t. Of note, Z1792M 
does not carry the 447-52D epitope. 
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Table 3.5: The effect of mutations identified by EMPIRIC on LN8 Env structure and function.  
LN8 Env  wt and 
mutants 
sCD4 447-52D 
-V3 
crown 
b6 
-CD4bs 
b12 
-CD4bs 
2G12 
-glycans 
PGT128 
-V3 
glycans 
PG9 
-V2 N160 
PGT145 
-V2 N160 
IC50s (μg/ml)  
LN8  wt 40.7 >50 >50 28.7 6.16 0.019 0.17 0.0006 
362 N362D 31.4 >50 >50 2.87 >50 0.033 0.19 0.0007 
363 Q363D 34.5 >50 >50 14.1 21.8 0.027 0.16 0.0004 
365 
S365A 25.4 >50 >50 48.5 6.59 0.028 0.13 0.0006 
S365V 8.0* >50 >50 26.9 3.61 0.015 0.05 0.0003 
373 
M373E 37.5 37.4 >50 >50 6.98 0.011 0.11 0.0004 
M373N 34.6 >50 >50 >50 6.87 0.012 0.22 0.0005 
375 
S375H 12.3 >50 >50 >50 30.8 0.027 1.0 0.0009 
S375W 3.4 >50 >50 >50 35.3 0.046 5.3 0.0011 
377 N377V 9.8 36.7 >50 30.1 6.71 0.016 0.22 0.0007 
380 
G380A 24.1 3.6 >50 2.1 7.36 0.02 0.16 0.0007 
G380P 0.76 <0.2 0.2 <0.2 1.85 0.019 4.3 0.0016 
sCD4, 447-52D, b6, b12, 2G12:  green, >10<25; yellow, >1<10, red, <1. 
PGT128: red, <0.1. PG9: yellow, >1; red, <1. PGT145: yellow, >0.001; red, <0.001. 
*50% neutralization at 8.0 μg/ml. However, neutralization curves were erratic and neutralization 
incomplete, reaching a maximum of 75-85% at 50 μg/ml. 
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Table 3.6: The effect of mutations identified by EMPIRIC on Z1792M Env 
structure and function 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Z1792M Env wt  
and mutants 
sCD4 b6 
-CD4bs 
PG9 
-V2 
N160 
PGT145 
-V2 N160 
IC50s (μg/ml) 
Z1792M wt 44.2 >50 0.20 0.29 
362 E362D >50 >50 0.14 0.3 
363 E363D >50 >50 0.15 0.14 
364 H364S >50 >50 0.18 0.15 
365 
S365A >50 >50 0.14 0.32 
S365V 46.3 >50 0.03 0.005 
369 L369P 12.1 >50 0.41 0.79 
373 
 
T373E 43.2 >50 0.08 0.03 
T373M 19.1 >50 0.32 0.6 
T373K 41.1 >50 0.12 0.54 
T373Q 43.1 >50 0.20 0.3 
375 
 
S375W 0.57 >50 2.6 >4.0 
S375Y 1.2 >50 1.5 1.89 
S375F 2.0 >50 0.46 0.55 
S375H 2.5 >50 1.2 1.28 
S375T 26.0 >50 0.22 0.89 
377 
N377V 13.5 >50 0.20 1.9 
N377L 15.0 >50 0.20 1.32 
N377T 45.4 >50 0.16 0.68 
380 
 
G380A 35.2 >50 0.12 0.64 
G380P 7.2 9.5 0.32 >4.0 
sCD4, b6, b12:  green, >10<50; yellow, >1<10, red, <1. 
PG9, PGT145: yellow, >1; beige, >0.1<1.0; red, <0.1. 
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Substitutions at G380 
G380P enhanced sCD4, b6 and b12 sensitivity for LN8 and conferred exquisite 
sensitivity to the V3 mab, 447-52D. G380P also enhanced sensitivity to sCD4 and b6 for 
Z1792M (Figure 3.6, Tables 3.5 and 3.6). These results indicate that G380P conferred 
more dramatic changes to the trimer conformation of LN40, LN8 and Z1792M Envs 
resulting in improved CD4 interactions and enhanced exposure of the V3 loop and b6 
epitope, consistent with a more open conformation of the trimer. 
Together, these findings indicate that substitutions at 375, 377 and 380 enhance 
Env/CD4 interactions and trimer function across diverse HIV-1 clades. 
 
L369P substitution in clade C Z1792M Env  
P369 is conserved on the clade B database, while L369 is dominant for clade C.  
A L369P substitution was made in clade C, Z1792M Env. The presence of P369, 
rendered Z1792M more sensitive to sCD4 (Table 3.6), perhaps indicating an Env trimer 
more open to nabs and possibly explaining the selective advantage of L over P at 369 for 
clade C Envs in patients. 
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The effects of Env substitutions on the V2q epitope of LN8 and Z1792M 
Unlike LN40, LN8 and Z1792M Envs carry the glycan at N160 in V2 and are sensitive to 
the trimer specific V2q mabs PG9 and PGT145 [354]. Measuring sensitivity to V2q mabs 
could help monitor whether trimers are closed for each mutant. Surprisingly, all LN8 and 
Z1792M substitutions remained sensitive to PG9 and PGT145, although Envs carrying 
each of S375W, N377V and G380P substitutions in LN8 and Z1792M were less sensitive 
to either PG9, PGT145 or both  (Figure 3.7a; Tables 3.5 and 3.6). The modest impact of 
these substitutions on sensitivity to V2q mabs is curious. How can the LN8 G380P Env 
trimer be open sufficiently to bind b6 and 447-52D, yet remain substantially sensitive to 
V2q mabs, PG9 and PGT145 that recognize closed trimers? One possibility is that PG9 
or PGT145 bind open trimers by retaining an interaction with monomeric gp120. 
However, using ELISAs, it was confirmed that these mabs do not bind LN8 or Z1792M 
gp120 monomers (not shown).  Perhaps, the G380P trimers transition to and from closed 
and open forms [355], so that b6 captures the open state, while V2q mabs capture the 
closed state (Figure 3.8B). Alternatively, the native trimer may take up a conformation 
where the PG9, PGT145 epitope in the TAD is largely maintained while still exposing 
the V3 loop crown and CD4bs including the b6 epitope (Figure 3.8A).  
 
An S365V substitution in a CD4 contact residue enhanced the V2q epitope 
 While substitutions downstream of the GGD-E (366-370) CD4 contact 
residues, resulted in changes consistent with TAD and trimer opening, mutations in 
upstream residues had little effect on sensitivity to sCD4 and other mabs  
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Figure 3.7: Env substitutions in the CD4 binding loop modulate the trimer specific, 
V2q epitope 
 
 
 
 
 
 
 
Figure 3.7 Env substitutions in the CD4 binding loop modulate the trimer specific, V2q 
epitope. (a) Env substitutions proximal to the Phe-43 cavity, reduced sensitivity to V2q, mabs, 
PG9 and PGT145, consistent with a more open TAD and trimer. (b) Substitution S365V on the 
variable, N-terminal flank of the CD4 binding loop enhanced sensitivity to V2q mab PGT145, 
consistent with a modified (but not more open TAD conformation). 
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Figure 3.8: Alternative models to explain how Env trimers may expose the CD4bs 
while retaining a closed TAD at the trimer apex 
 
 
 
 
 
 
 
 
Figure 3.8 Alternative models to explain how Env trimers may expose the CD4bs while 
retaining a closed TAD at the trimer apex. (a) The Env trimer moves from a closed to open 
form and back again. V2q mabs capture the closed form, CD4bs mabs capture the open form. (b) 
Localized conformational changes expose CD4bs epitopes without impacting the TAD and V2q 
epitopes.  
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(Table 3.3, 3.5 and 3.6). Exceptions include N362D, Q363D and Q363E, which enhanced 
b12 sensitivity for either LN8 or LN40.  
An S365V substitution modestly increased sensitivity to both PG9 and PGT145, 
particularly for Z1792M. Effects on LN8 were more marginal, although S365V was still 
the most sensitive LN8 mutant for PG9 and PGT145 (Figure 3.7b, Tables 3.5 and 3.6). 
The 373E substitution also enhanced (rather than reduced) the V2q epitope, although less 
than for S365V.  
 
Discussion 
 An HIV-1 vaccine that induces potent and broad nabs will require detailed 
knowledge of the residues that control the configuration of the Env trimer. This 
information will help design Env immunogens that optimally present the best epitopes for 
eliciting the most rigorous vaccine response. 
A novel saturation mutagenesis approach, EMPIRIC, was applied to investigate 
the role of residues in a 20 amino acid stretch of gp120 in regulating the conformation of 
the TAD and trimer. This region encompasses the CD4 binding loop and flanking regions.  
Several residues were identified that modulated the TAD and trimer (Figure 3.9). 
However, different residues enhanced Env: CD4 interactions by imparting distinct TAD 
conformations with differential exposure of the V3 loop and other epitopes usually 
occluded within the trimer. The majority of mutations that modified LN40 TAD and  
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Figure 3.9: CD4 binding loop residues identified that control trimer conformation 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.9 CD4 binding loop residues identified that control trimer conformation. Residues 
are depicted as spheres in different colors. The V1 (yellow), V2 (green) and V3 (orange) loops 
that form the trimer association domain [168] are shown at the trimer apex. Light yellow spheres 
show the NAG (N-acetyl glucosamine) of N160 (Cyan) on the top of the trimer. CD4 contact 
sites 2, are red in the cartoon structure. Structure is based on a side view of trimer (PDB 4NCO 36). 
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trimer had similar effects on LN8 and clade C, Z1792M, indicating that residues 
identified, control Env conformation across clades.  
Mutations likely to affect trimer conformation were identified in competition 
assays by replication in PBMCs. This approach selects for mutations that support viral 
replication in the absence of nabs and enabled the identification of residues infrequent on 
the HIV sequence database. For example, residues 375W, 377V and 380P increased CD4 
binding and led to more open trimers where epitopes (usually occluded) are exposed. 
Two types of substitution were observed. (1) Substitutions that modified the local 
structure around the CD4bs e.g. N362D in LN8, where the b12 epitope was exposed 
without affecting other sites. (2) Substitutions that modified distal sites including V3 and 
the TAD e.g. S375W, N377V ad G380P. One concern with the competition assay was 
whether spontaneous mutations contributed to enhanced replication. This was not 
investigated. However, many mutations mediated significant effects on the trimer when 
investigated individually using pseudoviruses carrying mutant Envs. These observations 
confirm that EMPIRIC identifies physiologically relevant amino acid substitutions and is 
a formidable mutagenesis tool for analyses of Env conformation, fitness or other 
properties, relevant for vaccines. 
Two libraries were prepared covering residues 361-370, and 371-380 (Figure 3.1). 
Library-361-370 contained the variable N-terminal flank [168] and CD4 contact residues 
GGD368-E370. Few mutants from this library were identified that increased replicative 
capacity over wt virus or conferred a more open Env conformation. Nevertheless, many 
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variant residues on the N-terminal flank conferred wt-like replication, contrasting with 
mutations in conserved CD4 contact residues where wt residues predominated during 
PBMCs replication (Figure 3.4b, c). These observations indicate that these latter amino 
acids have been highly selected during evolution as would be predicted for sites 
contacting a major receptor. The lack of beneficial mutants in the variable 361-365 region 
was curious, since a motif on this variable flank region was previously identified that 
influenced the non-mac-tropic phenotype of LN40 Env [177]. However, this motif 
required the presence of further determinants in V3 to mediate maximal effects on LN40 
Env properties [177].   
A small number of substitutions on the N-terminal flank did affect Env properties. 
LN40 Q363D and Q363E mutants were more sensitive to the CD4bs mab, b12. However, 
minimal effects on sCD4, 447-52D and 2G12, suggested a localized effect on b12 
binding, rather than significant trimer opening. The 365V substitution conferred a small 
(not significant) increase in replication for LN40 Env+ virus in PBMCs. When 
introduced into other Envs, an increase in sensitivity to PG9 and PGT145 was detected 
for Z1789M (and more marginally for LN8) consistent with effects on the conformation 
of the TAD but without detectable opening of the trimer. 
 Several residues in library-371-380 could be replaced by residues that enhanced 
replication in PBMCs. These residues had major effects on the TAD and trimer 
conformation as indicated by significant increases in sensitivity to sCD4, CD4bs mabs b6 
and b12, and to V3 crown mab 447-52D depending on substitution. The positions in 371-
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380 are each closely associated with the Phe-43 cavity and likely play a role in 
controlling Env conformational changes in response to CD4 binding [333, 334].  
 Residues that opened the TAD and trimer had different effects on the exposure of 
mab epitopes. Several residues in the 371-380 region conferred enhanced sCD4 
sensitivity, yet affected exposure of the 447-52D V3 epitope differently. Thus, G380P 
increased sensitivity to sCD4 in LN40, LN8 and Z1792M, but also imparted greatly 
enhanced sensitivity to 447-52D for both LN40 and LN8. In contrast, S375W, S375Y and 
S375F mediated increases in sCD4 sensitivity but had no effect on 447-52D resistance. 
Thus different residues associated with the Phe-43 cavity, regulate distinct conformations 
of the TAD at the trimer apex and highlight a potential role for this region in regulating 
immune protection. 
For several mutants that had modified TAD and/or trimers, it was noted that 
sensitivity to 2G12 was reduced. Mab 2G12 recognizes several glycans on gp120 and its 
ability to bind and neutralize virions depends on their orientation.  Reduced sensitivity to 
2G12 suggests that modified, more open Envs have shifted the glycans forming this 
mab’s epitope as previously reported [182]. 
The glycan N160 in V2 is a target for V2q antibodies and its lack explains why 
LN40 Env is insensitive to PG9 and PGT145 mabs. This was unfortunate since V2q mabs 
can be used to investigate changes in TAD configuration. Introduction of the potential 
glycan site at N160 in LN40 Env failed to restore sensitivity to V2q mabs. However, the 
presence of the glycan site at N160 increased sensitivity to sCD4 and V3 mab, 447-52D. 
146 
 
These observations indicate that in the context of LN40, N160 modified the trimer 
conformation, exposing the V3 loop and increasing access for CD4. N160 also enhanced 
the effects of other substitutions on Env conformation. For example, 373E, 377V and 
380P were all more sensitive to V3 loop mab, 447-52D in the presence of N160. N160 on 
LN40 may loosen the TAD and facilitate some substitutions to confer more extensive 
shifts in conformation. It is worth noting that the effects of the S375W substitution were 
not enhanced by N160. These observations add further support to the conclusion that 
S375 substitutions induce a trimer conformation distinct from those imposed by other 
substitutions e.g at 377, 380. 
It was surprising that several mutant LN8 and Z1792M Env trimers were 
sufficiently open to bind b6 and (for LN8 mutants) 447-52D, yet remained sensitive to 
V2q mabs (that predominantly recognize closed trimers), albeit with modestly increased 
IC50s. One explanation is that Envs transition from closed to open states and back, so 
that mabs b6 and 447-52D capture the open form, while the V2q mabs capture the closed 
form. However, it is also possible that some substitutions can expose the b6 epitope in the 
CD4bs region as well as the 447-52D epitope without significantly opening the TAD 
(Figure 3.8).  
In summary, mutations in the CD4 binding loop and flanks that affect trimer 
conformation were identified in replication competition assays. Different substitutions 
identified were associated with distinct conformations that impacted on the exposure of 
the V3 loop and TAD, the CD4bs and the efficiency of CD4 interactions in Envs from 
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different clades. The information presented contributes to the establishment of universal, 
cross clade rules for regulating trimer conformation and will be invaluable in the design 
of next generation Env immunogens. 
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Methods 
Construction of plasmid-encoded libraries 
Env saturation mutant libraries were generated using a previously described 
approach [51, 326]. Briefly, the env gene was cloned into pRNDM to generate a plasmid 
without BsaI restriction sites. Inverted BsaI sites were then introduced to allow for a 
cassette ligation strategy with each single codon randomized as NNN to efficiently 
generate libraries of all possible codon substitutions; a separate cassette was used to 
mutate each codon to all 63 non-parental ones. Libraries of single codon mutants at 10 
consecutive codons were combined and the resulting pool transferred from pRNDM to 
replication competent pNL4.3 with LN40 env, using sequence and ligation independent 
cloning (SLIC) [307]. A SLIC destination vector was generated that encoded the HIV 
genome with the majority of the env gene removed and a unique BmtI restriction site at 
this location. The destination vector was digested with BmtI and resected with T4 DNA 
polymerase as described previously [307] to leave approximately 30 base pairs of single 
stranded DNA at each end. Linear fragments of the env libraries from pRNDM with 
single stranded regions matching the prepared destination vector were generated by PCR 
(using Pfusion high fidelity polymerase and eight cycles of amplification to minimize 
amplification errors) and treatment with T4 DNA polymerase. The prepared library and 
destination DNA were mixed at equal molar amounts, annealed for 30 minutes at 37oC, 
and transformed into bacteria to generate the plasmid libraries encoding full-length viral 
genomes.  
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Viral library recovery and competition experiments 
2.5 μg of DNA encoding full length NL4.3 carrying LN40 or 361-370 and 371-
380 mutant library envelopes were transfected into 293T cells using calcium phosphate. 
Supernatants carrying full length NL4.3-LN40env or libraries (P0) were harvested 48 h 
after transfection, clarified (1,000g for 10 min), aliquoted, and stored at 152°C. HeLa 
TZM-bl cells were used to titrate the P0 stock libraries using the LTR-controlled β-
galactosidase reporter gene to identify infected cells as described previously [356]. 
20x106 PHA treated peripheral blood mononuclear cells (PBMCs) were recovered 
from a frozen stock and infected with 2 ml wild type (wt) LN40 virus, or with each 
library virus stock (P0) in duplicate. After 3 hours, infected PBMCs were centrifuged at 
1200 rpm for 10 min. Supernatant was harvested and frozen as day 0 (D0). Cells were 
washed with 5ml of RPMI/10% fetal calf serum twice before adding 10 ml RPMI/10% 
fetal calf serum with IL-2 (Roche Inc.). Medium was changed after 4 days and 
supernatants collected on day 8. 200 μl samples were treated with recombinant DNase I 
for 2h at room temperature to eliminate any carry over of plasmid DNA before extracting 
RNA using the High pure viral RNA kit (Roche Inc.).  
 
Sequence analyses and estimation of fitness 
HIV genomic RNA was extracted from supernatants containing virions using 
High Pure Viral RNA kit (Roche Inc.). Viral RNA was reverse transcribed into cDNA 
using primers binding downstream of randomized libraries and SuperScript III (Life 
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Technologies Inc.). Subsequent processing steps were as described previously for 
analyzing mutant frequency [326]. Briefly, samples were barcoded to distinguish 
replicates as well as plasmid, P0, and P1 samples and submitted for Illumina 36bp single 
read sequencing on a Genome Analyzer II. Reads with a phred score of 20 or above (>99% 
confidence across all 36 bases) were analyzed (Table 3.7). The relative abundance (A) of 
each point mutant of plasmid, P0 and P1 library was estimated from read abundances (R) 
as indicated below in equation (1).  
       
    
   
  (Eq. 1) 
The frequency change (F) of a mutation from P0 to P1 (equation 2) was used as an 
estimate of the enrichment or depletion during viral expansion. Two replicates of P1 were 
determined separately.  
          (Eq. 2) 
Selection coefficients (s) representing the experimental effects of each mutation were 
calculated by normalizing the median of stop codon to -1 (representing null fitness) and 
wild-type synonyms to 0 (representing no fitness effect), as indicated in equation 3.  
  
            
 
     
       
 (Eq. 3) 
The above analyses yielded estimates of fitness effects for each codon with 
frequency > 0.015% in the P0 library (Table 3.8). Mutations below this frequency in P0 
were likely subject to highly stochastic sampling in the pool of viruses used to start P1 
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passages. These mutations (4% of the data) also had very low frequency in the plasmid 
library. The high correlation between frequency of mutants in P0 and the plasmid library 
suggested that viral recovery by transfection provided sufficient sampling of mutants in 
the plasmid library (Figure 3.2E), so mutants with low frequency in P0 library was due to 
their inherent low frequency in the plasmid library and not due to a bottleneck effect or 
selection in viral recovery.  
As estimates of selection coefficient (s) had some noise, in particular in the 361-
370 library (Figure 3.4b,c), the median of s of synonymous codons encoding the same 
amino acid was used to represent s of that amino acid, to minimize impact from outliers.  
RMSD was determined between the two replicates to estimate variation in s of amino 
acids. The two replicates in P1 were then pooled to estimate the selection coefficient of 
amino acids to further improve reproducibility. Specifically, the median was computed 
for s of all synonymous codons encoding the same amino acid in both replicates as s for 
that amino acid (Table 3.1). 
 To determine whether a mutant is statistically beneficial, or wt -like, or 
deleterious, the s of each amino acid was compared to the median of s of resampled wt -
synonyms, and defined mutants with s significantly greater than that of wt -synonyms as 
beneficial; mutants with s significantly less than that of wt-synonyms as deleterious and 
the rest as wt -like. All wt-synonyms of both replicates were pooled for each library (38 
for Library-361-370 library and 50 for Library-371-380 library). For each amino acid, wt-
synonyms were resampled as twice the number of synonymous codons encoding that 
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amino acid and compared the median of s of resampled wt-synonyms with s of that amino 
acid. This process was repeated 10,000 times for each amino acid and computed the 
proportion (f) when s of amino acid is greater than median s of resampled wt -synonyms.  
1-f (if f>0.5) or f (if f<=0.5) is the empirical p value of this amino acid having a fitness 
effect greater than or less than wt -synonyms. Before multiple test corrections, mutants 
with p value <0.025 have a significantly different s with wt -synonyms (Table 3.1).  A 
two-sided 5% False Discovery Rate (FDR) was then applied as multiple test correction.  
After that, amino acid mutants with a sufficiently small p value were classified as 
statistically beneficial or deleterious and the rest as statistically wt -like. False negative 
rates were not estimated, so that a small number of mutants that were classified as wt-like 
might be beneficial or deleterious. Amino acids with more synonymous codons were 
treated as having more replicates so that they would have stronger statistical power in 
classification.   
 
 Cloning of individual mutants 
A panel of individual gp120 mutations were cloned into the pSVIIIenv vector that carried 
clade B LN40, LN8 or clade C Z1792M env genes and analyzed in isolation. A cassette 
with a single mutant was ligated into BsaI digested pRNDM, as described above, and 
then subcloned into pSVIIIenv. For LN40 env, one KpnI site in pSVIIIenv vector outside 
env coding region, was eliminated with quick change mutagenesis. pRNDM with mutants 
and pSVIIIenv were both digested by KpnI and SpeI, and the mutant fragments from 
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pRNDM ligated into digested pSVIIIenv. For LN8 env, two sets of primers were utilized 
to generate two fragments of env by PCR.  The 3’ region of one fragment shared a 27-
nucleotide homologous region with the 5’ region of the other fragment, and the 3 
nucleotides in the middle of the homologous region were mutated to desired mutations by 
PCR. Primers are described in Table 3.9. pSVIIIenv was digested by KpnI and SpeI, 
followed by T4 polymerase trimming to generate matched ends ready for homologous 
recombination. The digested vector and the two PCR generated fragments were then 
assembled back into the full length pSVIIIenv vector through Gibson assembly to 
generate a set of mutants (New England Biolabs, Ipswich, MA).   
 
HIV Env clones, sCD4 and monoclonal antibodies 
 EMPIRIC libraries were cloned into pNL4.3 carrying the LN40 env gene. 
A version of LN40 env was used that was chimeric with LN40 gp120 and gp41 
sequences derived from the B33, a brain env derived from the same subject as LN40. 
This chimeric Env is non-mac-tropic and carries determinants and properties of non-mac-
tropism in gp120 as reported previously [177, 335, 336, 343]. Soluble CD4 was from 
Progenics Inc. Monoclonal antibodies (mabs) PG9, PG16 (V2q), b12 (CD4bs), 447-52D  
PGT145 (V2q) and VRC0  (V3 loop) and 2G12 (glycans) were from Polymun Scientific  
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Table 3.9: PCR primers used to introduce individual mutations into Env expression 
vectors. 
 
Primer Set Primer nomenclature Primer 
Set 1 ln40_upKpnF GGGTCACAGTCTATTATGGG 
 ln40_downKpnR GTAAGTCATTGGTCTTAAAG 
Set 2 LN8_373E_F CCAGAAATTGTAgagCACAGTTTTAAT 
 LN8_373E_R ATTAAAACTGTGctcTACAATTTCTGG 
 LN8_373N_F CCAGAAATTGTAaatCACAGTTTTAAT 
 LN8_373N_R ATTAAAACTGTGattTACAATTTCTGG 
 LN8_375H_F ATTGTAATGCACcacTTTAATTGTGGA 
 LN8_375H_R TCCACAATTAAAgtgGTGCATTACAAT 
 LN8_375W_F ATTGTAATGCACtggTTTAATTGTGGA 
 LN8_375W_R TCCACAATTAAAccaGTGCATTACAAT 
 LN8_377V_F ATGCACAGTTTTgtcTGTGGAGGGGAA 
 LN8_377V_R TTCCCCTCCACAgacAAAACTGTGCAT 
 LN8_380P_F TTTAATTGTGGAccgGAATTTTTCTAC 
 LN8_380P_R GTAGAAAAATTCcggTCCACAATTAAA 
 LN8_380A_F TTTAATTGTGGAgctGAATTTTTCTAC 
 LN8_380A_R GTAGAAAAATTCagcTCCACAATTAAA 
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Inc. (Austria). (CD4bs) were prepared in house. Mab b6 (CD4bs) was provided by 
Dennis Burton (Scripps Research Institute), mab 17b (CD4i) by George Lewis (Institute 
of Human Virology) and mab PGT128 (V3, glycans) was provided by IAVI. 
 
Antibody neutralization assays and IC50 determination 
Env+ pSVIIIenv constructs carrying different single mutations were cotransfected 
into 293T cells with env-minus pNL43. Env+ pseudovirions were harvested after 48 
hours, clarified by low speed centrifugation and frozen as aliquots at -152°C. Env+ 
pseudovirions were titrated on HeLa TZM-bl cells cells, which carry β-galactosidase and 
luciferase reporter genes controlled by HIV LTR promoters [356]. Infected cells were 
visualized 48 hours after infection as focus forming units (FFU) following staining for β-
galactosidase activity. Since Env+ pseudovirions are only capable of a single round of 
replication, individual cells or small groups of divided cells were counted as foci.  
Neutralization and inhibition assays were performed as described previously 
using 200 FFU of Env+ pseudovirus and evaluating residual infectivity on HeLa TZM-bl 
cells via a luminescence readout [168, 336].  
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Chapter IV - A balance between inhibitor binding and substrate 
processing confers influenza drug resistance 
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Abstract 
 The therapeutic benefits of the neuraminidase (NA) inhibitor oseltamivir are 
dampened by the emergence of drug resistance mutations in influenza A virus (IAV). To 
investigate the mechanistic features that underlie resistance, we developed an approach to 
quantify the effects of all possible single nucleotide substitutions introduced into 
important regions of NA. We determined the experimental fitness effects of 450 
nucleotide mutations encoding positions both surrounding the active site and at more 
distant sites in an N1 strain of IAV in the presence and absence of oseltamivir. NA 
mutations previously known to confer oseltamivir resistance in N1 strains, including 
H275Y and N295S, were adaptive in the presence of drug, indicating that our 
experimental system captured salient features of real-world selection pressures acting on 
NA. We identified mutations, including several at position 223, that reduce the apparent 
affinity for oseltamivir in vitro. Position 223 of NA is located adjacent to a hydrophobic 
portion of oseltamivir that is chemically distinct from the substrate, making it a hotspot 
for substitutions that preferentially impact drug binding relative to substrate processing. 
Furthermore, two NA mutations, K221N and Y276F, each reduce susceptibility to 
oseltamivir by increasing NA activity without altering drug binding. These results 
indicate that competitive expansion of IAV in the face of drug pressure is mediated by a 
balance between inhibitor binding and substrate processing.  
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Introduction 
Influenza A virus (IAV) causes a highly contagious acute respiratory illness 
responsible for significant morbidity and mortality in humans. IAV has two surface 
glycoproteins, hemagglutinin (HA) and neuraminidase (NA) that are used to distinguish 
subtypes. The most common IAV subtypes that infect humans are H1N1 and H3N2. 
H1N1 IAV has caused several influenza pandemics, including the 1918 Spanish flu and 
the 2009 swine flu [183, 193]. HA binds to sialic acid that is part of glycoproteins located 
on the surface of host cells and is critical for initial attachment and infection. NA cleaves 
sialic acid from host cell glycoproteins during the release of newly formed viral progeny, 
thus reducing viral affinity for previously infected cells [209]. The NA competitive 
inhibitor oseltamivir is widely used for treatment of influenza [239]. Oseltamivir is a 
successful example of structure-based drug design, in which electrostatic interactions 
have been optimized between the drug and the protein [357]. As NA is an enzyme, the 
active site is more conserved than the rest of the protein surface to preserve the necessary 
activity for viral release [358]. Yet antiviral resistance is a persistent problem with IAV; 
the use of oseltamivir to prevent morbidity and mortality has been disappointing due to 
widespread drug resistance [359-361]. Improved approaches to combat influenza 
infection and an increased understanding of drug resistance mechanisms are in great 
demand.  
Clinical reports have shown the emergence of a handful of different oseltamivir-
resistance mutations in H1N1 IAV following the clinical use of oseltamivir [361]. Thus 
far, mutations that have been associated with oseltamivir resistance occur at only a few 
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positions that neighbor the NA active site [202, 264, 362, 363]. The most prevalent 
resistance mutation in H1N1 IAV encodes the H275Y substitution (N1 numbering system 
used throughout), which spread globally in 2008 [360]. Most oseltamivir resistance 
mutations that have been studied cause defects in viral expansion in the absence of drug 
pressure [252, 265]. For example, the H275Y mutation that is commonly observed in 
H1N1 isolates with oseltamivir resistance, caused a reduced titer in the absence of drug in 
the WSN strain [262]. In the case of H275Y, secondary mutations including R222Q and 
V234M can restore fitness and the combined H275Y/R222Q/V234M genotype became 
predominant in circulating H1N1 in 2008 [364]. The analyses of individual IAV clones 
indicate that costs of adaptation can mediate the mutations that emerge in response to 
drug pressure. Because only a limited number of mutations have been studied, often in 
different strain backgrounds, the extent to which fitness costs mediate the emergence of 
drug resistance mutations in IAV is unclear.  
To effectively probe drug resistance mechanisms, precise measurements of the 
effects of individual mutations are critical because small differences can distinguish 
mutants that will have different evolutionary outcomes. This remains a technical 
challenge despite exciting recent findings from gene-wide analyses of mutant effects in 
IAV [50, 71, 72, 75, 77, 365] and genome-wide analyses in poliovirus [366]. Gene-wide 
studies of mutations in IAV provide useful estimates of the average impact of mutations 
at each amino acid position and effectively delineate the strength of selection acting at 
each position in the NA, NS, NP and HA genes of IAV. However, the effects of specific 
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amino acid substitutions from gene-wide analyses of IAV [72, 77, 365] are only modestly 
reproducible (R2 ranging from 0.34 to 0.62).  
To measure fitness effects in IAV with high precision, we adapted the EMPIRIC 
(Exceedingly Meticulous and Parallel Investigation of Randomized Individual Codons) 
approach that we previously developed to investigate fitness landscapes in yeast [51, 53, 
54, 56, 326, 340, 367]. The EMPIRIC approach, along with related approaches developed 
by others [47, 57, 58, 368], utilizes bulk competitions of engineered mutational libraries 
and next generation sequencing to estimate the frequency of each mutation before and 
after selection. A similar strategy used by Sun and colleagues was successful in 
identifying resistance mutations in the NS5A gene of hepatitis C virus [76]. Here, we 
adapted the EMPIRIC approach to systematically quantify the fitness effects of mutations 
in the NA gene of influenza A/WSN/33, which is an H1N1 strain. The results of this 
study provide improved precision relative to other high throughput studies of IAV 
mutants and enabled a robust assessment of drug resistance and fitness costs in the 
absence of drug pressure. 
Our results indicate that a balance between mutant effects on binding to drug and 
processing of substrates mediates drug resistance mutations. In the absence of drug 
pressure, most mutations exhibited fitness defects. The presence of oseltamivir changed 
the fitness effects of many mutations including a handful that became adaptive. The 
strongest drug adaptive mutations (H275Y, N295S, and I223M) have previously been 
associated with drug resistance in clinical N1 isolates [255, 280, 360]. These drug 
adaptive mutations had similar fitness defects (30-33%) compared to the parental strain in 
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the absence of oseltamivir. In contrast, mutations associated with drug resistance in 
clinical N2 isolates caused severe fitness defects when introduced into the N1 strain used 
in our experiments (60-100% defects relative to the parental N1 strain in the absence of 
drug) that hinder them from being adaptive in N1. These observations suggest that fitness 
costs govern the resistance mutations that emerge in different IAV subtypes. We 
observed the vast majority of mutants at position 223 became adaptive to oseltamivir and 
had decreased drug binding. We also identified two drug adaptive mutations, K221N and 
Y276F that did not decrease drug binding, but increased the efficiency of substrate 
processing. These observations demonstrate that resistance to oseltamivir can occur by 
two distinct mechanisms: decreased binding to drug or increased efficiency of substrate 
processing.  
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Results 
We analyzed the fitness effects of all single nucleotide mutations in five specific 
30 base regions of NA, focusing on mutations encoding regions of NA immediately 
adjacent to the active site as well as a control region on the surface of NA far from the 
active site (Table 4.1 and Figure 4.1A). Regions around the active site were selected to 
include amino acid positions previously associated with oseltamivir resistance in human 
isolates, as well as positions that could encompass potentially novel mutations. Mutations 
were site-specifically engineered into plasmid-encoded viral genomes using a previously 
described plasmid system in which each influenza gene segment of the A/WSN/33 H1N1 
strain is encoded on an individual plasmid [369]. Libraries of NA plasmids containing all 
possible single nucleotide mutations at 30 consecutive bases were generated. The NA 
plasmid libraries were combined with plasmids containing the remaining seven segments 
and transfected into co-cultured 293T and Madin-Darby canine kidney (MDCK) cells to 
recover an initial viral pool containing engineered mutations (P0) (Fig. 4.1B). This pool 
was used to infect MDCK cells in the absence or presence of oseltamivir, a competitive 
inhibitor of NA. P1 viruses were isolated from these infected MDCK cells. 
 
Systematic approach to quantify the fitness effect of NA mutants with high precision 
 We analyzed a total of 50 amino acid positions in NA. The frequency of each 
mutation in the plasmid, P0, and P1 samples provided a direct estimate of the fitness 
effects of all 450 single nucleotide mutations in these regions without drug pressure  
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Figure 4.1: A high throughput approach was optimized to precisely analyze the 
fitness effects of NA mutations in influenza A virus  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.1 A high throughput approach was optimized to precisely analyze the fitness 
effects of NA mutations in influenza A virus. (A) Molecular image based on the PDB ID: 
3B7E structure [197] of NA showing a monomer with the regions near the active site as well as a 
control region far from the active site that were chosen for mutational analysis highlighted in 
magenta. A competitive inhibitor bound in the active site of NA is shown as yellow spheres. (B) 
Site-directed mutagenesis was used to introduce point mutations into the plasmid encoding the 
NA gene from the influenza A/WSN/33 mixed with plasmids encoding wild-type versions of the 
other seven gene segments from this strain. Plasmids were co-transfected into 293T/MDCK cells 
to generate an initial P0 library of viral particles that were subsequently expanded through 
infection of MDCK cells to generate a P1 library. Focused deep sequencing was utilized to 
quantify the enrichment or depletion of each mutation during viral expansion. (C) Reproducibility 
of high throughput estimates of fitness effects from experimental replicates of viral expansion. 
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Silent substitutions (wild-type synonyms) in this plot are green and nonsense mutations (stop 
codons) are red. (D) Reproducibility of estimates of fitness effects in replicates of viral expansion 
with 1 μM oseltamivir. (E) Correlation between fitness effects estimated for a panel of individual 
mutations analyzed in isolation with estimates from bulk competitions. 
 
 
 
 
Table 4.1: Amino acid regions of NA analyzed 
Region Amino acid positions 
Active-site proximal 1 112-121 
Active-site proximal 2 
220-229 
Active-site proximal 3 
271-280 
Active-site proximal 4 
292-301 
Surface loop distant from active site 83-92 
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(Table 4.2 and 4.3). Stop codons were universally depleted in P0 samples relative to 
plasmid.  In contrast, synonymous mutations were relatively unchanged in frequency 
between plasmid, P0, and P1 pools (Figure 4.2).  For mutations whose frequencies could 
be assessed in the plasmid, P0, and P1 pools, we observed consistent changes in 
frequency during viral recovery (plasmid to P0) and viral propagation (P0 to P1) (Figure 
4.3). These observations indicate that similar selection occurred during P0 viral recovery 
and P1 viral propagation. To compare the effects of mutations in different experiments 
with potential region-specific bias, we normalized fitness effects, setting the average stop 
codon for each bulk competition to -1 to represent null NA function and average 
synonymous substitutions in each competition to 0 to represent WT-like fitness. We 
estimated fitness effects of mutations independently from changes in frequency from 
plasmid to P0, and from P0 to P1. 
 Fitness estimates for mutations based on P1 analyses in the absence and presence 
of drug are shown in Fig. 4.1C and Fig. 4.1D, respectively, and results were highly 
reproducible with R2 > 0.9 for experimental replicates of viral expansion. Comparing 
bulk analyses with mutations analyzed in isolation is an important control that probes 
both stochastic noise and potential systematic differences between these independent 
approaches. We performed fitness analyses on a panel of 22 clones of individual 
mutations and observed strong correlation with fitness estimates from our bulk analyses 
(Figure 4.1E and Figure 4.4). These observations indicate that our bulk studies are 
accurate estimates of fitness effects of isolated clones. 
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Figure 4.2: Observed effects of nonsense mutations encoding stop codons and silent 
mutations  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.2 Observed effects of nonsense mutations encoding stop codons [38] and silent 
mutations encoding wild-type synonyms (green) in P0 library relative to plasmid library (A), 
without drug (B) and with 1 μM oseltamivir (C). Panels B and C depict the average and 
standard deviation for each class of mutations without normalization. Data in (B) and (C) are 
represented as mean ± SEM. (D) Distributions of observed effects for stop codons and wild-type 
synonyms across all regions analyzed with normalization within each region of stop codons to -1 
and wild-type synonyms to 0. 
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Figure 4.3: Mutant frequency changes between plasmid and P0 correlate with 
changes between P0 and P1  
 
 
 
 
 
 
 
 
 
 
 
Figure 4.3 Mutant frequency changes between plasmid and P0 correlate with changes 
between P0 and P1. Fitness effects under standard conditions for all regions were determined 
based on enrichment or depletion estimates from sequencing. For each region, stop codons were 
normalized to s = -1, and wild-type synonyms to s = 0. 
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Figure 4.4: Studies of individual mutations analyzed in isolation 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.4 Studies of individual mutations analyzed in isolation. (A) Titers of individual 
mutants after P0 rescue determined by plaque assay. Error bars indicate the standard deviation of 
three independent titer determinations. (B) Average outer diameter of plaque size of individual 
mutants with titers greater than 104. Error bars indicate the standard deviation of measurements of 
20 randomly chosen plaques. N.D. indicates radius of plaques not determined due to very low 
titer. Data in (A) and (B) are represented as mean ± SEM. (C) Images of plaques for all mutants 
with P0 titer greater than 104. 
 
 
170 
 
Fitness effects of mutations in NA without drug pressure 
We examined how missense mutations that change the amino acid sequence 
impact fitness in the absence of drug pressure (Figure 4.5A). The vast majority of amino 
acid changes in regions of NA close to the active site caused severe fitness defects. In 
contrast, many amino acid changes in the control region located far from the active site 
were compatible with robust fitness (Figure 4.5B). These observations are consistent with 
the intuition that enzyme catalysis is sensitive to the physical composition of the amino 
acids surrounding the active site. To estimate the sensitivity of each amino acid position 
to mutation, we calculated the average fitness effect observed for missense mutations 
(Figure 4.6A). This metric of mutational sensitivity correlated (R2 = 0.46) with solvent 
exposure (Figure 4.6B), indicating that solvent exposure contributes to the sensitivity of a 
position to mutation. 
We examined the relevance of these experimental fitness analyses of the WSN 
strain under laboratory conditions to natural evolution. The WSN strain was chosen for 
these experiments because it can be efficiently recovered from plasmids, which helped 
facilitate the recovery of diverse viral libraries necessary for the competition experiments. 
WSN was cloned from a strain originally isolated in 1933 that had subsequently been 
passaged under laboratory conditions. The NA gene of WSN contains an unusual deletion 
in the stalk region that has been observed to partially impair viral expansion in chicken 
eggs, but not in mammalian cells [370]. The sequence of amino acids that comprise the 
active site of NA are similar to circulating viruses. To investigate how lab adaptation of 
WSN may influence the interpretation of our results, we compared the experimental  
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Figure 4.5: Fitness effects of mutants in WSN correspond to the frequency of amino 
acids observed in sequenced H1N1 isolates 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.5. Fitness effects of mutants in WSN correspond to the frequency of amino acids 
observed in sequenced H1N1 isolates. The distribution of fitness effects observed for mutations 
in four regions proximal to the active site (A) and one region distant from the active site (B). 
Null-like and WT-like fitness effects are colored red and green and were based on observations of 
stop codons and WT synonyms. Fitness effects of amino acid changes were compared to the 
frequency of amino acids observed in 6205 sequenced H1N1 isolates (C) and 5279 sequenced 
H3N2 isolates (D) available from the Influenza Research Database [371]. (E) Relative MUNANA 
activity of NA variants of WSN expressed in 293T cells monitored using a fluorescent substrate. 
Cells lacking the NA gene were included as a blank control. Error bars indicate the standard 
deviation of 3 biological replicates. 
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Figure 4.6: Sensitivity to missense mutations of each amino acid position 
 
 
 
 
 
Figure 4.6 Sensitivity to missense mutations of each amino acid position. (A) The sensitivity 
to mutation of each amino acid position. In graphs, bars are colored red if the average fitness 
effect of a missense mutation was null-like, green if it was wild-type-like, and grey for all others. 
(B) Correlation between average experimental fitness effect and fraction of solvent accessible 
surface area of each amino acid position.  
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fitness effects of amino acid changes that we observed in WSN with the frequency of the 
same amino acids in 6,205 sequenced H1N1 isolates available from the influenza 
research database [371] (Figure 4.5C).  
The amino acids most frequently sampled in the sequenced H1N1 isolates, 
including the most frequent amino acid at each position that we experimentally analyzed, 
all supported robust viral expansion when generated in the WSN genetic background 
(Figure 4.5C). In contrast, the vast majority of mutations that caused severe experimental 
fitness defects in WSN were either never or rarely observed in sequenced H1N1 isolates. 
Multiple factors could contribute to the observation that some mutations with severe 
fitness defects in WSN were rarely observed in sequenced isolates including a strong 
dependence on genetic background for these mutations as well as potential rare errors in 
the sequencing process of these isolates. Overall, the correspondence we observe between 
WSN fitness effects and the frequency of amino acids observed in sequenced H1N1 
isolates suggests that our analyses of NA mutations in WSN capture many salient 
features of natural selection acting on the NA protein of circulating H1N1 IAV.  
To investigate the extent to which our fitness experiments in WSN could extend 
to other IAV strains, we compared them to the frequency of amino acids observed in 
5,279 sequenced H3N2 isolates available from the influenza research database [371] 
(Figure 4.5D). Many of the most common amino acids identified in H3N2 sequenced 
isolates were moderately to strongly deleterious when generated in WSN. This 
observation indicates that strongly epistatic or context-dependent amino acid 
substitutions have accrued during the divergence of the N1 and N2 proteins. 
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N1 and N2 subtype specific mutant effects 
To further examine how divergence of N1 and N2 proteins contribute to fitness 
effects of mutants in different genetic backgrounds, we analyzed the mutations E119V 
and R293K, which have been specifically associated with oseltamivir resistance in N2 
isolates. Both E119V and R293K had strong fitness defects when generated in the N1 of 
WSN: E119V was lethal and R293K exhibited a 62% defect relative to the parental WSN 
strain without drug pressure. We attempted to recover viral stocks from individually 
cloned plasmids encoding E119V and R293K in WSN, but neither yielded measureable 
titers (data not shown). The failure to recover viral stocks of these variants is consistent 
with the severe fitness defects observed for these mutations in our bulk competitions. A 
previous study demonstrates that oseltamivir binding is decreased by the E119V mutation 
in the WSN strain and showed that E119V dramatically reduces the susceptibility of 
WSN NA to oseltamivir inhibition compared to both the parental wild type NA as well as 
the H275Y variant that is most commonly associated with oseltamivir resistance in the 
N1 strain[263]. In the same study, the enzymatic activity of the R293K mutation was too 
low to be accurately measured by the NA inhibition experiment [263]. When expressed in 
293T cells, both the E119V and R293K variants of WSN NA had enzyme activity in the 
absence of oseltamivir that was less than 5% that observed for wild type NA in the 
absence of oseltamivir (Figure 4.5E). These observations suggest that severe fitness costs 
in the absence of oseltamivir prevent E119V and R293K from contributing to drug 
adaptation in WSN. In future research beyond the scope of this work, it will be of interest 
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to investigate the process by which N1 and N2 proteins have accumulated context-
dependent amino acid substitutions. 
 
Fitness effects of mutations in NA with oseltamivir 
To examine the impact of drug pressure on NA mutations, we compared fitness 
effects observed with and without oseltamivir (Figure 4.7A). To provide a sensitive 
readout, we utilized a concentration of drug (1 μM) that partially reduced expansion of 
the parental WSN strain. Using a Student’s t-test with multiple test correction, we 
identified 24 drug responsive mutations whose fitness effect was significantly increased 
in the presence of this concentration of oseltamivir (Table 4.4; plotted in orange in Figure 
4.7A). Most of these drug responsive mutations exhibited fitness defects without drug, 
indicating that they reduce substrate processing as well as drug binding. The fitness 
defects of many of the drug responsive mutations hindered their ability to outcompete the 
parental strain under the conditions of these experiments. Using a similar statistical 
approach, we determined that only five mutations (K221N, I223M, H275Y, Y276F, and 
N295S, N1 numbering system) were significantly more fit than the parental strain in the 
presence of 1 μM oseltamivir, and we refer to these mutations as drug adaptive. 
Three of these five drug adaptive mutations from our experiments (H275Y, 
N295S, and I223M) have previously been associated with oseltamivir resistance (Table 
4.5) [280, 361, 372]. In our experiments, H275Y was the strongest drug resistance 
mutation, with greater than two-fold increased fitness in the presence of oseltamivir 
compared to  
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Table 4.5 Experimental fitness effects of previously reported oseltamivir resistance 
mutants that were covered in the libraries analyzed in the study [255, 274, 277, 279-
281, 283, 361, 372, 373] 
Mutation Subtype No oseltamivir 
1 M 
oseltamivir 
Increase in 
fitness effect 
I117V H5N1 -0.14 0.12 0.26 
E119V H3N2, H7N9 -1.10 -1.00 0.10 
I223K H1N1, H7N9 -0.54 -0.15 0.39 
I223R H1N1, H7N9 -0.56 -0.13 0.43 
I223M H5N1 -0.33 0.23 0.56 
I223T H1N1, H5N1 -0.25 -0.01 0.24 
I223L H5N1, H3N2 -0.40 -0.02 0.38 
H275Y H1N1, H5N1 -0.31 1.12 1.43 
R293K H3N2, H7N9 -0.62 -0.38 0.24 
N295S 
H1N1, H5N1, 
H3N2 
-0.30 0.49 0.79 
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wild-type (Figure 4.7A). H275Y is the predominant oseltamivir resistance mutant that 
has appeared in seasonal and pandemic H1N1 influenza virus [361]. The N295S mutation, 
which exhibited a 50% fitness improvement in the presence of oseltamivir compared to 
wild-type in our experiments, has also been associated with oseltamivir resistance in 
different serotypes of IAV, although less frequently than H275Y [255, 274, 372]. The 
I223M mutation has been associated with oseltamivir resistance in H5N1 IAV [280]. 
These three drug adaptive mutations (H275Y, N295S, and I223M) all had similar fitness 
defects ranging from 30-33% relative to the parental strain in the absence of drug. These 
observations indicate that the influenza virus can tolerate large fitness costs in the face of 
a novel selection pressure. In principle, fitness defects of this magnitude impose 
subsequent selection for compensatory mutations that can restore substrate processing 
and fitness. This scenario has been observed with influenza viruses carrying the H275Y 
mutation that accumulated the compensatory R222Q/V234M mutations and became the 
dominant circulating strain in 2008 [364]. 
To examine if mutations with more extreme fitness costs could outcompete the 
parental strain at different drug concentrations, we measured the fitness effects of 
mutations at positions 292-301 under a range of oseltamivir concentrations (Table 4.6). 
This region includes two drug responsive mutations with different fitness costs relative to 
the WSN virus without oseltamivir: N295S (30% fitness cost) and R293K (70% fitness 
cost). These mutations both exhibited fitness effects that increased with oseltamivir 
concentration (Figure 4.7B), supporting the conclusion that these mutations reduce 
susceptibility to oseltamivir. While we observed fitness effects responding to oseltamivir  
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Figure 4.7: Oseltamivir adaptive mutations were identified by comparing fitness 
effects of NA mutations in the presence or absence of oseltamivir 
 
 
 
 
 
 
 
 
 
 
Figure 4.7 Oseltamivir adaptive mutations were identified by comparing fitness effects of 
NA mutations in the presence or absence of oseltamivir. (A) Comparison of the fitness effects 
of NA mutations with and without oseltamivir.  Mutations with a statistically significant (detail in 
Materials and Methods) increase in fitness effect in the presence of oseltamivir compared to 
without drug (above and to the left of the diagonal) are colored orange. Mutations that were 
significantly more fit than WT in the presence of drug (above the horizontal dashed line) are 
labeled.  (B) Fitness effects of two mutations associated with oseltamivir resistance in H1N1 
(N295S) or H3N2 (R293K) from bulk competitions performed over a range of oseltamivir 
concentrations. The mutations exhibited fitness effects that increased with escalating amounts of 
oseltamivir. (C) Expansion of individually isolated mutations as a function of oseltamivir 
concentration. 
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concentration, the changes in fitness effects were small (2-fold) relative to the changes in 
oseltamivir concentration (16-fold). Over this range of oseltamivir concentrations, the 
R293K mutation is always less fit than the parental strain. These observations suggest 
that the strong fitness cost of the R293K mutation hinders its ability to outgrow the 
parental strain and cause drug resistance. 
We investigated how the fitness effects of mutations based on bulk competitions 
in the presence and absence of oseltamivir compared with analyses of individual clones 
of five variants (Figure 4.7C). This comparison is complicated because different 
references are utilized in each experiment: in bulk competitions, the fitness of mutations 
are determined directly relative to WT, and in the analyses of individual clones the effect 
of drug is relative to the expansion rate of each viral variant in the absence of drug. The 
response of an isolated clone to oseltamivir when not in competition with other viruses 
should be a function of fitness effects measured in bulk competitions both with 
oseltamivir and in the absence of drug. Consistent with this principle, the order of the 
sensitivity of four isolated clones to oseltamivir (Figure 4.7C) was the same as the order 
of mutations based on the difference between fitness effects with and without oseltamivir 
(Y276F < I223M < N295S < H275Y). 
 
Position 223 is a hotspot for mutations that decrease binding to oseltamivir   
Hotspots have been associated with drug resistance in many systems [374, 375]. 
To scan for potential hotspots that impact oseltamivir binding relative to substrate 
processing, we calculated the average drug responsiveness (defined as change in average 
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fitness effect of mutations with oseltamivir compared to without drug) at each analyzed  
position (Fig. 4.8A). Mutations at position 223 and 275 exhibited the strongest averaged 
oseltamivir responsiveness. Analyzing the individual mutations at these positions 
indicated that the responsiveness of position 275 was almost completely due to one 
mutation (H275Y) of very large effect (Fig. 4.8B). In contrast, the responsiveness of 
position 223 was due to multiple mutations with intermediate drug responsive effects. 
 To investigate the drug responsive effects of mutations at position 223 in further 
detail, we generated individual clones and examined their responsiveness to oseltamivir 
in vitro (Figure 4.8C). We observed that six different mutations at position 223 (Arg, Lys, 
Met, Leu, Thr, and Val) were less sensitive to oseltamivir than WT. All of the mutations 
at position 223 that we analyzed were more sensitive to oseltamivir than the H275Y 
mutation. Together, our results indicate that a very specific physical change at position 
275 is required to disrupt drug binding. This is consistent with structural analyses of 
H275Y, which indicate that subtle conformational rearrangements mediated by the side 
chain of E277 that is located between position 275 and oseltamivir are responsible for 
disrupting drug binding [202]. While position 275 does not directly contact oseltamivir or 
substrate, position 223 is located at the substrate binding site and can directly contact 
oseltamivir (Figure 4.8D). Position 223 contacts hydrophobic atoms in oseltamivir that 
are outside the substrate envelope and that differ in physical properties from the polar 
substrate. Distinctions between substrate and inhibitors have been associated with 
hotspots for drug resistance in HIV protease [376]. The differences between oseltamivir 
and substrate where these contact position 223 likely cause this position to be a hotspot 
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Figure 4.8: Multiple mutations at position 223 reduced the apparent binding affinity 
of NA to oseltamivir 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.8 Multiple mutations at position 223 reduced the apparent binding affinity of NA 
to oseltamivir. (A) To identify hotspots for mutations with adaptive potential to oseltamivir, we 
examined the average effect of mutations at each position on responsiveness to oseltamivir in the 
bulk competitions. (B) Oseltamivir responsiveness of single nucleotide mutations at positions 223 
and 275. (C) Enzyme activity of individually isolated viral variants as a function of oseltamivir 
concentration. The activity of I223K and I223R was estimated in 293T cells while the activity of 
other mutants and WT was estimated using virus. (D) Structural image of an NA monomer 
indicating the location of positions 223 and 275 relative to oseltamivir and a substrate analog. The 
image was generated from PDB ID: 3CL2 [202] and PDB ID: 1F8B [377]. 
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for mutations that disrupt drug binding in NA. Of note, the I223K, I223R, and I223T 
mutations have been observed in 2009 H1N1 isolates with reduced sensitivity to 
oseltamivir [279, 281], although other mutations at position 223 have not yet been 
associated with adaptation to oseltamivir in the H1N1 subtype to the best of our 
knowledge.  Structural analyses of neuraminidase with I223R demonstrate that this 
mutation physically disrupts binding to oseltamivir [277].  
 
Drug adaptive mechanism of Y276F and K221N 
The Y276F and K221N mutations had similar or slightly improved fitness 
compared to the parental strain in the absence of drug pressure (Figure 4.9A). In bulk 
competition experiments, K221N exhibited smaller differences in fitness effects with and 
without drug compared to Y276F. The small fitness differences observed for K221N in 
bulk competitions would be difficult to discern with experiments on an individual clone. 
For these reasons, conclusions regarding K221N must be considered cautiously. Y276F 
exhibited a larger fitness increase and in isolation we observed that it did require elevated 
concentrations of oseltamivir to slow expansion relative to WT (Figure 4.7C). Taken 
together, our observations indicate that Y276F improves the fitness of WSN both in the 
presence and absence of oseltamivir. To the best of our knowledge, the Y276F mutation 
has not previously been associated with oseltamivir resistance.  
To investigate potential drug adaptive mechanisms of K221N and Y276F, we 
closely examined structural and biochemical properties of each mutation. The C-C 
bond of amino acids at positions 221 and 276 are oriented away from the active site  
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Figure 4.9: K221N and Y276F are adaptive in the presence of oseltamivir because 
they increase NA activity without altering drug binding 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.9 K221N and Y276F are adaptive in the presence of oseltamivir because they 
increase NA activity without altering drug binding. (A) Fitness effects of mutations that were 
statistically more fit than WT during bulk competitions with oseltamivir. Zero represents WT 
fitness, positive values represent increased fitness relative to WT, and negative values represent 
decreased fitness relative to WT. Error bar indicates standard error of the mean with N =3. (B) 
Structural image of an NA monomer indicating the location of positions 221 and 276  relative to 
oseltamivir (blue) and a synthetic substrate used in enzymatic assays (yellow). The image was 
generated from PDB ID: 3CL2[202] and PDB ID: 1F8B [377]. (C) Relative activity of isolates 
of individual viral variants determined using the fluorescent substrate MUNANA. Enzyme 
activities were normalized to viral titer to estimate the relative enzyme activity per infectious unit. 
Error bars indicate the standard deviation of 5 biological replicates. The standard deviations are 
as follows: WT: 0.0499, Blank: 0.0002, E119V: 0.0004, R292K: 0.0001 (D) Enzyme activity of 
individually isolated viral variants as a function of oseltamivir concentration. The experimentally 
determined IC50’s are as follows: WT: 0.89 nM, K221N: 1.04 nM, and Y276F: 0.55 nM. 
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(Figure 4.9B) such that the side chains are unlikely to directly contact either the inhibitor 
oseltamivir or the sialic acid moiety of the substrate. This observation suggests that the 
fitness effects of the K221N and Y276F mutations are likely due to subtle alterations to 
the conformation or dynamics of nearby positions that do contact substrate and inhibitor. 
We analyzed the enzymatic activity of K221N and Y276F as well as the other 
three identified drug adaptive mutations (I223M, H275Y, and N295S) in vitro using a 
fluorescent substrate (Fig. 4.9C). The three drug-adaptive mutations with fitness costs in 
the absence of drug (I223M, H275Y, and N295S) all had reduced enzymatic activity 
relative to WT. These results suggest that reduced substrate turnover caused by these 
mutations is responsible for decreased fitness in the absence of drug pressure. In contrast, 
K221N and Y276F both exhibited increased enzymatic activity relative to WT. In 
principle, mutations that increase enzymatic activity without impacting drug binding can 
provide an adaptive advantage in the face of drug pressure. For example, a mutation that 
increases the efficiency of substrate processing two-fold without impacting drug binding 
will increase WT enzymatic activity in the presence of drug concentrations that reduce 
the WT enzyme efficiency 2-fold. To examine if this mechanism is relevant to the 
K221N and Y276F mutations, we analyzed the effects of these mutations on inhibition by 
oseltamivir in vitro (Figure 4.9D). Full experimental titration experiments with WT 
indicate that the results of this inhibition assay are highly reproducible. Both K221N and 
Y276F had inhibition profiles and 50% enzyme-inhibitory concentration (IC50) values 
that were similar or slightly more sensitive to oseltamivir than WT (Figure 4.9D). These 
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results indicate that the adaptive advantage of K221N and Y276F are due to increased 
efficiency of substrate processing rather than decreased binding to drug. 
 
Discussion 
Many pathogens, including IAV, accumulate mutations that make them resistant 
to currently available drugs. While some mutations that cause influenza to become 
resistant to oseltamivir have been identified, the impact of most mutations has not been 
fully resolved. In particular, the effect of most mutations in the absence of drug pressure 
has not been experimentally characterized. Here, we systematically analyzed all possible 
single nucleotide mutations in regions of the active site of the viral NA gene using the 
EMPIRIC method. Our approach provides rapid and highly reproducible fitness 
measurements of IAV mutants. We comprehensively examined fitness effects of all 
possible single nucleotide mutations in defined regions of NA in the absence and 
presence of oseltamivir, identifying mutations that confer resistance to oseltamivir and 
validating mutations with individual clones. 
Our results support the conclusion that a balance between substrate processing 
and drug binding determines the potential of an NA mutation to adapt to oseltamivir 
(Figure 4.10A).  Mutations with either decreased drug binding (Figure 4.10B, purple line) 
or increased substrate processing (Figure 4.10B, green line) should expand more 
efficiently compared to WT in the presence of drug (Figure 4.10B, black line). In 
principle, mutations that decrease drug binding without causing a defect in substrate 
processing provide the ability for viruses to expand most efficiently over the broadest  
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Figure 4.10: Mechanisms of adaptation to drug pressure 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.10 Mechanisms of adaptation to drug pressure. (A) Drug resistance is a balance 
between the effects of mutations on drug binding and substrate processing. Mutations that 
increase substrate processing or reduce drug binding favor drug resistance. (B) Theoretical model 
of the efficiency of substrate processing as a function of inhibitor concentration for mutations 
with different impacts. (C) Structural representation based on 3CL2.PDB of a NA subunit 
illustrating the location of mutations that either increased substrate processing (colored pink), or 
decrease binding to oseltamivir (colored green). Oseltamivir is shown in yellow and the catalytic 
tyrosine at position 406 is shown in cyan. 
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concentrations of drug (Figure 4.10B). Multiple lines of evidence indicate that this type 
of mutation is extremely rare: none were identified in our mutational scan, and drug 
resistance mutations identified in clinical isolates exhibit fitness costs without drug [252, 
265]. Instead, most mutations associated with oseltamivir resistance in clinical isolates 
had clear experimental fitness defects (~30%) in our experiments (Figure 4.10B, red line). 
The fitness defects of these drug-resistant mutations should impose selection for 
compensatory mutations that increase the efficiency of substrate processing, which has 
been observed both experimentally [378] and in the majority of H1N1 clinical isolates 
from 2008 [364]. 
Our results indicate that NA mutations can also provide an adaptive advantage in 
the presence of oseltamivir by increasing the efficiency of substrate processing without 
decreasing sensitivity to drug. The Y276F mutation that exhibited the largest increase in 
substrate processing efficiency and fitness effect with oseltamivir has been observed at 
low frequency (0.1%, only observed in 2009-2010) in sequenced H1N1 isolates.  The low 
frequency of Y276F in sequenced H1N1 isolates suggests that the effects of Y276F may 
be distinct in different N1 sequence backgrounds. Nonetheless, our observations of the 
effects of Y276F in WSN highlight the general mechanistic conclusion that increased 
efficiency of substrate processing by NA without reduced sensitivity to oseltamivir 
binding can lead to drug adaptation. While this type of mutation does not provide 
resistance to high levels of oseltamivir, it may act as an enabling mutation that provides 
greater sampling of secondary mutations that could lead to strong drug resistance. For 
example, a mutation that increases the efficiency of substrate processing may offset the 
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fitness costs of a mutation that reduces binding to drug and processing of substrate such 
that the double mutant disrupts binding to drug while maintaining efficient substrate 
processing. 
Our results, as well as other studies [364, 379], indicate that multiple mutations in 
NA are required to reduce oseltamivir binding while maintaining efficient substrate 
processing. The evolution of drug resistance in this scenario will be a complex 
combination of mutational probabilities as well as the effects of individual and combined 
mutations on binding to drug and processing of substrate. Additional studies of 
combinations of mutations will be critical to appreciate the full spectrum of potential 
oseltamivir resistance NA variants. This should also serve as a caution that widespread 
use of oseltamivir at sub-neutralizing concentrations will likely lead to an increased 
frequency of multiple NA mutations with adaptive benefits. 
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Materials and Methods 
Construction of plasmid-encoded libraries 
NA point mutant libraries were generated using a previously described approach 
[326, 380]. Plasmids encoding the parental NA gene as well as the other seven gene 
segments encoding the H1N1 A/WSN/33 strain in the pHW2000 vector were kindly 
provided by R. Webster (St. Jude Children’s Research Hospital, Memphis, TN). The NA 
gene was cloned into pRNDM to generate a plasmid without any BsaI restriction sites. 
Inverted BsaI sites were then introduced to enable a cassette ligation strategy to 
efficiently generate libraries of single nucleotide mutations; a separate cassette was used 
to mutate each base to all three non-parental bases. Libraries of single nucleotide mutants 
at 30 consecutive bases were combined and blended with parental (wild-type) plasmid as 
well as a panel of three stop codons at about 4-fold elevated frequency as negative 
controls for NA function. The resulting pool of NA libraries was transferred from 
pRNDM to pHW2000 [369] using sequence and ligation independent cloning (SLIC) 
[325, 380]. The pHW2000 construct contains a CMV promoter to drive expression of 
mRNA and a polII promoter in the opposite orientation to generate genomic negative 
strand RNA.  
 
Cell culture 
293T and MDCK cell lines were obtained from the American Type Culture 
Collection (Manassas, VA). The 293T cell line was maintained in 293T cell culture 
media consisting of Opti-MEM I reduced serum media (Gibco, Grand Island, NY) 
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supplemented with 5% fetal bovine serum (Hyclone, Logan, UT), 100 U/mL penicillin, 
and 100 μg/mL of streptomycin at 37°C and 5% carbon dioxide. The MDCK cell line 
was maintained in Eagle's minimal essential medium (MEM) supplemented with 10% 
fetal bovine serum, 2 mM L-glutamine, 10 mM sodium pyruvate, 1X non-essential amino 
acid, 100 U/mL penicillin, and 100 μg/mL of streptomycin at 37°C and 5% carbon 
dioxide. All cell culture reagents were from Corning (Manassas, VA) unless otherwise 
indicated.  
 
Viral library recovery and selection experiments 
Viral libraries were recovered from plasmids as previously described [369]. 
Briefly, equal numbers of 293T and MDCK cells were mixed in 293T cell culture media, 
and seeded in 6-well plates at a density of 2–6 × 105 cells/well. 293T-MDCK co-cultures 
were transfected with 1 μg of NA plasmid library and 1 μg of each plasmid encoding the 
other seven gene segments (8 μg total plasmid) using TransIT-LT1 Reagent (Mirus, 
Madison, WI). The ratio of DNA (μg) to TransIT-LT1 (μL) was 1:2. At 6 hours post-
transfection, cell growth media was replaced with fresh Opti-MEM I reduced serum 
media. At 30 hours post-transfection, TPCK-trypsin (Sigma-Aldrich, St. Louis, MO) was 
added to cell growth media to a final concentration of 0.5 g/mL. At 72 hours post-
transfection, supernatant containing viral particles was harvested and centrifuged at 
300xg for 15 minutes to remove cell debris. Supernatants were stored at -80°C . These 
recovered pools of viral variants are referred to as P0 libraries. Plaque assays were 
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performed to determine the titer (plaque forming units or PFU/mL) of each P0 sample as 
previously described [68].  
 MDCK cells were used for additional viral competition experiments. 106 MDCK 
cells were seeded in individual wells of a 6-well plate and grown for one day. Cells were 
washed twice with 1X PBS and once with cDMEM/BSA (DMEM, 100 U/mL penicillin, 
100 μg/mL streptomycin, and 7.5% BSA) before infection. P0 viral libraries were diluted 
in influenza virus growth medium (IVGM: cDMEM/BSA with 1 μg/mL TPCK trypsin). 
MDCK cells were infected at a multiplicity of infection [178] of 0.001. For each 
experimental dataset, three independent infections were conducted in the presence or 
absence of 1 μM oseltamivir. Replicate datasets were obtained by performing three 
additional independent P1 infections. Oseltamivir carboxylate was a kind gift from 
Hoffmann-La Roche Pharmaceuticals (Basel, Switzerland). Viral binding was conducted 
at 37°C with 10% carbon dioxide for one hour, followed by two washes with PBS. After 
washing, 2 mL of fresh IVGM was added to each well of MDCK cells, which were 
maintained at 37°C with 10% carbon dioxide. The supernatant containing viruses was 
collected when 50%-90% CPE was observed or at 120 hours post-infection. Supernatants 
were centrifuged at 300xg for 15 minutes and stored at -80°C. Samples recovered from 
MDCK expanded viral pools were referred to as P1.  
 
Analyses of individual mutants 
A panel of individual NA variants were cloned into plasmids and analyzed in 
isolation. Viral samples were recovered from 293T-MDCK cells as described for library 
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samples. Titers of P0 samples were determined for each variant using plaque assays. For 
variants that produced P0 samples with titers >10,000 PFU/mL, we also analyzed plaque 
size. Plaque size was measured using a Nikon SMZ1500 microscope for 20 randomly 
selected and well separated plaques for each variant analyzed (Figure 4.4).  
For a subset of variants, infectivity was analyzed as a function of oseltamivir 
concentration as previously described [381]. Briefly, confluent MDCK cells in 24-well 
plates were infected at an MOI of 0.01. The infection was conducted in a range of 
oseltamivir concentrations (0, 0.1, 0.3, 1, 3, 10, 30 and 100 μM), and incubated at 37°C 
with 10% carbon dioxide. Supernatants were collected 3 days post-infection and virus 
titer was determined by plaque assay. 
 
Analyses of enzyme activity in vitro 
Enzyme activity of NA was determined using fluorogenic 
2’‐(4‐methylumbelliferyl)‐alpha‐D‐N-acetylneuraminic acid (MUNANA) substrate 
according to the manufacturer’s instructions (Life Technologies, Carlsbad, CA). Briefly, 
recombinant viruses were incubated with MUNANA substrate at a final concentration of 
0.1 mM for one hour at 37°C  with shaking. After this incubation, fluorescence was 
measured using a Victor X5 plate-reader (PerkinElmer, Waltham, MA) with a 355 +/- 10 
nm excitation filter and a 460 +/-20 nm emission filter. RFU was normalized to the titer 
of viruses determined by plaque assay to obtain estimates of relative NA activity between 
different variants. To estimate sensitivity to oseltamivir, MUNANA assays were 
performed in the presence of a range of oseltamivir concentrations. Recombinant viruses 
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were incubated with various concentrations of oseltamivir for 45 minutes at 37°C with 
shaking and then reacted with MUNANA as described. The fluorescent signal at each 
concentration of oseltamivir was normalized to the signal in the absence of oseltamivir 
and the resulting data fit to a standard binding equation in order to estimate IC50 values. 
Enzymatic activity of E119V and R293K was estimated by transiently expressing NA on 
the surface of 293T cells according to a previously published protocol with modifications 
[364]. Briefly, an equal amount of plasmid harboring WT or mutant NA was transfected 
into an equal number of 293T cells using TransIT-LT1 Reagent (Mirus, Madison, WI). 
293T cells were harvested 24 hours post transfection and resuspended in non-lysis buffer 
before subject to MUNANA assays as described for recombinant viruses. Sensitivity of 
I223R and I223K to oseltamivir was also estimated by expressing NA in 293T cells and 
then incubated with oseltamivir, followed by reaction with MUNANA as described. IC50 
values were estimated by fitting normalized signal to a standard binding equation. 
 
Sequence analyses 
Influenza genomic RNA was extracted from supernatants containing virions using 
the QIAamp Viral RNA Mini Kit (Qiagen, Germantown, MD). Viral RNA was reverse 
transcribed into cDNA using primers binding upstream of randomized libraries and 
SuperScriptIII (Life Technologies, Beverly, MA). Subsequent processing steps were as 
described previously for analyzing mutant frequency [326]. Briefly, samples were 
barcoded to distinguish replicates as well as plasmid, P0, and P1 samples and submitted 
for Illumina 36bp single read sequencing on a Genome Analyzer II. 2.05 × 107 high 
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quality reads (>99.5% confidence across all 36 bases) were obtained and analyzed. Raw 
sequencing data has been submitted to the NIH Short Read Archive under accession 
number: Bioproject PRJNA272490 or SRA SRX839403. Read abundance (R) is the 
count of each mutant. The relative abundance (A) of each point mutant in plasmid or P0 
or P1 library was estimated from logarithmic frequency of mutant normalized to WT, as 
indicated below in Equation 1.  
       
    
   
  (Eq. 1) 
The frequency change (F) of a mutation from P0 to the mean of three P1 replicates 
(Equation 2) was used as an estimate of the enrichment or depletion during viral 
expansion. Estimates of selection during virus recovery were made by comparing 
frequency changes between plasmid and P0 using the same equations. 
           (Eq. 2) 
Selection coefficients (s) representing the experimental effects of each mutation on viral 
replication were calculated by normalizing the average stop codon to -1 (representing null 
fitness) and wild-type synonyms to 0 (representing no fitness effect), as indicated in 
Equation 3. Mutants with s less than 0 had a fitness defect, whereas mutants with s 
greater than 0 had a fitness benefit, relative to the parental sequence. 
  
            
 
     
       
 (Eq. 3) 
The above analyses yielded experimentally reproducible estimates of fitness 
effects for mutations with frequency greater than 0.2% (Figure 4.11). Mutations below 
this frequency in P0 were likely subject to highly stochastic sampling in the pool of  
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Figure 4.11: Plots showing pooled error estimate and the resulting residuals for all 
data sets 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.11 Plots showing pooled error estimate and the resulting residuals for all data sets. 
The header for each plot indicates the condition (labeled drug for 1 µM oseltamivir conditions, 
and no drug for standard conditions) and the first amino acid position of the region analyzed. The 
first and third graphs in each row show the actual standard errors as dots, and the estimated 
pooled error curve as solid black lines. Excluded data points, based on a 0.2% cutoff as explained 
in the Materials and methods, are shown in orange. The second and fourth graphs in each row 
show the residuals that are obtained from the pooled error regression. Residuals are evenly 
distributed around 0 throughout the whole range of initial read numbers, supporting the 
hypothesis that initial read number is the major source of noise. 
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viruses used to start P1 passages. The majority of mutations with low frequency in P0 
were prevalent at far greater abundance in the plasmid-encoded libraries. These 
observations indicated that selection during viral recovery depleted viruses with unfit NA 
mutations, and is consistent with expected viral expansion in MDCK cells during the co-
culture viral recovery to generate P0 samples. We observed that the frequency change of 
mutations from plasmid to P0 correlated (R2=0.89) with frequency changes from P0 to P1 
(Figure 4.3). From these observations we infer that selection pressure on NA mutations 
during plasmid to P0 rescue mimics selection during P0 to P1 expansion and that for 
mutations at high relative abundance in P0, frequency changes from P0 to P1 may be 
more accurate estimates of fitness effects than frequency changes from plasmid to P1. For 
these reasons, we calculated fitness effects without drug pressure for mutations with low 
frequency (<0.2%; 14% of our dataset) based on frequency changes from plasmid to P0, 
while for mutations that were abundant in P0 (>0.2%) fitness effects were calculated 
solely based on frequency changes from P0 to P1. The severe fitness defects for these 
mutations with low frequency in the absence of drug make it unlikely that they would 
contribute to drug resistance.   
 
Estimate of variation of experimental fitness measurements 
We assessed potential sampling limitations (e.g., bottlenecking) in our viral 
recovery and passaging experiments by analyzing stop codons and synonymous codons. 
Stop codons had consistent and strong depletion in P0 samples relative to plasmid, 
whereas synonymous mutations had very limited changes in frequency between these 
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pools (Figure 4.2). This indicates that selection on NA occurs during P0 viral recovery 
(consistent with infection of co-cultured MDCK cells during this step) and that sampling 
of plasmid variants during viral recovery is sufficient to reproducibly sample the number 
of mutations in our libraries. If sampling were insufficient, stochastic depletion of some 
synonymous mutations due to random under-sampling should have been observed.  In 
addition, four mutants with strong depletion in P0 samples relative to plasmid were 
studied in isolation and had strongly reduced or even no infectivity in an independent 
experiment, suggesting that mutants became depleted in P0 samples mainly because they 
had detrimental effects on viral infectivity.   
The variation in fitness effects between EMPIRIC experimental repeats (Figure 
4.11) suggests that sampling during initial viral entry was the main source of variance 
between replicates. This sampling was sufficient to analyze all single nucleotide variants, 
but would hinder the investigation of more complex libraries (e.g., libraries of all possible 
amino acid substitutions). To calculate confidence intervals on estimates of fitness effects 
from mutants that passed the P0 cutoff, we used a pooled error function for each data set. 
This approach provides a more robust estimate of standard errors for each mutant than 
calculations of the standard error of the mean based on three measurements. Pooled error 
functions were obtained by a log-linear regression of the individual standard deviations as 
a function of mutant frequency in P0 (Figure 4.11). An evaluation of the resulting 
residuals supported the validity of the pooled error approach. Mutations whose standard 
error appeared as an outlier of the estimated error distribution, which indicates potentially 
different sources of error for these mutations, are identified in Table 4.3. To estimate 
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noise from sample processing and sequencing, viral samples generated solely from wild-
type NA were processed by identical procedures and sequenced as control (Table 4.2).  
 
Statistical analysis to determine oseltamivir responsive mutants 
t-tests using 2×(N-1) degrees of freedom (where N represents independent fitness 
measurements for each amino acid substitution in both drug and no-drug conditions) were 
used to compare fitness effects of amino acid substitutions with and without oseltamivir 
together with a multiple-test correction using a 5% false discovery rate. 
 
Analysis of mutant frequency in natural isolates 
6205 H1N1 NA protein sequences and 5279 H3N2 NA protein sequences isolated from 
humans were downloaded from the Influenza Research Database [371]. These sequences 
were from viruses collected from 1933 to 2013, although the majority of viruses (76%) 
were from the 2004-2013. The dataset was curated to exclude partial sequences and 
duplicate entries. Multiple sequence alignment was conducted using Multiple Sequence 
Comparison by Log- Expectation, MUSCLE [382]. Positional amino acid frequencies 
were tabulated and compared to experimental fitness measurements. 
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Chapter V – General Discussion 
Summary  
 The work presented in this dissertation is mainly focused on applying high 
throughput systematic mutagenesis approaches to understand sequence-function-fitness 
relationship and explore sequence space for molecular adaptation in diverse proteins and 
organisms. In Chapter II, I first applied the EMPIRIC approach developed by Hietpas et 
al to investigate a fundamental protein sequence-function relationship question about 
effect of interplay between protein expression and sequence on organismal fitness. We 
discovered a non-linear relationship between yeast growth rate and Hsp90 expression: 
nearly 80% reduction in Hsp90 expression does not have strong effect on yeast growth, 
while stronger reduction in Hsp90 expression significantly impairs yeast growth. Many 
mutations that exhibit WT-like fitness effect at endogenous level of Hsp90 expression 
show fitness defect at reduced expression level, indicating that high expression of 
essential proteins, e.g. Hsp90, mask the fitness defect of many mutations and buffer the 
detrimental effect of many stochastic mutations on organismal fitness. In Chapter III, I 
optimized the EMPIRIC approach to map the functional constraint on the CD4 binding 
loop and flanking regions of the trimeric env complex of HIV. We show that the vast 
majority of mutations at these positions cause intermediate to strong fitness defect, 
indicating the functional significance of these residues. Only wild-type amino acids are 
functional at residues in the CD4 binding loop (GGDPE), whereas several residues in the 
flanking regions are tolerant of amino acid substitution even with distinct physical-
chemical properties. Thirteen mutations are beneficial compared to the WT sequence 
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under the experimental condition that mainly selects for higher infectivity. These 
mutations all exhibit stronger affinity to sCD4 than WT, suggesting higher CD4 affinity 
as a common pathway to enhanced infectivity. Neutralization profiles of these mutations 
reveal that many of these beneficial mutations also impose distinct and complicated 
impact on the conformation of the trimeric env complex. In Chapter IV, I optimized the 
EMPIRIC approach to quantify the fitness of mutations in the active site and proximal 
regions of NA in influenza virus in the presence or absence of a NA competitive inhibitor 
(oseltamivir) and screen for beneficial mutations that adapt to drug selection. We identify 
previously known drug resistance mutations, which validate our approach. We also 
identify novel drug resistance mutations that have not been clinically associated with 
reduced sensitivity to oseltamivir. The majority of these drug adaptive mutations occur in 
the active site, in particular at the drug resistance hotspot residue 223. Biochemical 
analyses on drug adaptive mutations uncover two distinct biochemical pathways towards 
drug resistance: reduced binding to drug and increased substrate processing. In summary, 
I start with a basic protein sequence-function relationship question about collective effect 
of protein expression and protein sequence in a well-characterized model system, 
Saccharomyces cerevisiae. Then I map functional constraints on important regions of the 
receptor of a fast evolving virus that causes pandemics, HIV. Lastly, I approach a more 
clinical relevant problem about drug resistance by systematically screening for mutations 
with reduced drug sensitivity in influenza virus and using biochemical assays to dissect 
underlying mechanisms.               
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Distinct distribution of fitness effect in yeast and RNA viruses   
 Although mutations can be broadly divided into three categories: deleterious, 
neutral and beneficial based on their effect on organismal fitness (fitness effect), the 
fitness effect is actually a continuous parameter, i.e. deleterious mutations have distinct 
detrimental effect, while beneficial mutations have distinct advantageous effect. The 
relative frequency of mutations with different fitness effect can be described by the 
distribution of fitness effect (DFE). DFE is essential for mapping the architecture of 
sequence space and genetic variation for any gene and provides valuable information for 
frequency of neutral and beneficial mutations that mediate neutral and adaptive evolution 
[383]. In the presented thesis, I investigated the DFE of Hsp90 for yeast, Env of HIV and 
NA of IAV (Figure 5.1). These proteins are all essential proteins that determine 
organismal fitness, and these regions under investigation are involved in protein-protein 
interaction or substrate processing.  
  
 Under standard laboratory growth condition, the yeast Hsp90 exhibits a bimodal 
distributed DFE with one major peak at the WT-like fitness and the other minor one at 
the null-like fitness, indicating that a large fraction of mutations have little effect while 
several mutations have strong deleterious effect (Figure 2.2). Only a small fraction of 
mutations exhibit intermediate fitness defect. RNA viruses (HIV and IAV), on the other 
hand, has a quite distinct unimodal DFE: the majority of mutations exhibit strong fitness 
defects while very few mutations exhibit WT-like fitness (Figure 3.4 and 4.5). Notably, 
no mutations are strongly beneficial under standard laboratory condition in yeast or IAV,  
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Figure 5.1 Relationship between fitness and total protein function as a predominant 
determinant of the distribution of fitness for different proteins    
 
 
 
 
 
 
Figure 5.1 Relationship between fitness and total protein function as a predominant 
determinant of the distribution of fitness for different proteins. The relationship between 
organismal fitness and protein total function (upper panel) and the distribution of fitness effect 
(DFE, lower panel) is shown for a substrate/receptor binding site for yeast Hsp90 (A), HIV Env 
(B) and influenza NA (C).  
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indicating that the sequences of these proteins have been highly optimized after repeated 
culturing and adaptation. Another shared feature is that few mutations in either yeast or 
RNA viruses have intermediate deleterious fitness, indicating that missense mutations 
either maintain or completely abolish protein functions. The distinct DFE between yeast 
and IAV indicate that yeast is much more robust to mutations than IAV. Most mutations 
in other cellular organisms (e.g. E. coli and C. elegans) also have little effect on growth 
[384, 385], while many mutations in RNA or single strand DNA (ssDNA) viruses 
generally exhibit detrimental effect on viral infectivity [386].   
 
 Genome complexity appears to correlate with sensitivity to mutations [387]. 
Signaling network with abundant redundancy and alternative metabolic pathway in 
cellular organisms are able to buffer the detrimental effect of mutations, so cellular 
organisms are more tolerant of mutational effects. However, absence of these robustness 
mechanisms from the simple and compact genomes of RNA or ssDNA viruses 
potentiates the effects of selection pressure, sensitizing RNA viruses to mutational effects. 
In fact, this differential sensitivity to mutations suggests two distinct evolutionary 
strategies. Cellular organisms accumulate many cryptic mutations that appear neutral. 
These mutations may provide growth advantage in a shifted environmental condition. 
This prediction is consistent with buffering role of Hsp90 in masking phenotypes of 
cryptic mutations. Only upon occasional environmental stresses that tax the buffering 
capacity of Hsp90 and impose more selection pressures, the effect of mutations becomes 
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revealed and beneficial mutations are selected and fixed. RNA viruses are constantly 
subject to strong purifying selection, so most deleterious mutations will be purged. 
However, lack of buffering mechanisms also accelerate fixation of adaptive mutations. 
This hypothesis is consistent with the notion that mutation rates should maximize 
adaptation by modulating the balance between sampling adaptive mutations and 
tolerating deleterious mutations. The low mutation rate of cellular organisms ensures 
relatively low mutation load, which can be suppressed by the buffer system; high 
mutation rate of RNA viruses enables efficient purification of deleterious mutations and 
fixation of adaptive mutations. The intermediate genome complexity, tolerance of 
mutational effect and mutation rate of double strand DNA viruses also support this 
explanation [388].          
 
 Differential sensitivity to mutations leads to distinct strengths of beneficial 
mutations. In yeast, mutations confer growth advantage up to 7% under elevated salinity 
selection [56]. In contrast, adaptive mutations in IAV confer up to ~110% benefit under 
drug selection pressure (Figure 4.5), consistent with potentiated mutational sensitivity of 
IAV. The DFE of HIV presents an interesting case. The env gene was cloned from a 
patient sample, so it is mal-adapted under the standard laboratory condition. Adapting the 
patient derived env to the laboratory condition leads to beneficial mutations of growth 
advantage up to ~63%, 9 fold higher than that of yeast adaptive mutations (Figure 3.4 and 
Table 3.3). Mutations of large benefit have also been reported in ssDNA phages [389, 
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390]. Beneficial mutations of large effect rapidly spread, mediating adaptation of RNA 
viruses to changing selection pressures, such as immune response and cross-host barrier.     
 
Different regions of the genome appear to have varied shape of DFE, depending 
on their functional importance. In an exterior loop of NA, more than half of the mutations 
have little defect, while few mutations have strong fitness defect [Figure 4.5B]. This 
indicates that regions of greater functional or stability significance (catalysis, substrate 
binding or scaffolding) tend to be more sensitive to mutations, whereas regions of less 
functional or structural significance appear to be more tolerant of mutations. DFE from 
randomly selected mutations across the genome for several RNA and ssDNA viruses 
assumes a bimodal distribution with one peak at WT-like fitness and the other one at 
null-like fitness, though the relative height of two peaks vary among different viruses 
[292-295]. The combined DFE for the active site and proximal regions and exterior loop 
of NA exhibits a bimodal distribution similar to that observed for other RNA and ssDNA 
viruses, indicating that DFE derived from fitness effects of randomly generated mutations 
across the genome represents a convolution of DFE from functionally important and 
unimportant regions. Indeed, different genes of ssDNA virus f1 exhibited varied 
sensitivity to missense mutations [295]. In summary, genome wide DFE may mask local 
variation in sensitivity to mutations, so determining region specific DFE may reveal 
functional significance of different regions of a genome.    
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Protein activity per molecule as a predominant determinant of fitness  
The bimodal DFE is consistent with a model that proposes protein stability as a 
dominant determinant of fitness [297]. This model is based on two assumptions: positions 
that are critical for protein function are rare and native protein folding is required for 
protein function. The elasticity-like non-linear relationship between protein stability and 
function suggests that most mutant proteins are either completely folded or unfolded. 
There is only a narrow range corresponding to partially folded mutant proteins [297, 391]. 
This predicts a bimodal distribution of protein function and hence a bimodal DFE. 
Simulation using protein stability as the sole parameter to model fitness successfully 
produces bimodal DFE in in silico viruses [296]. In the stability model, mutations at 
critical residues that abolish protein function are rare and therefore make little 
contribution to DFE.  
 
Protein function per molecule (F) derived from the fitness measurements and the 
elasticity function between fitness and protein function indicates that F without apparent 
contribution from stability effect also contributes to determine organismal fitness. The 
estimated F exhibits a unimodal distribution, indicating that most mutations reduce F. 
This is inconsistent with a bimodal distribution of F derived from stability effect alone, 
suggesting stability independent effect that also contribute to protein function per 
molecule, e.g. catalysis and substrate binding. Most mutations exhibiting intermediate 
deleterious effects also indicate that more mutations directly affect protein function than 
predicted by a stability model. Notably, our definition of F combines all properties 
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including stability, binding affinity and catalysis efficiency, providing a more 
comprehensive measurement of mutational effect on protein function. Fitness 
measurements of Hsp90 mutations display very weak correlation with their stability 
effect estimated by Rosetta simulation (Figure 2.13C) [104, 321]. Together with results 
from biochemical assays (circular dichroism spectra and urea-induced unfolding curve) 
on a panel of six mutations [Figure 2.16 B and C], they verify the minor contribution of 
stability effect to protein function and yeast growth for mutations in this region of yeast 
Hsp90. Of note, this region is not involved in ATP binding and hydrolysis, but implicated 
in substrate binding. The unimodal distribution of protein function per molecule is 
consistent with its potential biological function. The frequency of regions of biological 
function may vary among different proteins and will be examined in future experiments 
that systematically map rate-limiting regions.   
 
Distinct conformation of the Env mutants with enhanced binding 
affinity to CD4         
 All Env mutants with increased infectivity exhibited enhanced binding affinity to 
CD4 (Table 3.3), indicating that stronger binding of the trimer Env complex for CD4 
serves as a common evolutionary pathway to higher replication fitness in a standard 
laboratory condition. The parental strain (LN40) shows relatively weak binding to CD4 
due to steric restrictions and/or refractory to conformational changes. Thus, the increased 
CD4 binding of these beneficial mutations suggest enhanced exposure of the Env to CD4. 
Of note, S375W drives the conformation of the Env into a more CD4-bound and open 
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state, increasing the exposure of the trimeric env complex to CD4 [176]. The bulk 
competition was conducted in a standard laboratory condition without selection pressure 
from immune response in vivo, so it should select for mutations with more open Env 
conformation, elevated affinity for CD4 and hence higher infectivity. However, Env with 
open conformation is often more vulnerable to antibody neutralization, so the complex in 
vivo condition should select for mutations that are best able to keep a delicate balance 
between escaping neutralizing antibody and maximizing infectivity. The differences in 
environmental conditions select for distinct adapting gp120 mutations, indicating the 
enormous potential of HIV to adapt to varied environmental conditions even with the 
simplest evolutionary step – single amino acid substitutions.   
 
We were able to examine the sensitivity of these beneficial mutations to b6, b12, 
447-52D and 17b. This combination of antibodies enables interrogation of 
conformational changes at regions that are critical for CD4 and/or coreceptor binding. 
Both b12 and b6 targets the CD4 binding site, but they are only exposed in the 
monomeric gp120. Increased sensitivity to these antibodies indicate opening of the trimer 
and exposure of their epitopes, which are excluded in the trimer [166, 350]. In particular, 
b6 requires extensive opening of gp120 and fails to neutralize almost all primary isolates 
[350]. 447-52D binds to the V3 apex, which is only exposed after sufficient opening of 
the env trimer, so it only neutralizes lab-adapted strains [392]. 17b is a CD4 binding 
induced antibody (CD4i) and neutralizes gp120 that completes CD4 induced 
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conformational change [161, 351]. This set of antibodies allows us to gauge the openness 
of the trimeric env complex. 
 
 The trimeric Env spike exhibits varied conformational state and sensitivity to 
different neutralizing antibodies. The parental strain (LN40) is generally resistant to 
antibodies that target epitopes exposed only in Env monomer. These epitopes are 
excluded in trimeric Env complex, but become exposed after trimer dissociation. Many 
mutations at residue 373, 375, 377 and 380 were more sensitive to b12, indicating that 
mutations at these positions facilitate exposure of the b12 epitope and probably opening 
of the trimer. These residues are within or very close to the Phe43 cavity, so local 
perturbations are likely to affect gp120:CD4 interaction. This is supported by increased 
sensitivity of these mutations to sCD4 neutralization. Only G380A and G380P exhibited 
measurable sensitivity to both b6 and 447-12D, indicating that mutations at this residue 
open up the trimeric Env complex more than mutations at other positions. However, none 
of these mutations were sensitive to 17b, indicating that they are not open enough to 
expose the 17b epitope. Interestingly, most beneficial mutations developed intermediate 
resistance to glycan-targeted 2G12 compared to the parental strain, indicating that these 
mutations confer a shift in glycan distribution, presumably at residue 386 [182]. However, 
these mutations and the WT were still highly sensitive to PGT128, which targets a 
different conserved glycan at V3 [393], indicating that the glycan shift is restricted 
locally.    
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 These beneficial mutations in LN40, a clade B HIV, impose similar effect on the 
conformation states of the trimeric Env complex from another clade B (LN8) and a clade 
C (Z1792M) primary isolate. For example, mutations at residue 373, 375, 377 and 380 
were more sensitive to neutralization by sCD4, indicating that they enhance the binding 
interaction between CD4 and gp120. Moreover, pseudovirus with G380P became 
extremely sensitive to b6, b12 and 447-52D, indicating that this mutation opens up the 
trimer complex and unmasks many epitopes not available in the closed trimer. Thus, 
despite large sequence variation among different HIV strains and/or clades, many 
mutations have similar effect on conformation states of the trimer Env complex. LN8 and 
Z1792M both carry a glycan at N160, which forms the epitope recognized by the trimer 
specific V2q mab PG9 and PGT145 [354, 394]. In fact, they are both very sensitive to 
PG9 and PGT145 (Table 3.5 and 3.6). Thus, sensitivity to PG9 and PGT145 reflects the 
epitope integrity, which is part of the trimer association domain [168], so disruption of 
the TAD should lead to resistance to PG9 and PGT145 neutralization. As shown before, 
many mutations at residue 373, 375, 377 and 380 (in particular G380P) appear to drive 
the trimeric env complex into a more open and exposed conformation, which should 
disrupt the TAD. Surprisingly, these mutations are still sensitive to PG9 and PGT145 as 
compared to the WT (Table 3.5 and 3.6), indicating an intact TAD and closed 
conformation of the trimer. One explanation to this apparent contradiction is that these 
mutations promote more frequent transition into CD4-bound state of gp120 without 
triggering a trimer-opening event, so that these mutants are sensitive to both trimer-
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specific and CD4BS antibodies. This is consistent to a recent finding that applied FRET 
to determine the conformation dynamics of Env: despite a ground closed conformation 
state, neutralization sensitive strain NL4.3 frequently transits into the open state, while 
neutralization resistant strain JR-FL mostly stays in the closed state [355]. Another 
possible explanation is that some mutations are able to expose the CD4 binding site and 
simultaneously maintain the TAD.  
 
Permissive/compensatory mutations of oseltamivir resistance mutations 
 The majority of oseltamivir resistance mutations identified in the EMPIRIC 
screening exhibit fitness defect (mostly 20-50% defect) in the absence of drug pressure 
[Table 4.5]. For example, I222M, H275Y and N295S show ~30% defect. The observed 
fitness defect in the bulk competition is consistent with reduced infectivity measured on 
individual generated clones. For example, H275Y and N295S in NA all show negative 
effect on the replication and/or transmission capability of IAV [252, 262, 263, 265]. 
Adaptive mutations to one particular selection pressure frequently results in fitness defect 
under other environmental conditions, which is known as cost of adaptation. The tradeoff 
in fitness during adaptation to distinct selection pressures is common for many 
microorganisms in response to shifting environments [395-399]. For example, numerous 
yeast mutations that confer up to 7% benefit under high osmotic pressure exhibit fitness 
defect under standard growth condition [56]. Another example is that mutations in HIV 
protease or reverse transcriptase that reduce binding to HLA molecule tend to have 
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impaired in vitro replicative fitness [400]. Many of these studies also focused on negative 
pleiotropic effects of mutations that conferred antibiotic resistance on other cellular 
functions [396-399]. This is consistent with predictions from the Fisher’s geometric 
model (FGM) [56]. In a phenotypic space, each single phenotypic optimum corresponds 
to a different selection pressure. When the wild-type sequence is highly optimized for 
adaptation to one selection pressure, it is located very close to the optimum. Under a 
different selection pressure, mutations that reduce the distance to the new optimum are 
considered adaptive mutations, but these mutations typically deviate away from the initial 
optimum. Thus they are deleterious mutations under the original selection pressure.  
 
Most oseltamivir resistance mutations occur at either functional or framework 
residues in the active site of NA. They appear to interfere with the binding of NA for 
oseltamivir as well as the natural substrate [252, 281, 401]. For instance, H275Y leads to 
greater than 400 fold higher Ki, but also approximately 2 fold higher Km. H275Y also 
leads to reduced surface NA enzymatic activity when NA is expressed in mammalian 
cells, mainly due to reduced surface expression of NA [364, 401]. Destabilizing 
mutations may cause reduced surface NA expression, while mutations that impair 
catalysis or substrate binding may decrease enzymatic activity per NA molecule (data not 
shown).   
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Permissive or compensatory mutations restore the fitness cost of oseltamivir 
resistance mutations. Secondary permissive or compensatory mutations are able to 
compensate for the loss of the total enzymatic activity and restore replication efficiency. 
Pioneering work by Bloom et al showed that R194G, R222Q and V234M are able to 
raise the reduced surface expression of H275Y mutant NA in the seasonal and pandemic 
H1N1 strains and rescue their replication fitness defect [364]. These permissive 
mutations had very high frequency in H1N1 in the influenza season of 2007 and 2008 
[207, 401]. Fixation of permissive mutations provides a plausible explanation for 
competent growth and transmission fitness of H275Y and its global circulation in the 
influenza season of 2007-2008 even in the absence of massive use of oseltamivir. 
Experiments in a ferret model showed that V241I and N369K rescued the replication and 
transmission defect of a pandemic H1N1 strain with H275Y [379]. I222V partially 
restored the enzymatic activity (Vmax) of NA in a seasonal H3N2 strain and rescued the 
fitness cost of E119V [402].  
 
Y276F is a hyperactive mutation that increases the enzymatic activity of NA and 
has the potential to rescue the fitness defect of oseltamivir resistance mutation through 
buffering loss of NA activity. Y276F exhibits big increase in fitness in the presence of 
oseltamivir, indicating that it is an adaptive mutation to oseltamivir. However, it shows 
similar affinity to oseltamivir as compared to the WT, indicating that other features 
initiate its adaptation to oseltamivir. Y276F turns out to be a hyperactive mutation that 
enhances the enzymatic function (per infectious unit) of NA by approximately 70% 
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(Figure 4.9). It creates a buffer zone in NA activity, which compensates for the inhibition 
of NA activity by oseltamivir. The residual NA activity is able to support growth of IAV 
and confers superior replication fitness compared to the WT. I hypothesize that Y276F 
might compensate for the loss of NA activity from oseltamivir resistance mutations and 
rescue their growth. Notably, Y276F is in close proximity of residue 275, so it might also 
be able to change the local conformation and offset the fitness defect from H275Y (data 
not shown). 
 
Merits and limitations of EMPIRIC in studying viral evolution          
The EMPIRIC approach has been proved useful in exploring the evolvability of 
RNA viruses (e.g. IAV) to therapeutic selection pressures (Chapter IV). It has also been 
shown instrumental in mapping biophysical constraints on important regions of RNA 
viruses (e.g. HIV) under strong purifying selection (Chapter III). A major advantage of 
utilizing EMPIRIC to investigate viral evolution is its high reproducibility. The R-
squared value (R2) of the correlation between fitness measurements from two replicates 
of IAV expansion is greater than 0.9, which is higher than whole-gene mutational 
scanning approaches (0.34-0.62), indicating highly reproducible measurements of IAV 
replication fitness. For HIV, the R2 is approximately 0.6-0.8, which is still higher than R2 
of most other approaches of higher throughput. The improved precision in fitness 
measurements ensures accurate characterization of individual mutations regarding their 
survival probability under purifying selection and adaptation potential under positive 
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selection, e.g. drug pressure. This is important in screening for rare adaptive mutations 
where small differences in fitness may lead to distinct evolutionary outcome. In addition, 
accurate assessment of fitness for mutations in the absence of therapeutic selection 
pressure enables robust analysis of likelihood of fixation of mutations in the treatment-
naïve population. Precise gauging of cost and benefit of adaptation is critical for thorough 
characterization of drug resistance mutations.  
 
Other advantages of EMPIRIC include systematic mutagenesis and relatively 
simple experimental setup. EMPIRIC uses cassette ligation to generate every possible 
single codon or nucleotide substitution. The former enables fitness characterization for all 
possible amino acid mutations, leading to detailed delineation of positional amino acid 
preference and adapting potential. The latter provides fitness measurements for mutations 
that are only one nucleotide step away from the WT, revealing evolutionary potential for 
the most likely mutational step in nature. Several other approaches that employ error-
prone PCR based random mutagenesis may not cover all possible single substitutions. 
Gene-wide mutational scanning encompasses large number of mutations (usually > 
10000), so it is inherently prone to bottleneck effect during transfer of libraries (e.g. 
transfection or infection). To achieve higher reproducibility, whole-gene mutational 
scanning requires huge number of cells and virions in many replicates, increasing the 
difficulty to manage such large scale experiments. In contrast, EMPIRIC focuses on 
specific regions of interest and uses relatively smaller scale of reagents.      
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The major limitation of EMPIRIC is its intermediate throughput. EMPIRIC has 
been used for systematic mutational scanning of several ten-amino-acid regions in several 
parallel experiments, while other approaches allow for whole-gene (hundreds of amino 
acids) mutational scanning in a single experiment. EMPIRIC can be scaled up to 
investigate an entire gene, but it requires considerable experimental effort. There are two 
rate-limiting steps: library construction and bulk competition. Cassette based randomized 
mutagenesis is more labor-intensive than PCR based one used in most whole-gene 
mutational scanning approaches. Because each library only contains ten amino acids, 
several libraries are analyzed in parallel. As the number of libraries grows, the workload 
involved with bulk competition and sequencing sample preparation grows 
correspondingly, leading to more effort than studying an entire gene in a single pooled 
library. Another limitation is that EMPIRIC requires prior information such as structure, 
chemical properties, function, and conservation of proteins to select which part(s) of the 
protein to analyze. Conversely, the whole-gene mutational scanning follows a shotgun 
concept and relies less on other information. This may prove useful for investigating 
function of proteins with limited prior information. However, the intermediate throughput 
of EMPIRIC significantly contributes to the improved reproducibility of fitness 
measurements. In fact, a recent whole-gene mutational scanning study on PA of IAV 
used a “small library” approach similar to EMPIRIC: they divided the gene into nine 
sections, generated nine independent libraries and analyzed them individually to get 
higher experimental reproducibility [74]. Although pursuing higher throughput proves 
rewarding in many ways, it is critical to retain the balance between throughput and 
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reproducibility of results. This balance is particularly important for mutational scanning 
on viral proteins, which are especially sensitive to bottleneck effect during library 
transfer.        
 
EMPIRIC can be further optimized from several perspectives. In the yeast system, 
population management is robust to bottleneck effect since yeast can be grown to high 
density. A barcode can be engineered into the plasmid outside the open reading frame 
and associated with individual mutations by pair-end Illumina sequencing. For example, 
an 18 consecutive nucleotide randomized barcode encompasses nearly 69 billion unique 
combinations, so each individual mutation is most likely to be associated with a unique 
barcode that is several nucleotides different from any other barcode. Although additional 
experimental and computational steps are required, this modification enables combination 
of multiple ten amino acid libraries into a single pool, which can be subject to diverse 
environmental conditions for rapid probe of genotype-environment relationship. In 
addition, the barcode strategy allows sequencing error correction by taking consensus of 
multiple sequencing reads of the same barcode. Secondly, the Illumina read length was 
36bp when EMPIRIC was first developed, which was sufficient to sequence a 10 amino 
acid region (30 nucleotides). It has now grown to be 300bp, allowing for more residues in 
a single library. A library with more residues reduces the workload of bulk competition 
and sequencing sample preparation, because fewer libraries are processed for the same 
number of amino acids analyzed. Thirdly, EMPIRIC can be combined with other higher 
throughput whole-gene mutational scanning approaches. For example, whole-gene 
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scanning identifies critical residues that are sensitive to mutations; EMPIRIC on these 
residues then generates reproducible fitness measurements on individual mutations under 
various selection pressures. In summary, EMPIRIC can be further improved regarding 
throughput and efficiency by taking advantage of longer sequencing reads and novel 
barcoding strategies.  
 
Future directions        
 EMPIRIC can be used to map resistance profile for other competitive inhibitors of 
NA. There are four competitive NA inhibitors (NAI): oseltamivir, zanamivir, peramivir 
and laninamivir. The first three have been approved by FDA, while Laninamivir is still in 
clinical trial in the US. All four NAI are derived from the natural substrate (sialic acid) 
using structural based drug design. Thus, it is of utmost clinical, pharmacological and 
basic science interest to compare the resistance profiles of these four closely related NAIs. 
From a clinical standpoint, knowing resistance mutations to each NAI and whether 
mutations develop cross-resistance to two or more NAIs assists clinical monitor of drug 
resistance mutations and rationale administration of NAI to avoid or delay drug resistance. 
From a pharmacological standpoint, associating differences in resistance profiles to 
divergences in chemical structures of NAIs provides valuable information to design novel 
ones with minimized resistance. From a basic science standpoint, biophysical and 
biochemical measurements of drug resistance mutations are likely to provide training set 
for machine learning algorithm that predicts drug resistance mutations. In addition, 
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fitness landscape of NA mutations in response to different but closely related drug 
selection pressure will illuminate evolutionary and biochemical pathways of molecular 
adaptation of IAV. EMPIRIC can be used to determine the fitness landscape of NA with 
different NAIs and answer the above questions.   
  
 EMPIRIC may be incorporated into development of new inhibitors of RNA 
viruses. During preclinical development, EMPIRIC analysis may identify mutations with 
reduced sensitivity to the inhibitor. The biochemical and structural features of drug 
resistance mutations may aid refinements of the initial inhibitor to target isolated drug 
resistance mutations. Current EMPIRIC approach and many mutational scanning 
approaches use lab adapted strains because they generally have robust growth and 
efficient reverse genetic systems, which lead to higher reproducibility. In order to be 
incorporated into drug discovery pipeline, EMPIRIC needs to be optimized for generating 
highly reproducible measurements on primary isolates. This has been tested in a patient 
derived HIV env (Chapter III), but has yet to be implemented in other pathogenic RNA 
viruses.  
 
 EMPIRIC can be utilized to isolate escaping mutations from broad neutralizing 
antibodies of HIV. There has been no successful HIV vaccine to date. High mutation rate 
of HIV enables rapid diversification of HIV, so strain-specific antibodies are incapable of 
neutralizing a heterogeneous population of different HIV strains. Several antibodies that 
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were isolated from patients with chronic HIV infection exhibit much broader spectrum of 
neutralization. These broad neutralizing antibodies (bNab) are able to neutralize 50-95% 
of primary isolates, providing a novel avenue for HIV vaccine research. EMPIRIC can be 
used to analyze the adaptive potential of the epitopes of HIV Env under the selection of 
bNabs. The structural information of escaping mutations should assist in optimization of 
naturally evolved bNab to achieve broader breadth and even higher potency.              
 
EMPIRIC can also be adapted to analyze the functional constraints and 
evolutionary potential of other fast growing organisms such as HCV and cancer cells. 
There have been numerous reports of drug resistance in other pathogenic RNA viruses 
such as HCV and dengue viruses [403, 404]. EMPIRIC can be optimized to investigate 
drug adaptive potential of these viruses with robust reverse genetics system. Of note, 
there has been one study that used an EMPIRIC-like approach to identify drug resistance 
mutations in NS5A of HCV in response to Daclatasivr [76], corroborating the potential of 
applying EMPIRIC to other RNA viruses. Cancer cells quickly evolve resistance to 
traditional chemotherapy or recently developed targeted therapy, leading to poor 
prognosis of many tumors [405]. EMPIRIC has the potential to elucidate the adaptive 
fitness landscape of mutations in tumors under the selection pressure of chemo or 
targeted therapy, revealing drug resistance mutations and associated molecular 
mechanism. For example, EMPIRIC has been successfully applied to study secondary 
mutations in BRAF-V600E melanoma that confer resistance to a targeted drug - 
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PLX4720. A novel mutation with reduced sensitivity to both BRAF and MEK inhibitors 
was discovered, which was later isolated from a BRAF mutant melanoma patient treated 
with PLX4720 [341, 406]. This indicates that EMPIRIC can be modified to pinpoint 
single substitutions that cause resistance to targeted cancer therapy.     
 
Broader impact  
 The sequence-function relationship is a fundamental question at the 
intersection of different disciplines of biomedical studies. In this dissertation, I utilize a 
novel mutagenesis approach – high throughput mutational scanning to map the sequence-
function relationship in diverse proteins under various selection pressure. I analyze the 
interplay between protein function and sequence on organismal fitness, unifying the 
combined effect of two mechanisms for protein evolution. I explore the adaptive 
landscape of pathogenic RNA viruses, illuminating the collective constraints of positive 
and negative selection on governing the evolutionary pathway of RNA viruses. In 
summary, the work presented in this dissertation explores the role of sequence-function 
relationship in basic protein evolution and clinical relevant adaptation of RNA viruses to 
immune/drug selection pressure, opening up many new avenues to demarcate the 
sequence space and underlying molecular mechanisms available for continual adaptation 
to the ever-changing environment.   
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Appendix – Systematic identification of zanamivir resistance mutations 
 
Introduction 
Zanamivir is a competitive inhibitor of neuraminidase (NAI) of IAV. Zanamivir is 
administered through inhalation and has been used for IAV treatment since 1999. 
Compared to the other NAI, oseltamivir, zanamivir has showed much less drug resistance. 
Some explanations include its close resemblance to the natural substrate and less clinical 
usage. NA mutations (E119V and R293K, N1 numbering) displaying reduced sensitivity 
to zanamivir were identified in cell culture prior to clinical use of zanamivir, but these 
mutations caused severe fitness defect and were not observed in patients under treatment 
of zanamivir[407-409]. Many oseltamivir resistance mutations, including the 
predominant H275Y, impair the binding of pentyloxyl group at C-6 of oseltamivir. Since 
zanamivir has a glycerol group at C-6, these mutations still allow zanamivir binding and 
remain sensitive to zanamivir [202]. Several mutations, including I223R and N295S (N1 
numbering used throughout), do impair binding of NA for zanamivir and hence confer 
zanamivir resistance. They generally dampen interactions between contact residues of 
NA and functional groups of NAI, so they cause cross resistance to both oseltamivir and 
zanamivir [202, 249, 282, 283]. However, the majority of these mutations were only 
isolated sporadically from patient samples or only characterized as possessing reduced 
sensitivity to zanamivir in vitro. These mutations also affect the binding of NA for the 
natural substrate and severely impair the replication fitness of IAV, so they are unlikely 
to reach a high frequency in human populations. To systematically map the adaptive 
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potential of NA under selection of zanamivir, we utilized EMPIRIC, which was 
optimized to determine the mutational fitness landscape in IAV, to quantify the fitness 
effects of NA mutations with or without zanamivir.       
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Result and discussion  
 Sialic acid (Neu5Ac), zanamivir and oseltamivir share similar chemical backbone, 
but had different chemical groups at critical positions (Figure 6.1). The major difference 
between Neu5Ac and zanamivir is that a hydroxyl group at C-4 of Neu5Ac was replaced 
with a guanidinyl group in zanamivir. Introducing a larger and more basic group at C-4 
improves the affinity between NA and zanamivir through interactions between 
Glu119/228 of NA and the guanidinyl moiety of zanamivir. The major difference 
between Neu5Ac and oseltamivir is that a polar glycerol group at C-6 is substituted with 
a large and hydrophobic pentyloxyl group. The hydrophobic group at C-6 orients E277 of 
NA away from the active site to create a hydrophobic pocket, while glycerol group at C-6 
forms hydrogen bonds with E277. The distinction in chemical structure of zanamivir and 
oseltamivir appears to elicit different drug adaptive mutations 
 
 We utilized EMPIRIC to determine the fitness effects of all possible single 
nucleotide substitutions in focused regions of NA in the presence or absence of zanamivir 
(Figure 6.2A). Plasmid libraries of mutations at four regions in the active site and 
proximal regions, one in the tetramerization interface and the other one in an exterior 
loop were examined (Table 6.1). These regions were chosen because they encompassed 
the zanamivir binding site and were most likely to encompass zanamivir resistance  
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Figure 6.1: The natural substrate and competitive inhibitors of NA  
 
 
 
 
 
 
Figure 6.1 The natural substrate and competitive inhibitors of NA. Chemical structure of 
sialic acid (Neu5Ac), zanamivir and oseltamivir carboxylate.  
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Figure 6.2: A high throughput approach to determine the fitness effect of mutations 
in NA with or without zanamivir  
 
 
 
 
 
 
 
 
 
 
Figure 6.2 A high throughput approach to determine the fitness effect of mutations in NA 
with or without zanamivir. (A) An overview of the experimental setting. (B) The molecular 
structure image of NA (PDB ID: 3B7E). The NAI, zanamivir, is represented as yellow spheres in 
the active site. The regions with engineered all possible single nucleotide substitutions are in light 
blue. 
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mutations (Figure 6.2B). This approach was previously developed for measuring fitness 
effect of mutations with or without oseltamivir (Chapter IV). NA plasmid harboring 
single nucleotide substitutions and plasmids encoding the other 7 IAV gene segments 
were co-transfected into co-culture of 293T and MDCK cells to recover viral library of 
mutants (P0). P0 library was used for infection of fresh MDCK cells with or without 
zanamivir. The supernatant containing viral progenies (P1) were harvested. Both P0 and 
P1 viruses were sequenced to determine log frequency change as a proxy of fitness effect. 
The NA mutation libraries had two internal controls: stop codons (nonsense mutations) 
and WT-synonyms (silent mutations). Nonsense mutations produce truncated NA, which 
should abolish NA function and impair IAV infection; silent mutations do not change the 
primary sequence of NA, which should support robust IAV infection. Indeed, nonsense 
mutations exhibited strong depletion while silent mutations behaved similarly to the WT 
(Figure 6.3). Thus, the log frequency change from P0 to P1 was normalized to that of 
nonsense mutations and silent mutations to so that fitness effect of -1 corresponded to 
null-like fitness and 0 indicated WT-like fitness.  
 
Few mutations were adaptive or responsive to zanamivir         
 We compared the fitness effects of all mutations with or without zanamivir to 
identify mutations that were either adaptive or responsive to zanamivir selection (Figure 
6.4A). We used 1M of zanamivir for two reasons. Firstly, it was about 10 fold higher 
than EC50 (data not shown), allowing for amplification of small differences in fitness  
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Figure 6.3: Stop codons were strongly depleted, while WT-synonyms did not have 
much change in frequency 
 
 
 
 
 
 
 
Figure 6.3 Stop codons were strongly depleted, while WT-synonyms did not have much 
change in frequency. The average log2 frequency change of stop codons (nonsense mutations, 
colored in red) and WT-synonyms (silent mutations, colored in green) were measured without 
zanamivir (A) or with zanamivir (B). The error bar is standard error of the mean with N equal to 
number of stop codons or WT-synonyms in each library.  
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Figure 6.4: Comparison of fitness effects of all mutations +/- zanamivir revealed few 
mutations that were adaptive or responsive to zanamivir 
 
 
 
 
 
Figure 6.4 Comparison of fitness effects of all mutations +/- zanamivir revealed few 
mutations that were adaptive or responsive to zanamivir. (A) Comparison of fitness effect of 
all mutations with or without zanamivir. 0 indicates WT-like fitness while -1 corresponds to null-
like fitness. Zanamivir responsive mutations (mutations with increased fitness effect with 
zanamivir than without) are colored in orange. Zanamivir adaptive mutations (mutations that are 
more fit than WT in the presence of zanamivir) are labeled by their positions and amino acid 
changes. (B) Venn diagram to show mutations that were adaptive to oseltamivir or zanamivir or 
both. (C) Venn diagram to show the number of mutations that were responsive to oseltamivir or 
zanamivir. The position and amino acid change of the mutation that was responsive to both 
oseltamivir and zanamivir was shown. (D) Bar graph to show changes in fitness effect (S) +/- 
zanamivir or oseltamivir for a panel of oseltamivir responsive mutations. S for zanamivir is 
shown in light blue, while S for oseltamivir is shown in dark blue. Error bars are standard 
deviation with N = 3.     
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effect with zanamivir. Secondly, it was the same concentration used for oseltamivir bulk 
competition experiment, enabling comparison of fitness landscape of mutations with 
oseltamivir or zanamivir. As shown in figure 6.4A, most mutations had similar fitness in 
the presence or absence of zanamivir, indicating that zanamivir only affected the fitness 
effect of a small fraction of mutations. Thus the inhibitory effect of zanamivir on most 
mutations appeared to be similar to the WT. To identify mutations that had statistically 
significant differences in fitness effect +/- zanamivir, we used student t-test with multiple 
test correction to compare the fitness effect of mutations with or without zanamivir. We 
identified 7 mutations that had statistically significant higher fitness with zanamivir 
compared to without zanamivir (Table 6.2). These mutations were coined zanamivir 
responsive mutations. As shown in Chapter IV, responsive mutations to NAI frequently 
have reduced sensitivity to NAI. Notably, none of these mutations had been clinically 
associated with zanamivir resistance, demonstrating the power of EMPIRIC to identify 
novel mutations with reduced sensitivity to zanamivir. Several other mutations exhibited 
large increase in fitness with zanamivir compared to without zanamivir, but they were not 
statistically significant. Using a similar statistical approach, we identified only Y276F 
that was significantly more fit than the WT in the presence of zanamivir, indicating that 
Y276F was the only drug adaptive mutation under this experimental condition. In 
summary, we only identified very few mutations that exhibited adaptation or 
responsiveness to zanamivir, indicating high barrier for NA to evolve resistance to 
zanamivir.   
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We sought to compare the resistance profile of zanamivir and oseltamivir (Figure 
6.4B and C). As stated above, Y276F was the solely identified adaptive mutation to 
zanamivir. It was also adaptive to oseltamivir (Figure 6.4B), indicating the potential of 
this mutation to confer cross resistance to both oseltamivir and zanamivir. Four other 
mutations (K221N, I223M, H275Y and N295S) were adaptive to oseltamivir, but not 
zanamivir, so zanamivir might be administered as a substitute of oseltamivir to treat 
patients carrying these oseltamivir specific adaptive mutations. Of note, the predominant 
H275Y remained sensitive to zanamivir. The structural explanation is that the binding of 
zanamivir for NA does not rely on conformational change of E277 to create a 
hydrophobic pocket, which is disrupted by H275Y [202]. Moreover, only one mutation 
(F115L) exhibited responsiveness to both zanamivir and oseltamivir. The limited overlap 
of resistance profiles of oseltamivir and zanamivir suggests low probability of mutations 
simultaneously developing resistance to both zanamivir and oseltamivir. Notably, 24 
mutations were responsive to oseltamivir while only seven mutations were responsive to 
zanamivir, indicating that NA is less likely to develop resistance to zanamivir than 
oseltamivir.  
 
Most Oseltamivir responsive mutations were sensitive to zanamivir. As shown in 
Figure 6.4C, only F115L appeared to be responsive to both zanamivir and oseltamivir, 
indicating that the other 23 identified oseltamivir responsive mutations were still 
sensitive to zanamivir. Several of these mutations were isolated from patient samples and 
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shown to have reduced sensitivity to oseltamivir by in vitro biochemical assays (Figure 
4.8C and Table 4.5). We compared their change in fitness effect in the presence and 
absence of oseltamivir or zanamivir (Figure 6.4D). Six out of the ten selected mutations 
showed little changes in fitness effect with or without zanamivir, confirming their 
sensitivity to zanamivir. Four of the ten mutations appeared to have increased fitness 
effect with zanamivir, though not statistically significant. It indicates that these four 
mutations (I117V, I223K, I223R and Y276F) exhibited a general trend to become 
refractory to zanamivir, but the trend was not as strong as that for oseltamivir. In 
summary, the majority of mutations that were responsive to oseltamivir remained 
sensitive to zanamivir.              
 
We analyzed the structural basis underlying the higher resistance barrier for 
zanamivir. As competitive inhibitors of sialic acid, both zanamivir and oseltamivir 
resemble the chemical structure of sialic acid. Although they are built upon similar 
backbones, zanamivir entails minimal modification to the native structure of sialic acid. 
The large and basic group at C-4 of zanamivir strengthens interactions with conserved 
residues of NA without additional perturbations, while the hydrophobic group at C-6 of 
oseltamivir forces local conformational changes in NA. The binding of oseltamivir for 
NA requires reorientation of E277, which is not necessary for the binding of sialic acid, 
so it increases the possibility of mutations with reduced binding to oseltamivir, consistent 
with a substrate envelope hypothesis [410]. In summary, compared to oseltamivir, 
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zanamivir better resembled the natural substrate and selected for fewer mutations with 
adaptive potential.  
 
Y276F was a drug adaptive mutation to both zanamivir and oseltamivir  
We identified only Y276F that was adaptive to both zanamivir and oseltamivir 
(Figure 6.5). In the absence of any NAI, Y276F exhibited significantly positive fitness 
effect, indicating that it was more fit than the WT even without NAI. In fact, it showed 
the highest fitness effect among the pool of examined mutations (Figure 6.4A). In the 
presence of oseltamivir or zanamivir, Y276F became more fit and exhibited 30-50% 
higher fitness than the WT (Figure 6.5A), indicating that it was highly adapted to 
selection pressure from oseltamivir or zanamivir. Of note, Y276F has not been clinically 
associated with resistance to oseltamivir or zanamivir, so it is important to examine its 
adaptive potential to NAI in a clinical relevant IAV strain. Y276F has been isolated from 
patient samples sporadically in 2009 and 2010, indicating a high probability that it may 
have similar effect on clinical isolates.  
 
We sought to explore the molecular mechanism of higher fitness of Y276F with 
oseltamivir or zanamivir. We measured the enzymatic activity of Y276F or WT to cleave 
a synthetic substrate (MUNANA) in increasing concentrations of oseltamivir by a 
fluorescent readout. Y276F appeared to have similar binding affinity to oseltamivir 
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Figure 6.5: Y275F was the sole identified zanamivir adaptive mutation  
 
 
 
 
 
 
Figure 6.5 Y275F was the sole identified zanamivir adaptive mutation. (A) The fitness effect 
of Y275F in the presence or absence of oseltamivir or zanamivir. Two no drug controls from two 
independent viral propagation experiments were shown. Error bars are standard deviation with N 
=3. (B) Molecular structure image of residues 275-278 of NA bound to oseltamivir or zanamivir. 
The structure image of NA bound to oseltamivir (PDB ID: 3TI6, dark green) is superimposed 
onto the structure image of NA bound to zanamivir (PDB ID: 3TI5, light green). The distance 
between carboxyl group of E277 and glycerol group of zanamivir indicates formation of 
hydrogen bonds.   
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compared to the WT (Figure 4.9D). Thus, we predicted that its affinity to zanamivir 
might also be similar to the WT based on structure similarity of oseltamivir and 
zanamivir, though additional experiments are necessary for validation. Then we used the 
same MUNANA approach to measure the enzymatic activity of Y276F and WT 
normalized to the viral titer (infectious unit). Y276F had approximately 70% higher 
activity than WT, consistent with its higher fitness (Figure 4.4B and 4.9A). It also 
suggests that enhanced enzymatic activity of Y276F may contribute to its further 
increased fitness in the presence of either oseltamivir or zanamivir. One explanation is 
that it may create a buffer zone in NA activity, which compensates for the inhibition of 
NA activity by oseltamivir or zanamivir. The residual NA activity is able to support 
growth of IAV, leading to higher fitness of Y276F compared to WT.      
 
To investigate the biophysical underpinnings of increased enzymatic activity of 
Y276F and adaptation of Y276F to oseltamivir and zanamivir, we examined the 
conformation of Tyr276 in the crystal structure of NA (Figure 6.5B). The C-C of 
Tyr276 appeared to orient away from the binding substrate without forming any strong 
interaction with the substrate. In addition, the only difference between tyrosine and 
phenylalanine was that tyrosine had an extra hydroxyl group, but the hydroxul group 
pointed away from the substrate. Y276 is located between a framework residue H275 and 
two functional residues E277 and E278, so perturbations to Y276 may affect the 
conformation of these residues and hence binding interaction of sialic acid or NAI for NA. 
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Molecular dynamics analysis on NA with the WT sequence showed that Y276 formed a 
stable hydrogen bond with W303 through its hydroxyl group, so Y276F should break the 
hydrogen bond (personal communication, Prachanronarong). However, the effect of loss 
of the hydrogen bond has not been experimentally tested. One hypothesis is that 
disruption of the hydrogen bond makes residues 275-278 more flexible, enhancing the 
activity of the catalytic residue E278. Moreover, the increased flexibility may allow the 
region to restore the integrity of the hydrophobic pocket and better accommodate H275Y. 
Indeed, Y276F restored the enzymatic activity of H275Y and rescued its fitness defect, 
consistent with this hypothesis (data not shown).    
 
Responsive mutations to zanamivir exhibited strong fitness defect without drug  
 We sought to explore common features shared by identified zanamivir responsive 
mutations. Six of the seven identified zanamivir responsive mutations showed strong 
fitness defect (>50% defect) in the absence of zanamivir (Figure 6.6A and table 6.3), 
indicating a strong fitness cost associated with adaptation to zanamivir. The severe cost 
of adaptation provides another rationale explanation for the difficulty of NA to evolve 
resistance to zanamivir: most mutations that adapt to selection pressure from zanamivir 
strongly impair the fitness of IAV in the absence of zanamivir, hindering their 
propagation and spread. Of note, the fitness of E119A was almost null-like without 
zanamivir, but became comparable to the WT with zanamivir, indicating that zanamivir 
exerted strong selection pressure on the replication of IAV. We mapped these zanamivir 
responsive mutations to the crystal structure of NA bound to zanamivir (Figure 6.6B). 
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Figure 6.6: Fitness effects of zanamivir responsive mutations 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.6 Fitness effects of zanamivir responsive mutations. (A) A bar graph of fitness effects 
of zanamivir responsive mutations with (red) or without (green) zanamivir. Error bars are 
standard deviation with N=3. (B) Molecular structure image of NA (PDB ID: 3B7E). Residues 
with zanamivir responsive are colored purple. (C) A bar graph of fitness effects of mutations with 
only small fitness defect in the presence of zanamivir. The fitness effect of mutations with 
zanamivir is colored in green, without zanamivir colored in red. Error bars are standard deviation 
with N=3. (D) Structure image of NA (PDB ID: 3B7E). Residues that harbor mutations with 
small fitness in the presence of zanamivir are colored light blue.   
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Surprisingly, four of the seven identified zanamivir responsive mutations were within or 
close to the tetramizaiton interface. Three of them were almost lethal without zanamivir, 
indicating that tetramization of NA was required for the enzymatic function of NA. 
Mutations to the tetramization interface exhibited reduced sensitivity to zanamivir, 
indicating that tetramization of NA was also required for efficient binding of zanamivir 
for NA. The other three mutations (E119A, H275Q and E277D) occurred at functional or 
framework residues in the active site. They caused strong fitness defect, indicating that 
these mutations severely impaired NA function, presumably by reducing their binding 
affinity to NA; however they should also hinder binding of zanamivir to NA. 
 
 We also identified several mutations with little fitness defect (less than 20%) in 
the presence of zanamivir, though they were not more fit than WT. Most of them had 
approximately 45-80% fitness defect without zanamivir, except for K111Q, which 
appeared to be null-like (Figure 6.6C and Table 6.3). Although their increase in fitness 
effect with zanamivir was not statistically significant, collectively they displayed a 
general trend to be responsive to zanamivir. Moreover, three of the six mutations 
exhibited reduced sensitivity to zanamivir in IAV samples isolated from patients [249, 
282, 283]. We mapped these mutations to the crystal structure of NA and discovered a 
similar spatial distribution to that of zanamivir responsive mutations (Figure 6.6D). These 
mutations were also clustered at the tetramization interface and the active site, confirming 
important roles of these regions in mediating adaptation to zanamivir. In particular, two 
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mutations were identified at residue 223 (I223K and I223R) and 275 (H275N and H275Q) 
respectively. Position 223 had been identified as a hotspot for oseltamivir responsive 
mutations (Figure 4.8). Amino acids with positive charges appeared to reduce binding of 
zanamivir for NA presumably by impairing interactions between C-5 of zanamivir and 
R225 of NA. Position 275 harbored the predominant N1 oseltamivir resistance mutation 
H275Y. Polar amino acids, instead of the parental positively charged histidine with an 
aromatic ring, appeared to affect the binding of zanamivir for NA. In summary, we 
identified several mutations that were responsive to zanamivir at the tetrameriation 
interface and active site of NA, but strong cost of adaptation likely hindered their fixation 
in human population.     
 
To sum up, we identified a limited number mutations that exhibit adaptive 
potential to zanamivir. These mutations were clustered in the tetramizaiton interface or 
active site of NA and incurred strong fitness defect in the absence of zanamivir selection. 
Our results demonstrated the higher resistance barrier to zanamivir and revealed cost of 
adaptation as a predominant determinant of limited resistance to zanamivir. 
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Material and methods 
The plasmid library construction, viral library recovery, bulk competition, 
sequencing sample preparation, sequencing and statistical analysis are described in the 
material and methods section of Chapter IV.  
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